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ABSTRACT 
Clinicopathological and community studies have demonstrated misdiagnosis in 
Parkinson’s disease (PD). Clinical trials of antiparkinson medication have also shown a 
subset of patients labelled as having PD have normal functional brain dopaminergic imaging. 
Conditions commonly misdiagnosed as PD include Essential tremor (ET), vascular 
Parkinsonism (VP) and dystonic tremor (DT). 
 
This thesis examines the accuracy of clinical diagnosis of PD in a community setting 
by identifying misdiagnosed cases and supervising antiparkinson medication withdrawal. 
Prescription database searches and GP case record review were carried out in 92 West 
Scotland GP practices within a population of 511,927. 610 patients on antiparkinson 
medication for a PD diagnosis were identified and age-adjusted prevalence was 129.5 per 
100,000. Patients were invited for assessment if there was (a) no increase in dopaminergic 
drug dose or (b) no recorded progression of disease over time, suggestive of possible 
misdiagnosis. 64 patients were assessed and this was supplemented with FP-CIT SPECT 
scanning in 25 uncertain cases. Patients considered unlikely to have PD were advised to 
reduce and discontinue antiparkinson drugs, with repeat PD motor scoring over 6 months. 33 
of 64 patients (51.6%) successfully completed antiparkinson medication withdrawal. An age, 
sex and disease duration matched control group was also assessed.  
 
The selection criteria allowed identification of a high proportion of misdiagnosed 
cases and FP-CIT SPECT was a useful diagnostic tool for assessing patients (previously 
diagnosed as PD) in whom there was diagnostic doubt. 
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SUMMARY 
The diagnosis of Parkinson’s disease (PD) is clinical. The most widely used criteria 
are the UK Parkinson’s disease society Brain Bank criteria. Fulfilment of Brain Bank criteria 
requires 3 steps: 
1. diagnosis of a parkinsonian syndrome; 
2. exclusion of other causes of parkinsonian syndromes; and 
3. supportive features of a PD diagnosis (eg. persistent asymmetry of signs, excellent 
clinical response to Levodopa and a history of disease progression). 
 
Often the diagnosis of PD is straightforward. However, clinicopathological studies 
have shown that patients, diagnosed with PD in life, have an alternate underlying diagnosis in 
up to 25% of cases. Greatest diagnostic accuracy is achieved when patients are assessed 
within a specialist movement disorder service and followed up over time. Community studies 
have suggested that up to 26% of PD patients do not have clinical evidence of Parkinsonism. 
Patients misdiagnosed with PD are often commenced on antiparkinson therapy and may be 
given inappropriate prognostic information. The most common conditions misdiagnosed as 
PD in the community are essential tremor (ET) and vascular Parkinsonism (VP).  
 
Diagnosis of PD may be especially difficult in early disease and other causes of 
tremor (eg. ET, dystonic tremor) must be considered. Recently functional brain imaging 
using [
123
I]N-w-fluoropropyl-2-carbomethoxy-3-(4-iodophenyl)nortropane (FP-CIT) to 
determine presynaptic dopaminergic function in striatum (reduced in PD) using single photon 
emission computed tomography (SPECT) has been shown to accurately differentiate 
degenerative Parkinsonism from non-degenerative tremor disorders. FP-CIT SPECT imaging 
is normal in ET, drug-induced and psychogenic Parkinsonism and has proved an extremely 
valuable tool in the diagnosis of patients with clinically uncertain syndromes. A subset of 
patients labelled as having PD who have been entered into clinical trials of antiparkinson 
drugs have normal dopaminergic imaging and have been referred to as SWEDDs (subjects 
with scans without evidence of dopaminergic deficiency) and the underlying diagnoses in this 
group of patients has been debated. 
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The aim of this thesis was to identify patients misdiagnosed with PD from searches 
within primary care and to supervise gradual withdrawal of antiparkinson medication in this 
group. The methodology used also allowed examination of prevalence of parkinsonian 
syndromes and analysis of antiparkinson drug prescription.  
 
Searches of prescription databases and GP case records were performed in 92 West 
Scotland GP practices across 5 community health partnerships: South East Glasgow, South 
West Glasgow, South Lanarkshire, East Dunbartonshire and West Dunbartonshire. All 
patients prescribed antiparkinson medication (Levodopa, dopamine agonists, monoamine 
oxidase B inhibitors, catechol O-methyl transferase inhibitors, anticholinergic drugs and 
Amantadine) were identified. The indication for antiparkinson drug prescription was derived 
from patient case records. 
 
In the areas studied 959 of 511,927 patients were prescribed antiparkinson medication 
for a non-parkinsonian syndrome (eg. anticholinergics co-prescribed with antipsychotic 
medication, dopamine agonists for pituitary tumour and restless legs syndrome, Amantadine 
for multiple sclerosis and Levodopa for dopa-responsive dystonia). 610 of 511,927 patients 
were prescribed antiparkinson medication for a PD diagnosis giving a crude PD prevalence of 
119.2 per 100,000 and age-adjusted prevalence of 129.5 per 100,000.  
 
Patients on antiparkinson medication for a PD diagnosis were invited for clinical 
assessment if there was no progression of movement disorder symptoms documented in the 
case records or if there was no increase in antiparkinson drugs in the 3 years preceding the 
search date. 64 of 89 patients (71.9%) meeting selection criteria were assessed by 2 
movement disorder specialists. Following clinical assessment and FP-CIT SPECT (in 25 
selected cases of diagnostic uncertainty) 36 of 64 patients (56.3%) were considered to be 
suitable for antiparkinson therapy withdrawal. 35 of 36 patients consented to supervised 
antiparkinson therapy withdrawal and were followed up for a mean period of 8.2 months. At 
serial out-patient clinics patients underwent repeat scoring on validated PD motor scales by a 
blinded PD nurse specialist. 2 of 35 patients (5.7%) had worsening of movement disorder 
xix 
 
symptoms at 3 months following medication withdrawal. FP-CIT SPECT was then performed 
and was found to be abnormal in both cases. Both cases were considered to have PD and 
clinically improved following prompt re-introduction of antiparkinson therapy. 33 of 35 
patients (94.3%) successfully completed therapy withdrawal without deterioration in 
movement disorder symptoms.  
 
A control group of 64 patients (matched for age, sex and disease duration) was also 
assessed. Following clinical assessment and FP-CIT SPECT scanning (in 4 cases of 
diagnostic uncertainty) 3 of 64 control patients (4.7%) were considered to have a non-PD 
diagnosis and successfully completed therapy withdrawal. The final diagnostic break-down 
for patients considered to have a non-PD diagnosis in both groups was: ET = 17 cases; VP = 
12 cases; drug-induced Parkinsonism = 3 cases; dystonic tremor = 3 cases; indeterminate 
tremor = 5 cases and gait ignition apraxia = 1 case. 
 
We can conclude: 
 There remains significant misdiagnosis of PD in the community; 
 The selection criteria described in this study allow identification of a high 
proportion misdiagnosed cases;  
 FP-CIT SPECT is a useful diagnostic tool in the assessment of patients 
labelled as having PD in whom there is diagnostic doubt; and 
 Supervised antiparkinson medication withdrawal is safe in selected patients. 
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CHAPTER 1 
INTRODUCTION: THE PATHOLOGY AND DIAGNOSIS OF PARKINSON‟S DISEASE 
 
 2 
The pathology of Parkinson‟s disease 
Parkinson‟s disease (PD) is a progressive neurodegenerative condition, affecting 
1-2% of the over-65 population, causing dopamine deficiency within the nigrostriatal 
system. Pathologically there is loss of neurones within the subtantia nigra pars compacta 
and other subcortical nuclei associated with the widespread occurrence of Lewy bodies. 
PD manifests clinically after the pathology has reached an advanced stage, with loss of 
approximately 50% of dopaminergic neurones (Jellinger 1987). 
 
Lewy bodies are regarded as the morphological markers of PD (Forno 
1986;Spillantini et al. 1997). They are found within surviving neurones within the 
substantia nigra and other subcortical and cortical locations (Jellinger 2002). Lewy bodies 
are spherical cytoplasmic inclusions (8-30μm in diameter) with a hyaline eosinophilic 
core. The major component of Lewy bodies is the pre-synaptic protein alpha-synuclein. 
 
In 2003 a pathological staging system, based on the topographical extent of the 
lesions, was proposed (Braak et al. 2003). Lesions initially occur in the dorsal efferent 
motor nucleus of the glossopharyngeal and vagal nerves and the anterior olfactory 
nucleus. From the lower brainstem the disease processes ascends with involvement of 
more rostral brainstem areas. Cortical involvement usually follows, beginning with the 
anteromedial temporal mesocortex. 
 
PD is a heterogenous disorder and is likely to result from a combination of genetic 
and environmental factors. Environmental toxins have previously been implicated in the 
development of Parkinsonism.  In 1983 young intravenous drug abusers in California 
inadvertently synthesized and injected 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine 
(MPTP) and developed an unremitting parkinsonian syndrome (Langston et al. 1983). In 
experimental models, the MPTP metabolite 1-methyl-4-phenylpyridium (MPP+) was 
shown to be taken up specifically in monaminergic neurones via the dopamine and 
serotonin transporters and to inhibit the multi-enzyme complex 1 of the mitochondrial 
electron-transport-chain (Betarbet et al. 2000;Fornai et al. 2005). The degenerative 
changes caused by MPP+ are most prominent in the dopaminergic neurones, suggesting 
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that these cells are especially vulnerable to inhibition of the mitochondrial respiratory 
chain.  
 
Whilst the vast majority of PD is sporadic the identification of genes implicated in 
the development of familial PD has aided in the understanding of the pathogenesis of the 
sporadic form. However, the combination of all monogenic forms of PD accounts for 
only 5-10% of the total PD population (Gandhi & Wood 2005).  
 
In common with other neurodegenerative conditions, it is thought that the 
pathogenesis of PD results from: 
 The abnormal aggregation and processing of mutant or damaged protein 
 The cellular response to that protein 
 
Genetic causes of Parkinson‟s disease 
Linkage studies of families with an apparent Mendelian pattern of inheritance 
have helped to identify the following genes implicated in monogenic forms of PD: 
 
PARKIN (PARK 2) – This gene was first described in Japanese families with 
autosomal recessive juvenile Parkinsonism (Kitada et al. 1998). The gene is located on 
chromosme 6q and more than 100 mutations, including point mutations, exon deletions 
and multiplications, have been identified in many different ethnic groups (Mata et al. 
2004).. In a European study of 73 affected families this gene caused 49% of familial 
early-onset PD and 18 % of sporadic early-onset disease (Lucking et al. 2000). Parkin is 
expressed in pre- and post-synaptic processes and functions as an E3-type ubiquitin-
protein ligase that participates, in the selective transfer of ubiquitin molecules to protein 
substrates leading to their proteasomal degradation by the ubiquitin proteasome system 
(UPS) (Shimura et al. 2000;Zhang et al. 2000). Most parkin mutations are thought to 
cause loss of function resulting in the accumulation of parkin-specific toxic substrates 
(Gosal et al. 2006).  
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The clinical phenotype is variable and has most commonly resembles sporadic 
disease (Gosal, Ross, & Toft 2006). However, features that have been reported include:  
early onset (often before 40 years), an excellent and sustained response to Levodopa, a 
symmetrical presentation, early development of dystonia, hyperreflexia, early 
development of Levodopa-induced dyskinesias, early postural instability and gait 
abnormalities (Kitada et al. 1998;Lucking et al. 2000;Lohmann et al. 2003). Interestingly, 
it has been reported that olfaction is preserved in parkin-related cases, unlike in sporadic 
disease (Khan et al. 2004). 
  
The few neuropathological studies of parkin-positive early-onset patients with 
homozygous exonic deletions have shown selective nigrostriatal cell loss without the 
presence of Lewy bodies (Takahashi et al. 1994;Mori et al. 1998). However, Lewy body 
pathology has been described in heterozygous parkin-positive patients with later-onset 
disease (Farrer et al. 2001;van de Warrenburg et al. 2001;West et al. 2002). 
 
LRRK 2 (PARK 8) – Mutations in the leucine-rich repeat kinase 2 (LRRK2) 
gene can cause an autosomal dominant pattern of PD. These mutations are the most 
common identified in familial or sporadic disease (Elbaz 2008). This gene, located on 
chromosome 12, was initially mapped in a large Japanese family, known as the 
Sagamihara kindred (Funayama et al. 2002). LRRK2 encodes a large protein – dardarin. 
The functions of dardarin are not clear, although it is thought to have a role in vesicle 
dynamics and secondary messenger signalling (Cookson et al. 2005). To date 7 mutations 
of this gene have been recognised in patients of different ethnic origin, the most common 
being the G2019S mutation with lifetime penetrance of up to 74% (Schapira 2006;Healy 
et al. 2008a). Recent studies have demonstrated high proportions of PD patients carrying 
LRRK2 mutations in certain ethnic groups, namely North African Arabs (39% of 
sporadic cases, 36% of hereditary cases) and 10% in Ashkenazi Jews (10% of sporadic 
cases, 28% of hereditary cases) (Abou-Sleiman et al. 2006;Hulihan et al. 2008;Healy et 
al. 2008a). 
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Typically it presents clinically in  patients over 50 years and phenotypically 
resembles sporadic disease with asymmetrical tremor, rigidity, bradykinesia, a good 
response to Levodopa and dyskinesia (Kachergus et al. 2005). The neuropathological 
findings of LRRK2-positive patients have been pleomorphic (Yang et al. 2009). 
Although there is striatonigral neuronal cell loss in all cases, some demonstrate 
widespread Lewy body pathology, whilst others have evidence of neurofibrillary tangles 
and tauopathy (Wszolek et al. 2004;Zimprich et al. 2004).   
 
Recently there has been debate whether genetic testing for the G2019S LRKK2 
mutation should be offered. Given that this mutation is only found in 2% of sporadic in 
white populations blanket testing of all cases is not appropriate (Healy et al. 2008c). 
However, testing of patients with an affected first degree relative or from high-risk 
populations (North African Arab or Ashkenazi Jew) has been recommended by some; 
although the absence of available neuroprotective therapies makes this controversial. 
 
ALPHA SYNUCLEIN (PARK1) – The A53T mutation in the alpha-synuclein 
gene, located on chromosome 4q, was first identified in 1997 within a large Greek-Italian 
family known as the Contursi kindred and in 3 unrelated families of Greek origin 
(Polymeropoulos et al. 1996;Polymeropoulos et al. 1997).  Alpha-synuclein is 
particularly abundant at pre-synaptic terminals but its normal function is largely 
unknown.  
 
There are 3 known point mutations which are thought to act via a toxic gain in 
function (Schapira 2006). This is probably mediated by intracellular accumulation of 
abnormal alpha-synuclein inhibiting proteasomal function, leading to Lewy body 
formation and dopaminergic cell loss. The abnormal alpha-synuclein protein has an 
increased propensity to aggregate, a crucial step in the development of Lewy bodies 
(Gosal, Ross, & Toft 2006). It is unclear why dopaminergic neurones are selectively 
vulnerable to the toxic effects of alpha-synuclein.  Elevated levels of wild-type alpha-
synuclein may also cause PD, as suggested by the discovery of patients with duplication 
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and triplication of the alpha-synuclein gene, in the absence of any mutation (Singleton et 
al. 2003;Farrer et al. 2004).  
 
The clinical phenotype is fairly typical for idiopathic Parkinson‟s disease with 
tremor, rigidity, bradykinesia, postural instability and a good response to Levodopa 
therapy (Golbe et al. 1996). However, age at onset is typically under 45 years and there is 
often rapid disease progression.  
 
Neuropathological examination of alpha-synuclein positive patients has shown 
neuronal cell loss in the substantia nigra and locus coeruleus with Lewy bodies in the 
brainstem, cortex and glial cell inclusions (Gosal, Ross, & Toft 2006). Lewy body 
pathology appears to be more widespread when these cases are compared with sporadic 
disease. 
 
PINK 1 (PARK 6) – Homozygous mutations in PTEN induced kinase 1 (PINK 
1) cause autosomal recessive early-onset disease. This gene is located on the short arm of 
chromosome 1 and was identified following studies of 3 consanguineous Italian / Spanish 
families (Valente et al. 2004a). Further mutations have been identified in Asian and 
North American families (Hatano et al. 2004). The gene encodes a mitochondrial kinase 
and may protect cells against stress conditions that affect the mitochondrial membrane 
potential (Valente et al. 2004b). Mutations in this gene are thought to cause loss of 
function (Cookson, Xiromerisiou, & Singleton 2005). 
 
The clinical phenotype includes onset in 20s and 30s, asymmetric onset, slow 
progression of disease, early onset of Levodopa-induced dyskinesia, sustained response 
to dopaminergic stimulation and rarely atypical features (Valente et al. 2004b). Affected 
patients have homozygous mutations. However, studies of early-onset sporadic cases 
have identified a higher proportion of patients with heterozygous mutations when 
compared with controls (Rogaeva et al. 2004;Healy et al. 2004;Valente et al. 
2004b;Gosal, Ross, & Toft 2006). Heterozygous mutations therefore may confer an 
increased risk.   
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There are no neuropathological correlates in the literature. However, an 
18
F-dopa 
PET study has shown a different pattern of dopaminergic dysfunction to sporadic disease, 
perhaps suggestive of different neuropathological features (Khan et al. 2002). 
 
DJ-1 (PARK 7) – This gene, located close to the locus for PINK-1 on 
chromosome 1p, was identified in 2003 in 2 families in Holland and Italy with early-
onset autosomal recessive disease (Bonifati et al. 2003). These loss-of-function mutations 
in DJ-1 are rare and are thought to account for around 1% of early-onset cases (Abou-
Sleiman et al. 2003). 
18
F-dopa studies of clinically unaffected heterozygote carriers are 
normal, suggesting that heterozygosity is not a risk factor for developing PD (Dekker et 
al. 2004). 
 
The function of DJ-1 is not fully known. It is expressed in the mitochondrial 
membranes of astrocytes and is thought to be a sensor of oxidative stress. It has been 
shown that oxidative stress, using mitochondrial complex 1 inhibitors, wild-type DJ-1 
translocates from the nucleus and cytoplasm to the outer mitochondrial membrane, 
suggesting a neuroprotective action (although it is not known how this protective action 
is conferred) (Canet-Aviles et al. 2004). 
 
The clinical phenotype includes early-onset (20-40 years), asymmetrical onset, 
slow progression of disease, psychiatric disturbance, dystonia and sustained response to 
Levodopa therapy. In addition, psychiatric symptoms and focal dystonia are common 
(Abou-Sleiman et al. 2003). There are no neuropathological correlates in the literature.  
 
UCH-L1 (PARK 5) – A single missense mutation in the Ubiquitin carboxy-
terminal hydrolase L1 (UCH-L1) gene located on chromosome 4p was identified and felt 
to be the cause of an autosomal form of PD in 2 German siblings (Leroy et al. 1998). The 
protein UCH-L1 is a component of the UPS, involved in recycling of polyubiquitin 
chains back to monomeric ubiquitin and targeting proteins for UPS degradation. 
Dysfunction of this enzyme may lead to loss of recycling of ubiquitin monomers and 
subsequent dysfunction of the proteasomal-proteolytic pathway.   
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The clinical phenotype is fairly typical for PD: disease onset at 50 years and good 
response to Levodopa. There are no reported neuropathological correlates. This mutation 
has not been reported in any other families and its significance is not yet clear. 
 
The clinical value of genetic testing in PD is not yet clear and no formal 
diagnostic testing guidelines exist. Testing is now available for mutations in parkin and 
PINK 1 genes. However, these tests are expensive, only done in certain centres and the 
results are often inconclusive. 
 
Clinicopathological studies of Parkinson‟s disease 
There is no known biological marker for PD. The clinician is required to 
differentiate idiopathic PD from other parkinsonian syndromes. Clinical diagnostic 
accuracy in PD is important for therapeutic and prognostic reasons. It is also fundamental 
for accuracy in epidemiological studies and clinical trials. Pathological examination 
remains the gold standard for diagnosis of PD. Unfortunately, there are no widely 
accepted pathological criteria defined for this diagnosis.  
 
The usefulness of any diagnostic test can be assessed using sensitivity, specificity 
and positive and negative predictive values. The sensitivity of diagnostic criteria for PD 
is the proportion of patients with the disease who fulfil the criteria. The specificity of the 
criteria is the proportion of patients who do not have PD who do not fulfil the criteria. 
Given that sensitivity is conditional on the disease being present and specificity on the 
disease being absent, they should be unaffected by disease prevalence. The positive 
predictive value of the criteria is the probability that the patient has PD given that they 
meet diagnostic criteria. The negative predictive value of the criteria is the probability 
that the patient does not have PD, given that they do not meet diagnostic criteria. Positive 
and negative predictive values are dependent on the underlying prevalence of PD within 
the population being studied. 
 
Traditionally the diagnosis of PD required the presence of 2 out of the 3 motor 
cardinal features of: bradykinesia, rigidity and resting tremor. Several attempts at clinical 
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diagnostic criteria have been proposed, but few have been applied consistently or 
assessed for reliability (Gibb & Lees 1988;Ward & Gibb 1990;Calne et al. 1992;Larsen et 
al. 1994;Gelb et al. 1999;Litvan et al. 2003). The most widely accepted clinical 
diagnostic criteria are the UK Parkinson‟s disease society Brain Bank (UKPDSBB) 
criteria (Gibb & Lees 1989). Diagnosis of PD using the Brain Bank criteria requires three 
steps (see Appendix 1). The first step simply confirms Parkinsonism, defined as 
bradykinesia (slowness in the initiation of voluntary movement with progressive 
reduction in speed and amplitude of repetitive movements) plus one of the following: 
postural instability, muscular rigidity or a 4–6 Hz resting tremor. The second step of the 
criteria is exclusion of other causes of a parkinsonian syndrome, such as vascular, drug-
induced, post-encephalitic, post-traumatic Parkinsonism, and the Parkinson-plus 
disorders. Finally, the third step prospectively supports PD and includes unilateral onset, 
prominent rest tremor, good Levodopa response and dyskinesia. Central to the 
development of these criteria were the findings from a series of clinicopathological 
studies (Gibb & Lees 1988;Gibb & Lees 1989;Hughes et al. 1992a;Hughes et al. 
1992b;Litvan et al. 1998;Hughes et al. 2001b;Hughes et al. 2002;Rajput et al. 2004).  
 
A prospective clinicopathological described the post-mortem findings in 59 
patients  who were diagnosed as having PD in life (Rajput et al. 1991a). All cases had 
been assessed by a single neurologist. The clinical diagnostic criteria employed in these 
cases required at least 2 of 3 cardinal features in the absence of any identifiable cause for 
Parkinsonism. All neuropathological examination was carried out by one 
neuropathologist who was blinded to the clinical observations.  The pathological criteria 
used required substantia nigra neuronal loss greater than 50% and the presence of Lewy 
bodies. The patients were followed up for a median period of 11.7 years.  
  
The initial diagnosis was idiopathic PD in 43 of 59 patients. Pathological 
examination confirmed the diagnosis in 28 of 43 (65%) cases. The final clinical diagnosis 
was idiopathic PD in 41 patients. This was pathologically confirmed in 31 of 41 cases 
(76%). The 10 false positive cases comprised 4 cases of striatonigral degeneration, 2 
cases of striatonigral degeneration without Lewy bodies, 1 case of Alzheimer‟s disease 
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(AD), 1 case of drug-induced Parkinsonism and 2 cases where there was neurofibrillary 
tangle pathology in the substantia nigra and in the locus ceruleus. This was the first 
prospective clinicopathological study and suggested that 1 in 4 patients diagnosed with 
PD by a neurologist had an alternative diagnosis. It also demonstrated that clinical 
diagnostic accuracy improved when patients were followed up and re-evaluated over 
time.   
 
Similar findings were reported in a clinicopatholigical study from the Brain Bank 
(Hughes et al. 1992b). This study described the post-mortem findings of 100 consecutive 
patients, all diagnosed as having PD in life, collected between 1987 and 1990. These 
cases were from all over the UK and the diagnostic criteria employed were poorly 
defined. Neurologists associated with the Brain Bank had prospectively assessed 70 
patients, whilst other neurologists and geriatricians had assessed the remaining patients. 
76 of 100 cases (76%) were pathologically confirmed as PD. The remaining 24 false 
positive cases comprised 6 cases of progressive supranuclear palsy (PSP), 5 cases of 
multiple-system atrophy (MSA), 3 cases of AD, 6 cases of Alzheimer‟s –type pathology 
with striatal involvement, 2 cases of nigral atrophy without Lewy bodies, 1 case of post-
encephalitic Parkinsonism and one case that was pathologically normal. When the Brain 
Bank criteria were retrospectively applied to this patient group, using patient case notes, 
the diagnostic accuracy improved to 82% (73/89). The authors acknowledged that 
retrospective application of the clinical criteria was limited by how well the clinical 
findings had been documented.  
 
In a follow-up to this study the authors reviewed the clinical features of these 100 
cases (Hughes et al. 2001a). The proportion of cases with a specific clinical feature was 
then compared with the pathological findings. When certain features were present 
(asymmetrical onset, no atypical features and no possible aetiology for another 
parkinsonian syndrome) the diagnostic accuracy was increased to 93%. However, this 
was at the expense of decreasing the sensitivity of the clinical diagnosis (32% of 
pathologically confirmed cases of PD that were then rejected using these criteria). This 
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study found that a „tremor dominant‟ pattern of disease was the single best clinical 
criterion for diagnosing PD. 
 
A further Brain Bank study reported the pathological findings of 100 consecutive 
cases (Hughes, Daniel, & Lees 2001b). All patients were diagnosed as having PD during 
life. 90 of 100 cases (90%) were pathologically confirmed as PD. The 10 false positives 
consisted of 6 cases of MSA, 2 cases of PSP, 1 case of post-encephalitic Parkinsonism 
and 1 case of vascular Parkinsonism.  
 
A further study reported the pathological results of 143 patients who had been 
assessed by neurologists associated with the movement disorder team at the National 
Hospital for Neurology and Neurosurgery (NHNN) in London (Hughes et al. 2002). 73 
patients were clinically diagnosed with PD, and the remaining 70 patients were clinically 
diagnosed with atypical Parkinsonism. 72 of 73 patients (98.6%) diagnosed as PD were 
pathologically confirmed as PD. The single false positive case was pathologically 
confirmed as PSP.  7 of 70 (10%) patients diagnosed with atypical Parkinsonism were 
also pathologically confirmed as PD, giving rise to a sensitivity of 91.1%. This study 
reported greater diagnostic accuracy than previously found, perhaps suggesting that the 
clinical diagnosis of movement disorder specialists was more accurate than other 
clinicians.  
 
These clinicopathological studies should be interpreted with caution. There are no 
set of agreed pathological criteria for the diagnosis of PD. Many of these studies are 
retrospective and contain small numbers. In addition donor tissue is more likely to be 
received from patients who have died in hospital and in patients in whom there has been 
greater diagnostic uncertainty (Gibb & Lees 1988). The clinical criteria employed in 
these studies are often vague and in some not mentioned at all. However, these studies do 
suggest that a significant proportion of patients diagnosed with PD have an alternative 
diagnosis, and that diagnostic accuracy is greatest when patients are assessed by 
movement disorder specialists and followed over a long period. 
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Community Studies of Parkinson‟s disease 
 Over the past 10 years several community studies of patients diagnosed as 
PD have been carried out.  A North Wales study reported diagnostic accuracy for 
Parkinsonism and PD in a community based sample of patients (Meara et al. 1999). 
Patients on therapy for PD were identified using prescribing databases within 74 General 
Practices. Once identified patients were clinically assessed at a specialist movement 
disorder clinic, or seen at home.  
 
502 patients were identified as taking antiparkinson medication for a PD 
diagnosis. The diagnosis of Parkinsonism had been made by a General Practitioner in 296 
of 502 cases (59%). In total, 402 of 502 patients (80%) were examined. Parkinsonism 
was clinically detected in 299 of 402 cases (74%), with only 213 of 402 cases (53%) 
meeting Brain Bank criteria.  There was no clinical evidence of Parkinsonism in 103 of 
402 patients (26%). 50 of 103 patients (48%) were diagnosed with essential tremor (ET), 
37 (36%) with gait apraxia and 16 (16%) with Lewy body dementia.  
 
A further community study described searches of the computerised patient case 
records within 15 Greater London General Practices (Schrag et al. 2002). Those 
identified included all patients with a current or previous diagnosis of PD or 
Parkinsonism, all patients who had been prescribed antiparkinson therapy and all patients 
over 50 years in whom a tremor had been noted. Patients were excluded if they had been 
prescribed antiparkinson therapy for a separate diagnosis (eg. pituitary tumour, restless 
legs syndrome), if there was another known cause for tremor (eg. hyperthyroidism), if the 
patient had been prescribed dopamine depleting medications in the preceding 6 months, 
or if the patient had developed dementia prior to the onset of parkinsonian symptoms. 
Patients were assessed either at home, at their General Practice or in a specialist 
movement disorder clinic and PD was diagnosed using Brain Bank criteria.  
 
Searches identified 241 patients and 202 of 241 (84%) patients agreed to be 
examined. Of the 202 patients examined, 134 (66%) had previously been diagnosed with 
Parkinsonism (131 with PD, 2 with vascular Parkinsonism and one with atypical 
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Parkinsonism).  An additional 10 patients (5%) had been started on antiparkinson therapy 
without a specific diagnosis being applied. The diagnosis of PD was confirmed in 109 of 
131 patients (83%). An additional 2 patients (1.5%) were found to have possible PD and 
the diagnosis was rejected in 20 patients (15%). Of these 20 patients, there were 4 cases 
of non-parkinsonian tremor, 6 cases of vascular Parkinsonism, 4 cases of PSP, 3 cases of 
MSA, 2 cases of idiopathic torsion dystonia and one case of dementia without 
Parkinsonism. 
 
13 of 68 patients (19%) not previously diagnosed with PD, fulfilled Brain Bank 
criteria and a further 2 patients (3%) were classified as possible PD. Estimates of 
sensitivity, specificity and positive and negative predictive values for previous PD 
diagnoses were compared with diagnosis using Brain Bank criteria. Sensitivity was 
estimated at 88.1% and specificity 73.0%. Positive and negative predictive values were 
84.7% and 78.3%. These values were also estimated according to whether patients had 
originally been diagnosed by specialists or non-specialists. Neurologists and geriatricians 
had a sensitivity and specificity of 93.5% and 64.5%, compared to 73.5% and 79.1% for 
non-specialists. Positive predictive values were also greater for specialists (88.7%) than 
for non-specialists (73.5%).  
 
Although these two studies differ in their methodology, they agree that there is a 
significant proportion of patients in the community diagnosed as having PD and 
commenced antiparkinson medication that do not fulfil clinical diagnostic criteria.  
Common alternative diagnoses for these patients include benign tremor disorders, 
vascular Parkinsonism and dementia. The community and clinicopathological studies 
suggests that diagnostic accuracy in PD is greatest when patients are assessed within 
specialist movement disorder clinics, diagnosed using established diagnostic criteria and 
followed up clinically over time. 
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CHAPTER 2 
PREVALENCE OF PARKINSON‟S DISEASE IN THE WEST OF SCOTLAND 
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Introduction 
Epidemiological studies in Parkinson‟s disease (PD) provide insights into 
suspected risk and protective factors for developing PD. They also allow the estimation 
of social and economic burdens that result from the condition, facilitating healthcare 
planning (von Campenhausen et al. 2005).  Many studies have attempted to measure the 
prevalence of PD with varying results . There are two main sources of the variation 
observed: differences in case ascertainment methodology, and differences in the way the 
diagnosis is defined. However, studies have invariably found that both the incidence and 
the prevalence of PD increase sharply after 60 years of age. Therefore as the population 
ages, incidence and prevalence are also expected to increase. 
  
In broad terms there are 2 types of prevalence study. In a door-to-door prevalence 
study all subjects within the sample are assessed for the relevant disorder. The second 
method relies on searches of hospital, general practice or pharmacy records, sometimes in 
combination. Published door-to-door studies have tended to overestimate the prevalence 
of PD as strict diagnostic criteria were not applied. However, case finding methods 
underestimate the prevalence as they exclude patients who have not yet come to medical 
attention. In a recent review, 39 European prevalence studies of PD were identified with 
crude prevalence rates varying from 65.6 per 100,000 in Sardinia to 12,500 per 100,000 
for nursing home patients in Germany (Rosati et al. 1980;von Campenhausen et al. 2005). 
 
UK prevalence and incidence studies 
Several UK-based prevalence studies have been published (Brewis et al. 
1966;Sutcliffe et al. 1985;Mutch et al. 1986;Sutcliffe & Meara 1995;Schrag et al. 
2000;MacDonald et al. 2000;Porter et al. 2006). The crude prevalence rate for PD varies 
from 108 to 164 per 100,000. The crude prevalence rate relates to the observed 
population as a whole, without subdivision based on age, sex or other factors which 
influence the figures. These studies vary in their case finding methodology and the 
clinical diagnostic criteria for PD. No door-to-door prevalence studies have been 
undertaken in the UK.  
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A longitudinal study of a neighbourhood in Carlisle was published in 1966 
(Brewis et al. 1966). Hospital, GP, private practice, death certificate and Medical Officer 
of Health records were all screened. Clinical criteria used for the definition of PD were 
not stated, and the study predates the UK Brain Bank criteria and other similar 
algorithms. The prevalence rate was estimated at 112.5 per 100,000 and incidence at 12.1 
per 100,000, giving an approximate 9-fold difference between incidence and prevalence, 
which can be used to estimate average disease duration of around 9 years.  Some hint of 
overdiagnosis may be implied by this survival rate, which is higher than might be 
expected for this era – predating the use of Levodopa, at a time when the only available 
drug treatment for Parkinson‟s disease was anticholinergic therapy. 
 
In 1982 a cross-sectional study was carried out in Northampton (Sutcliffe et al. 
1985). Data was gathered from GP and hospital records. Patients identified in the study 
were then interviewed and examined by a neurologist. The diagnosis of idiopathic PD 
was made if there was an akinetic-rigid syndrome, with or without tremor (this study also 
pre-dated the UK Brain Bank criteria). Idiopathic PD cases were considered, whilst other 
causes of parkinsonism were excluded. The crude prevalence was reported as 108.4 per 
100,000. The same authors performed a further epidemiological study in Northampton in 
1992 (Sutcliffe & Meara 1995).  Again patients were identified from GP practice and 
hospital records. Diagnosis of PD was made using UK Brain Bank criteria. The crude 
prevalence was higher at 121 per 100,000 cases and incidence was estimated at 12 per 
100,000. In the latter study the authors found a greater proportion of patients with disease 
of lesser severity and they therefore attributed the apparent increase in prevalence over 
the 10-year period to diagnosis of PD at an earlier stage.  
 
A prospective incidence study of 148,600 patients in Aberdeen over an 18-month 
period reported a crude incidence of probable PD as 22.4 per 100,000 (Taylor et al. 
2006b). Patients were identified from referrals from GPs, hospital doctors, searching of 
all out-patient referrals to neurology and medicine for the elderly, electronic searching of 
GP practice coding and questionnaire screening of the over-65 population. Probable PD 
was defined as 2 or more of tremor, bradykinesia, rigidity or postural instability. The 
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authors felt that this higher rate of crude incidence resulted from diagnostic inaccuracy 
and improved case ascertainment. Whilst screening of the over 65 population may 
improve the case ascertainment, the incidence may be artificially increased by bringing 
forward the diagnosis of some patients who would otherwise have been diagnosed later. 
 
In 1986 the results from a cross-sectional study in Aberdeen were published 
(Mutch et al. 1986). In this study physicians were asked to refer all known PD cases. In 
addition records within nursing homes and psychiatric hospitals were checked. Patients 
were then assessed clinically by the authors. The crude prevalence rate from this study 
was 164.2 per 100,000.  
 
In a longitudinal study of 13 London GP practices 100,230 patients were followed 
for 18 months for incidence of a variety of neurological disorders including PD 
(MacDonald et al. 2000) . A further 27,658 patients were followed for lifetime 
neurological disease prevalence. Patients were identified by medical students and 
diagnosis was confirmed by neurologists. The age-adjusted incidence for PD was 19 per 
100,000 and the lifetime prevalence rate was 200 per 100,000.  
 
In 2000 a cross-sectional study of 15 GP practices in London was published 
(Schrag, Ben Shlomo, & Quinn 2000). Records were screened for a diagnosis of PD or 
Parkinsonism, antiparkinson drug usage and tremor occurring under the age of 50 years. 
The crude PD prevalence (probable and possible) was 128 per 100,000.  
 
Pharmacy records as a source of prevalence and incidence data 
Pharmacy records are a reliable source of drug exposure (Lau et al. 1997). The 
use of pharmacy records for identification of PD  patients in epidemiological studies is 
well established (Menniti-Ippolito et al. 1995;Chio et al. 1998;Martinez-Suarez & 
Blazquez-Menes 2000;van de Vijver et al. 2001;Lai et al. 2003;Porter et al. 2006;Brandt-
Christensen et al. 2006).  
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Pharmacy records were compared with the results of a community-based 
prospective cohort study  among persons aged over 55 years who were screened for PD 
in Rotterdam (van de Vijver et al. 2001). 86% of patients who were prescribed 
Amantadine, 94% who were prescribed Levodopa, 92% who were prescribed 
Bromocriptine and all patients prescribed either Selegiline or at least 2 antiparkinson 
medications had a diagnosis of PD.  The authors therefore concluded that prescription of 
antiparkinson medication was a reliable surrogate for a diagnosis of PD. Only 46% of 
those patients prescribed anticholinergic medications had a diagnosis of PD. 
 
In the British Columbia province of Canada (population 4 million) a regional 
pharmacy database (PharmaNet) which holds accurate information on prescriptions of 
approximately 97% of inhabitants was searched for antiparkinson medications (Lai et al. 
2003). However, this database does not hold information regarding the clinical indication 
for drug prescription. The prevalence of PD was estimated using the prescription of one 
or more of Levodopa, Bromocriptine, Pergolide and Selegiline as a marker. Other 
antiparkinson medications, such as anticholinergics and Amantadine were not included in 
the searches. The authors considered the following factors and made adjustments in their 
calculations accordingly: 
1. The proportion of undiagnosed patients with PD 
2. The proportion of patients misdiagnosed as PD 
3. The proportion of patients with PD not yet commenced on antiparkinson therapy 
4. The proportion of patients prescribed Levodopa and Bromocriptine for reasons 
other than PD  
 
The estimated prevalence of PD was 126 – 144 per 100,000 between 1996 and 
1998. While this study reports on a large population, a more accurate assessment would 
require validation of the correction factors used.  
 
A national prescription database (The Danish medicinal product statistics) was 
searched for patients using antiparkinson medications over a 7-year period (Brandt-
Christensen et al. 2006). This database holds accurate information regarding all 
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prescriptions issued in Denmark, but does not have any clinical information or diagnostic 
data. Crude PD prevalence and incidence were 219.8 and 55.9 per 100,000. When the 
population was age-standardised to the European standard population using the direct 
method these rates fell to 164 and 43.4 per 100,000, indicating that the Danish population 
was older than the European standard. The authors acknowledge that these figures were 
significantly higher than previously estimated, both for incidence and prevalence. They 
attributed this to the prescription of antiparkinson medication for conditions other than 
PD (eg. restless legs syndrome, dopa-responsive dystonia, pituitary tumour) and they also 
suggested that there was a high rate of misdiagnosis of PD. They did not estimate the 
proportion of patients prescribed antiparkinson drugs for alternative diagnoses.  
 
A further prevalence study of a population of 108,597 within North East England 
(Porter et al. 2006) was based on GP, consultant neurologist and geriatrician reporting of  
all patients with possible PD. GP and hospital pharmacy records were also checked to 
identify all patients on regular antiparkinson medications. All eligible patients were then 
invited for assessment at home, and diagnosis was based on UK Brain Bank criteria. The 
crude prevalence was estimated at 148 per 100,000. 
 
Pharmacy and diagnostic review in West Scotland 
In undertaking the programme of research central to this thesis, in which the main 
aim was to identify patients with an incorrect diagnosis of PD, the review of prescription 
databases within primary care allowed the calculation of incidence and prevalence, using 
methods similar to previous studies (Menniti-Ippolito et al. 1995;Chio, Magnani, & 
Schiffer 1998;Martinez-Suarez & Blazquez-Menes 2000;van de Vijver et al. 2001;Lai et 
al. 2003;Porter et al. 2006;Brandt-Christensen et al. 2006).  Accordingly, a comparison 
with other UK studies could be undertaken. Moreover, because of the additional 
availability of diagnostic information from full case record review in all cases, the 
proportion of cases prescribed antiparkinson drugs for alternative diagnoses added 
precision to the calculated rates.    
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Methods 
 Multi-centre ethics committee approval was given by the West Glasgow Ethics 
Committee. All GP practices within the following 5 West of Scotland Community Health 
Partnerships were contacted: South-East Glasgow, South-West Glasgow, South 
Lanarkshire, East Dunbartonshire and West Dunbartonshire.  
 
Individual GP practices were written to and invited to participate. In participating 
practices we recorded the total number of male and female patients and the proportion of 
patients within that practice over 65 and under 16 years of age. Searches were then 
completed of the prescription databases. Both acute and repeat prescriptions for all 
patients registered in each practice are contained within this database. Antiparkinson 
drugs (Levodopa, dopamine agonists, monoamine oxidase B inhibitors, catechol O-
methyl transferase inhibitors and anticholinergic drugs, as listed in Table 2.1) were 
searched for using their generic and trade names at all available doses.  
  
The GP case records of all patients prescribed one or more antiparkinson drugs 
were then reviewed. These case records contain all correspondence from consultations, 
ward admissions, and tests and results from attendance at secondary care, as well as on-
site recordings from consultations with the GP and associated staff, and prior records for 
the patient in cases of change of address and/or general practitioner.  The underlying 
diagnosis was obtained from this review of the full case record for each patient. It was 
noted whether the prescription of „antiparkinson‟ medication (Levodopa or dopamine 
agonist) was for other dopa-responsive conditions (eg. restless legs syndrome, pituitary 
tumour); whether anticholinergics were prescribed for alternative diagnoses (eg. 
Huntington‟s chorea, drug-induced tremor); and whether Amantadine was prescribed for 
lethargy in multiple sclerosis or other similar disorders. 
  
The date of diagnosis was also recorded from the case records. This date was 
taken as the first specific record of the making of the diagnosis, by the GP or the 
specialist, whichever came earlier. Patient age and the interval from diagnosis to the 
search date were also recorded.  
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Crude and age-adjusted prevalence were calculated using standard methods, based 
on the Scotland population in the 2000 census (General Register Office for Scotland 
2008). Differences within geographical areas were tested with chi-squared, using k 
proportion testing and the Marascuilo procedure (XLSTAT version 2007.3, AddInsoft, 
New York). Factors potentially influencing PD prevalence were derived from the Scottish 
Health Survey 2003 (The Scottish Government 2008). 
 
Results 
Of 120 GP practices within the 5 Community Health Partnerships (CHPs), 92 
(76.6%) agreed to participate in this study (no significant difference between CHPs). 
Searches were undertaken between December 2006 and August 2007 inclusive. The total 
patient population covered by these 92 practices was 511,927 (49.5% male, 50.5% 
female). South Glasgow and South Lanarkshire had larger populations than the remaining 
areas (See Table 2.2).There were 76,585 patients aged 65 and over, which represented 
15.0% of the total catchment population, and 40.8% in this age bracket were male, and 
59.2% female. 
  
The number of patients prescribed antiparkinson medication was 1568 (0.3% of 
the catchment population) (See Figure 2.1). 916 of the 1568 (58.4%) were on 
antiparkinson therapy for reasons other than a parkinsonian syndrome. 688 of 916 
(75.1%) patients were prescribed anticholinergic medication in relation to the use of 
traditional  antipsychotics; 97 patients (10.6%) were prescribed dopamine agonists for 
pituitary tumour; 62 patients (6.8%) were prescribed dopamine agonists for restless legs 
syndrome; 53 patients (5.8%) were prescribed Amantadine for symptoms of multiple 
sclerosis; and 16 patients (1.7%) were prescribed Levodopa for dopa-responsive dystonia. 
  
In total 653 patients were prescribed antiparkinson medication for a parkinsonian 
syndrome, of whom 610 (93.4%) had a diagnosis of PD. Of these 610 cases, 55.6% were 
male, and 44.4% female. Other parkinsonian syndromes were as follows (percentage 
figures are expressed out of the 653 cases): 
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a. Vascular Parkinsonism (VP): 23 (3.5%) 
b. Dementia with Lewy bodies (DLB): 8 (1.2%) 
c. Progressive supranuclear palsy (PSP): 6 (0.9%) 
d. Multiple system atrophy (MSA): 3 (0.5%) 
e. Drug-induced Parkinsonism: 2 (0.3%) 
f. Post-encephalitic Parkinsonism: 1 (0.2%) 
 
The crude prevalence of all parkinsonian syndromes was 127.6 per 100,000 (95% 
confidence interval: 118.8 – 136.4); and the prevalence for the population over 65 years 
was 728.6 per 100,000 (669.1 – 789.1).  
 
The crude prevalence for PD was 119.2 per 100 000 (109.7 – 128.6), and the age-
adjusted prevalence was 129.5 per 100 000 (119.6 – 139.4). The crude prevalence was 
significantly higher for males than females (133.1 per 100 000 (119.0-147.3) versus 
105.3 per 100 000 (92.8-117.9), p=0.004); and this was also true for age-adjusted results 
(males 146.7 (131.8-161.6) versus females 113.3 (100.3-126.3), p=0.001) (See Table 
2.3).  There was a statistically significant difference across the geographical areas, for 
both males and females, considering age-adjusted prevalence (See Figure 2.2), and crude 
prevalence (data not shown). This was seen in both sexes, and in particular comparing 
South Glasgow males (98.3, CI 78.7-117.9) and females (83.9, CI 65.6-102.2) with South 
Lanarkshire males (202.7, CI 175.0-230.4) and females (151.1, CI 127.7-174.5), both 
p<0.001.  
 
Crude prevalence in the over-65 population was 705.4 (645.1-765.8) which gave 
an age-adjusted prevalence of 723.4 (662.3-784.5) for this age group. There was an age-
related increase in prevalence for both males and females (See Figure 2.3).  
 
The overall proportion of patients attending a hospital clinic for PD management 
was 72.6%, but varied significantly across geographical areas: 62.2% in West 
Dunbartonshire, 64.1% in South Lanarkshire, 83.0% in South Glasgow, and 91.1% in 
East Dunbartonshire (p<0.0001).   
 23 
Factors with potential influence on the prevalence of PD, according to 
geographical area, are in Table 2.4. The highest cigarette smoking rate and greatest 
educational deprivation was seen in South Glasgow. Also, population density was 
greatest for South Glasgow and least for South Lanarkshire. However, limitation of 
access to services (which includes healthcare) was least in South Glasgow. 
 
Crude prevalence for other parkinsonian syndromes was as follows: VP 4.5 per 
100,000 (over 65 years: 30.0); PSP 1.2 per 100,000 (over 65 years: 6.5); and MSA 0.6 
per 100,000 (over 65 years: 3.9) (numbers too small to calculate confidence interval 
data). 
  
Table 2.6 shows the number of new incident cases per year of parkinsonian 
syndromes between 1996 and 2006 (full year data for 2007 was not available hence this 
year is not shown). These figures are from searches of patients prescribed antiparkinson 
medication for PD at the time of the database search (2006-2007), and therefore exclude 
patients diagnosed with PD during this 10-year period who have died prior to the index 
date. The most accurate figures are therefore from 2005 and 2006 as fewer of the patients 
in this group will have died prior to the index date. The 2006 incidence of parkinsonian 
syndromes is 18.6 per 100,000 (95% CI 14.8 – 22.3); and the incidence in patients over 
65 years was 124.0 per 100,000 (99.1 – 148.9). The incidence of PD was 15.4 per 
100,000 (12.0 – 18.8); and the incidence in patients over 65 years was 107.1 per 100,000 
(80.4 – 125.9). The incidence of VP was 2.2 per 100,000 (0.8 – 3.4); and the incidence of 
VP in patients over 65 years was 14.3 per 100,000 (5.87 – 22.8). 
   
Discussion 
 This study covered more than 10% of Scotland‟s population and is the largest 
epidemiological study of PD in the UK.  Review of patients‟ case records for diagnostic 
data greatly enhanced the understanding of the reasons for using antiparkinson 
medication, with an associated improvement in the accuracy of statistical interpretation. 
Most previous pharmacy-based epidemiological studies have not included case record 
review and the proportion of patients prescribed antiparkinson therapy for other 
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conditions was therefore only estimated (Martinez-Suarez & Blazquez-Menes 2000;Lai 
et al. 2003;Brandt-Christensen et al. 2006). The current study showed that antiparkinson 
medications are quite often prescribed for restless legs syndrome, pituitary adenoma and 
multiple sclerosis. However, the largest usage of „antiparkinson‟ drugs for a diagnosis 
other than PD was of anticholinergic drugs in patients prescribed traditional anti-
psychotic medications. Previous studies did not include anticholinergics within their drug 
searches (Lai et al. 2003;Brandt-Christensen et al. 2006), but may therefore slightly 
underestimate the number of PD cases; we found 2 cases with PD whose only treatment 
was an anticholinergic drug as monotherapy.  
 
In virtually all cases it was possible to determine the reason for the antiparkinson 
medication prescription from the case record. In cases where it was not clear, the 
indication was discussed with the patient‟s GP, which allowed a specific conclusion to be 
reached for all cases. The prescription database did contain diagnostic information for 
each patient. However, this information was often incomplete, and therefore full review 
of the case record was essential to the full understanding of the clinical reason for drug 
prescription.  
 
While the search strategy employed in our study was comprehensive, it will still 
miss patients within the population who are not registered with a GP, and those living in 
long-term institutions (such as psychiatric units and prisons).  Migration into and out of 
the area also may affect the figures. Only immigrants who have registered with a GP 
within their Community Health Partnership will be identified, whilst some patients who 
have moved away from the region may still have case records within the GP practice.    
 
The main unexpected finding was of significant variation in prevalence between 
geographical areas, in particular between a low rate in South Glasgow, and a high rate in 
South Lanarkshire. The size of the populations studied in these two areas was substantial 
and approximately equivalent. Our overall prevalence figures are comparable with 
previous UK studies (Sutcliffe et al. 1985;Schrag, Ben Shlomo, & Quinn 2000). There 
are several potential reasons for prevalence variations, of which case-finding and other 
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methodological differences have received greatest attention, but these are unlikely to 
influence the current findings. The study was conducted contemporaneously by the same 
investigator (EN) and employed the same search strategies, with similar acceptance rates 
by invited general practices. Other potential sources of variation, which could explain 
within-area differences, are now considered in turn. 
 
High cigarette smoking rate and lower education levels are both associated with 
lower rates of PD (Frigerio et al. 2005;Ritz et al. 2007). Other environmental factors 
implicated in the development of PD include rural living and certain occupational 
exposures (de Lau & Breteler 2006). While the observed higher rate of cigarette smoking, 
combined with higher levels of education deprivation, and greater urban community 
could reduce the PD prevalence in South Glasgow relative to South Lanarkshire, the 
magnitude of such effects (an approximate two-fold difference between the two areas) is 
larger than indicated from relative risk studies (Frigerio et al. 2005;de Lau & Breteler 
2006;Ritz et al. 2007), and suggests that other influences are likely to be present.  
 
Age is the greatest risk factor for developing PD, with an exponential increase 
above age 65. While significantly more patients were over 65 in South Lanarkshire 
versus South Glasgow, an even higher proportion of elderly was present in East 
Dunbartonshire, and the within-area prevalence differences persisted after age-adjustment 
to the Scottish population. Migration is minimal in the areas studied (0.5% over 10 years) 
(General Register Office for Scotland 2008), but selective migration following a 
diagnosis of PD might affect prevalence, for example reducing them in urban areas. 
 
Another potential reason for the difference in prevalence between areas studied to 
consider is genetics. Recent studies have demonstrated very high prevalence of the 
G2019S mutation in LRRK2 in North African Arabs and Ashkenazi Jews (Hulihan et al. 
2008;Healy et al. 2008b). It is possible that there is cohort of patients within South 
Lanarkshire carrying pathogenic mutations which explain the high PD prevalence. 
However, the South Lanarkshire population is not genetically homogenous, and 
immigration and emigration to surrounding areas makes this extremely unlikely. 
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Several additional inter-related factors, which might potentially be influenced by 
availability and access to specialist clinics, deserve consideration.  
 
A delay to reaching a diagnosis of PD (underdiagnosis) is a known influence on 
incidence and prevalence, and the proportion of these undiagnosed cases can be estimated 
from screening studies. The Europarkinson collaborative combined data from 5 
community prevalence studies in France, Italy, Holland and Spain; 24% of 468 PD cases 
had not been previously diagnosed, within a 14 636 population aged 65 years and older 
(de Rijk et al. 1997). In Aberdeen, Scotland, community screening by postal 
questionnaire of 1556 patients over 65 years identified 2 new cases of PD (Taylor et al. 
2006a),  which is numerically consistent with the Europarkinson report. The number of 
undiagnosed cases in the community is therefore substantial, and gives a further 
opportunity for prevalence variation between different areas.  
 
Overdiagnosis of PD as benign tremor disorders occurred in 10-26% of cases in 
UK community studies (Meara, Bhowmick, & Hobson 1999;Schrag, Ben Shlomo, & 
Quinn 2002), leading the National Institute for Clinical Excellence to recommend that PD 
patients are seen and their diagnosis reviewed frequently in a movement disorder service 
( 2006). Specialist management of PD, or possible PD, is likely to differ from that in 
general practice. Both health service access and specialist clinic attendance rates were 
better for South Glasgow than South Lanarkshire. One explanation is that the South 
Lanarkshire cohort includes a higher proportion of misdiagnosed cases.  
 
The timing of initiating antiparkinson therapy is also subject to known variations. 
By depending on prescription of antiparkinson therapy to find PD cases, we did not 
include diagnosed patients not yet commenced on therapy (mainly because they have 
mild early disease without significant functional disability). This proportion is estimated 
at 10-20% (Mutch et al. 1986;Tandberg et al. 1995), but may decrease in future if 
evidence strengthens about benefits of early treatment (Grosset & Schapira 2008). 
Variation in clinical practice between areas could again influence prevalence rates, within 
this subset of cases of PD. 
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The incidence and prevalence figures obtained in this study are comparable with 
previous UK studies (Brewis et al. 1966;Sutcliffe et al. 1985;Sutcliffe & Meara 
1995;Schrag, Ben Shlomo, & Quinn 2000).  A recent review estimated the incidence of 
PD between 16-19 per 100,000 (Twelves et al. 2003). Using the year 2006 figure as the 
most representative in our study, the incidence of PD in the West of Scotland is 15.4 per 
100,000, close to the lower point of the range from these studies. We cannot determine 
whether the incidence of PD is increasing over time using our data; this would require an 
additional search on a further index date. Whilst the total population covered by the 92 
GP practices will fluctuate with births, deaths, immigration and emigration, the West of 
Scotland population is fairly static, with only a 0.5% increase from 1996 to 2006 
(General Register Office for Scotland 2008). Current migration from East Europe to the 
United Kingdom is much greater, however, and this might potentially influence the 
analysis of any repeated searches within our study population.   
 
Some previous pharmacy-based epidemiological studies have not stated clearly if 
they included PD only or extended to all forms of Parkinsonism. In a recent US study the 
authors concluded that administrative patient data were limited in the ability to 
distinguish between PD and Parkinsonism using ICD-9 codes and pharmacy data 
(Swarztrauber et al. 2005). In our study we estimated the prevalence and incidence of 
several parkinsonian syndromes, VP, DLB, PSP and MSA, based on full case record 
review. However, the use of prescription databases in epidemiological studies of atypical 
Parkinsonism is not established and it is likely that it‟s incidence and prevalence is 
underestimated in the current study. This is primarily because we initially identified 
patients taking antiparkinson therapy, and many patients with atypical Parkinsonism are 
not prescribed such therapy. For example, patients presenting with MSA in which 
cerebellar or autonomic features are dominant will often not be appropriate for 
antiparkinson therapy, and some patients in the later stages of MSA and PSP, who may 
initially have shown some response to antiparkinson therapy, will have such drugs 
stopped when the response wanes and/or they develop therapy-associated side-effects 
such as postural hypotension. It is therefore to be expected that our prevalence rate of 0.6 
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per 100,000 for MSA is lower than published rates of 1.9 – 4.9 per 100,000  (Schrag et al. 
1999;Vanacore 2005). The situation is similar for PSP, where we found a rate of 1.2 per 
100,000 while the prevalence is reported at 6.4 per 100,000 (Schrag, Ben Shlomo, & 
Quinn 1999). In addition, the role of antiparkinson therapy in patients with vascular 
Parkinsonism and drug-induced Parkinsonism is not clearly established, and it is likely 
that the prevalence of such diagnoses is larger than implied by our observations.    
 
Conclusion 
Prescription database searches of antiparkinson medications followed by case 
record review provide epidemiological data on PD and other parkinsonian syndromes, 
with greater accuracy than simply analysing data from pharmacy databases which often 
do not have diagnostic information. Variation in PD prevalence between geographical 
areas occurs, which is not explained by methodological differences. While there are 
differences between areas for risk factors for the development of PD, the magnitude of 
prevalence variation is great, and justifies more detailed research into the relative 
importance of several potential causes.  
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Figure 2.1: Indication for antiparkinson therapy within a population of 511 927 patients. 
The most common reason for using antiparkinson therapy was anticholinergic use in 
patients prescribed antipsychotic drugs. Most patients with a parkinsonian syndrome had 
Parkinson‟s disease. 
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Figure 2.2: Prevalence of Parkinson‟s disease by area and sex. There was a significant 
variation in prevalence across geographical areas, for both males and females, in 
particular comparing South Glasgow with South Lanarkshire. Prevalence is age-adjusted 
to the Scotland population, and shown as mean (95% confidence interval). 
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Figure 2.3: Prevalence of Parkinson‟s disease by age and sex. There was an age-related 
increase in prevalence for men and women. Prevalence is shown as mean (95% 
confidence interval). 
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Table 2.1: Antiparkinson medications included in database searches 
 
Levodopa + carbidopa or benserazide 
Co-beneldopa, Co-careldopa, Madopar, Sinemet 
 
Levodopa + carbidopa + catechol O-methyltransferase inhibitor 
Stalevo 
 
Dopamine agonists 
Apomorphine, Bromocriptine, Cabergoline, Lisuride, Pergolide, 
Pramipexole, Ropinirole 
 
Catechol O-methyltransferase inhibitors 
Entacapone, Tolcapone  
 
Monoamine oxidase-B inhibitor 
Selegiline, Rasagiline 
 
Anticholinergic drugs 
Benzatropine, Orphenadrine, Procyclidine, Trihexphenidyl 
hydrochloride 
 
Other 
Amantadine 
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Table 2.2: Populations studied by geographical area and sex 
 
Area Male Female 
Total  
(% over 65 years) 
South Glasgow 97 832  96 086  193 918 (13.9%) 
South Lanarkshire 101 468  106 209  207 677 (15.5%) 
East Dunbartonshire 32 433  31 044  63 477 (16.5%) 
West Dunbartonshire 22 904  23 951  46 855 (14.8%) 
ALL 254 637  257 290  511 927 (15.0%) 
 
 
 
Table 2.3: Prevalence of Parkinson‟s disease in different areas of west Scotland 
 
 Males Females 
Area Crude Age-adjusted Crude Age-adjusted 
South  
Glasgow 
88.9 
(70.2-107.6) 
98.3 
(78.7-117.9) 
81.2 
(63.2-99.2) 
83.9 
(65.6-102.2) 
South 
Lanarkshire 
177.4 
(151.5-203.3) 
202.7 
(175.0-230.4) 
132.8 
(110.9-154.7) 
151.1 
 (127.7-174.5) 
East 
Dunbartonshire 
144.9 
(103.5-186.3) 
146.3  
(104.7-187.9) 
103.1 
(67.4-138.8) 
108.4 
(71.8-145.0) 
West 
Dunbartonshire 
109.2 
(66.4-151.9) 
142.7  
(93.8-191.6) 
83.5  
(46.9-120.1) 
89.0  
(51.2-126.8) 
TOTAL 133.1  
(119.0-147.3) 
146.7  
(131.8-161.6) 
105.3  
(92.8-117.9) 
113.3  
(100.3-126.3) 
Prevalence expressed per 100 000; Data are mean (95% confidence intervals) 
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Table 2.4: Factors with potential influence on Parkinson‟s disease prevalence 
 
Area 
Cigarette 
smokers 
Education 
deprivation 
Health 
deprivation 
Access to 
services 
deprivation 
Persons 
per 
hectare 
South  
Glasgow 
34.0 43.9 49.0 0.1 28.9 
South 
Lanarkshire 
26.2 16.6 16.3 11.1 1.7 
East 
Dunbartonshire 
18.6 2.4 2.4 7.9 6.2 
West 
Dunbartonshire 
33.3 17.8 17.8 10.2 5.9 
Data expressed as percentages (except persons per hectare) 
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Table 2.5: Prevalence and incidence of parkinsonian syndromes 
 
Parkinsonian 
syndrome 
Crude 
prevalence (per 
100,000) 
Prevalence in 
over 65’s  (per 
100,000) 
Incidence in 
2006 (per 
100,000) 
Incidence for 
over 65’s for 
2006 (per 
100,000) 
All parkinsonian 
syndromes 
127.6 
(118.8 – 136.4) 
728.6 
(669.1 – 789.1) 
18.6 
(14.8 – 22.3) 
124.0 
(99.1 – 148.9) 
Parkinson‟s disease 119.2 
(110.4 – 128.0) 
676.4 
(619.1 – 734.7) 
15.4 
(12.0 – 18.8) 
107.1 
(80.4 – 125.9) 
Vascular parkinsonism 4.5 30.0 2.2 13.1 
Dementia with Lewy 
bodies 
1.6 10.4 0.4 2.6 
Progressive 
supranuclear palsy 
1.2 6.5 0.2 1.3 
Multiple system 
atrophy 
0.6 3.9 0.4 2.6 
Drug-induced 
parkinsonism 
0.2 2.6 0 0 
Post-encephalitic 
parkinsonism 
0.4 1.3 0 0 
95% confidence intervals are in brackets 
 
 
 36 
Table 2.6: Number of incident cases of parkinsonian syndromes per year 1996 – 2006 
 
Year 
Total 
PS PD VP DLB PSP MSA DIP 
1996 16 15 0 1 0 0 0 
1997 22 22 0 0 0 0 0 
1998 30 28 1 0 0 1 0 
1999 38 36 2 0 0 0 0 
2000 41 41 0 0 0 0 0 
2001 44 40 1 1 2 0 0 
2002 52 49 3 1 0 0 0 
2003 82 77 4 0 0 0 0 
2004 62 60 0 0 1 0 1 
2005 75 70 1 1 2 0 1 
2006 95 79 11 2 1 2 0 
Total 557 517 23 6 6 3 2 
 
Total PS = all patients with a parkinsonian syndrome, PD= Parkinson‟s disease, VP= 
vascular parkinsonism, DLB= dementia with Lewy bodies, PSP= progressive 
supranuclear palsy, MSA= Multiple system atrophy, DIP= drug-induced parkinsonism 
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CHAPTER 3 
COST ANALYSIS OF ANTIPARKINSON THERAPY IN WEST SCOTLAND: A 
COMMUNITY STUDY 
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Introduction 
Parkinson‟s disease (PD) is treated pharmacologically with a combination of 
Levodopa, dopamine agonists, monoamine oxidase B inhibitors and catechol O-
methyltransferase inhibitors. Drug therapy aims to improve PD symptoms, but does not 
alter the underlying pathological process. In early disease drug therapy can improve 
symptoms such as bradykinesia, rigidity, and to a lesser extent tremor. Not all patients are 
treated immediately on diagnosis.  The traditional approach to drug management in PD 
has been to wait until there is significant functional impairment resulting from movement 
disorder symptoms before commencing antiparkinson drugs. There are also patients with 
early disease who remain undiagnosed. However, with progression of symptoms over 
months to years the large majority of PD patients will come to medical attention and be 
commenced on life-long drug therapy. In later disease, drugs are used increasingly in 
combination regimens, to try to control the motor fluctuations associated with long-term 
Levodopa. 
 
With an ageing population, it is expected that the incidence and prevalence of PD 
will also increase (See Chapter 2). The cost of managing PD patients is significant and 
increases with disease severity (LePen et al. 1999;Findley et al. 2003). Patients require 
greater access to primary and secondary care services, including specialist PD out-patient 
clinics. Younger patients may suffer loss of earnings and older or more advanced patients 
may require nursing care (Whetten-Goldstein et al. 1997;Hagell et al. 2002).  A UK-
based study reported the mean cost of care for 432 PD patients at £5993 per year (Findley 
et al. 2003). This study assessed employment status, utilization of social services, private 
expenditure, and primary care and secondary care costs. Costs increased significantly 
with disease severity (as measured using Hoehn and Yahr staging), and the single biggest 
factor was whether or not the patient required nursing care. Antiparkinson medication 
accounted for 24% of the overall costs. Mean drug costs were lower with increasing age, 
being £3.87 per patient per day in the under 65 age-group, and £1.56 in the over 85 age-
group. The cost of antiparkinson drugs did not change significantly with increasing 
disease severity, and the authors suggested this may result from simplification of drug 
regimens with increasing disability, especially cognitive impairment.  
 39 
Many new drug preparations have become available over the past 10 years but 
there has been relatively little examination of the costs and influences of antiparkinson 
drug prescription. Typically within the UK patients are commenced on a single 
antiparkinson drug. With clinical disease progression, the dose of this drug is increased 
and other drugs are added.  
 
A 2006 study compared the antiparkinson drug costs for a cohort of 286 German  
and 152 Norwegian PD patients attending a specialist PD clinic (Vossius et al. 2006). 
Both groups were comparable for age, disease duration and stage of disease. Mean daily 
drug costs were Euro 5.78 in the German group and Euro 3.92 in the Norwegian group, 
with higher drug expense with disease severity and duration.  The difference in costs 
between the two groups was explained by two factors: that antiparkinson drugs are 
around 20% more expensive in Germany and that there was greater prescription of 
multiple drugs at an earlier disease stage within the German group (48% of the 
Norwegian group were on antiparkinson monotherapy compared to 28% of the German 
group).  
 
A further study from Germany analysed antiparkinson medication from 6,500 PD 
patients who responded to a questionnaire addressing sudden onset of sleep from the 
deutsche Parkinson-Vereinigung (dPV), a national PD support group (Moller et al. 2005).  
94.2% of patients were prescribed Levodopa, 71.7% dopamine agonists, 40.1% 
Amantadine, 27.6% Selegiline, 20.4% Entcapone, 11.8% anticholinergics whilst only 14 
(0.21%) patients were prescribed subcutaneous Apomorphine. The mean daily drug cost 
per patient was Euro 13.10 and only 8.4% of patients were treated with monotherapy 
rather than a combination of antiparkinson drugs. 
 
A French study reported the medical costs of 294 PD patients (LePen et al. 1999). 
54 (18%) patients were managed by their GP and 240 (82%) attended a Neurology out-
patient clinic. The mean daily drug cost was Euro 2.83 per patient. Costs were higher in 
older patients and those with greater disease severity, motor complications, and in those 
patients who attended a Neurology clinic. A retrospective analysis of 127 Swedish PD 
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patients attending a movement disorder clinic found a mean daily drug cost of Euro 3.90 
(Hagell et al. 2002). A German clinic-based report of 409 PD patients reported a daily 
drug cost of Euro 5.50 (Dodel et al. 1998). This study found that drug costs were higher 
in those patients with motor complications and with the akinetic-rigid subtype of PD.  
Within the European studies there is therefore a wide variation in mean daily cost of 
antiparkinson therapies (Euro 2.83 - 9.10). 
 
As part of the larger study described in Chapters 2 and 4, in which the main aim 
was antiparkinson therapy withdrawal in patients erroneously diagnosed as PD, detailed 
information was obtained about antiparkinson drug doses, from which cost calculations 
could be made. It was also possible to relate drug usage to demographic factors, such as 
duration of the diagnosis. The following were the main aims of the current work:  
 To examine the pattern and cost of antiparkinson drug prescription within a 
primary care setting  in the UK 
 To identify factors that influence choice of antiparkinson drug therapy in this 
group 
 
Methods 
 Prescription databases within 92 GP practices within 5 West Scotland Community 
Health Partnerships were searched for all patients prescribed antiparkinson medications 
(See Table 2.1) between December 2006 and August 2007. The case records for all 
patients prescribed antiparkinson drugs were reviewed and all those prescribed therapy 
for conditions other than PD were excluded from analysis. 
 
 Information recorded included age, sex, time since PD diagnosis, current 
antiparkinson drug prescription and specialist clinic attendance. Movement disorder 
clinics only were considered as specialist clinics; neurology and general medicine clinics 
were considered as non-specialist clinics; patients without attendance for their PD at any 
hospital clinic were defined as primary care cases. 
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The cost of antiparkinson medications was calculated according to basic National 
Health Service prices, as listed in the British National Formulary (British Medical 
Association 2006). Doses of dopaminergic medication were compared using Levodopa 
equivalents (LE) (Grosset et al. 2004) (eg. 100 mg Levodopa =1 mg Pergolide = 1.5 mg 
Pramipexole salt = 6 mg Ropinirole = 1.5 mg Cabergoline). 
 
Statistical Analysis 
  Data for the cost of antiparkinson medications was not normally distributed and 
showed a positive skew and was therefore summarised as median and interquartile range. 
Drug costs between different groups were compared using unpaired t-tests and one-way 
ANOVA; proportions of patients prescribed different medications were compared using 
chi-squared contingency tables.  
 
Results 
 Out of a total population of 511 927, 610 patients were prescribed medications for 
PD. The total daily cost of these antiparkinson drugs for all patients was £1665.58. The 
median daily cost per patient was £0.79 (interquartile range: £0.34 to £3.76). The 
maximum daily cost for an individual patient was £31.38. Levodopa was prescribed in 
543 patients (89.0%) at a median daily cost of £0.44 (£0.26 to £0.97). Levodopa 
accounted for 32.0% of the total cost of antiparkinson medications. However, over 50% 
of the total cost of Levodopa resulted from the prescription of Stalevo (a combination of 
Levodopa and Entacapone) in 94 of 610 patients (15.4%). 
 
175 of 610 patients (28.7%) were prescribed a dopamine agonist at a median daily 
cost of £5.83 (£3.70 to £7.74). The cumulative cost of all dopamine agonists accounted 
for 63.4% of the total cost of antiparkinson medications. The two dopamine agonists 
prescribed most commonly were Ropinirole and Pramipexole. 98 of 610 patients (16.1%) 
were prescribed Ropinirole at a median daily cost of £5.83 (£4.50 to £7.52) and 57 
patients (9.3%) were prescribed Pramipexole at a median daily cost of £5.89 (£1.85 to 
£7.74). 
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380 of 610 patients (62.3%) were prescribed one antiparkinson drug (ie. 
monotherapy); 154 (25.2%) were on a combination of 2 drugs; 63 (10.3%) on 3 drugs; 12 
(2.0%) on 3 drugs and 1 (0.2%) patient on 5 drugs.  
 
 The most expensive antiparkinson drugs used were Apomorphine and 
Cabergoline with respective median daily costs of £8.04 (£3.66 to £16.08) and £8.30 
(£4.15 to £10.67) (see Table 3.1). Apomorphine was prescribed for 8 (1.3%) patients and 
Cabergoline for 12 (2.0%) patients. The cheapest drugs were Selegiline (£0.12/day, £0.12 
to £0.15) and Amantadine (£0.60/day, £0.30 to £0.90). Only 21 patients (3.4%) were 
treated with anticholinergic drugs and only 5 patients (0.8%) were treated with the 
relatively new monoamine oxidase B inhibitor Rasagiline. None of the patients studied 
were prescribed Tolcapone. 
 
355 of 610 patients (58.2%) had current attendance at a specialist clinic; 74 
(12.1%) had current attendance at a non-specialist clinic (40 of 74 (54.1%) at neurology 
and 34 of 74 (45.9%) at general medical clinics); 161 (26.4%) did not currently attend a 
clinic; 45 (7.4%) had previously attended a clinic but had no on-going clinic attendance; 
115 (18.9%) had never attended a clinic; and clinic attendance was unknown for 19 
(3.3%) (See Table 3.2). Patients currently attending a clinic (either specialist or non-
specialist) were significantly younger than those who had never attended a clinic (74.4 
years (67.7 to 80.2) versus 80.1 years (74.3 to 85.5), p<0.0001). A greater proportion of 
patients with current attendance at a clinic were male compared with those who had never 
attended a clinic (252 of 429, 58.7% versus 55 of 115, 47.8%, p<0.05).  Patients 
attending a clinic were prescribed a significantly higher dose of dopaminergic 
medications than those not attending a clinic (400 LE (300 to 658) versus 300 LE (150 to 
400), p<0.0001).  
 
The median daily cost of antiparkinson medication was greatest for patients who 
had previously attended a clinic but had no on-going clinic attendance (£2.77, £0.65 to 
£5.15) and lowest for those who had never attended a clinic (£0.48, £0.26 to £2.90). 
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Daily medication cost was significantly lower for patients who had never attended a 
clinic compared with those who had current attendance (£0.89 (£0.34 to £3.85), p<0.05). 
 
Significantly more patients who had never attended a hospital clinic for PD 
management were prescribed antiparkinson monotherapy (either Levodopa, or a 
dopamine agonist, or a monoamine oxidase-B inhibitor, or an anticholinergic) compared 
with those who had attended a clinic (either currently or previously) (84 of 115, 73.0% 
versus 283 of 475, 59.6%, p<0.01). The percentage of patients prescribed monotherapy 
according to the duration of diagnosis is shown in Figure 3.1. The proportion on 
monotherapy was higher in patients who had never attended a hospital clinic throughout 
the first 10 years following the PD diagnosis, but slightly lower at more than 10 years 
following diagnosis. All patients prescribed Apomorphine, Bromocriptine, Pergolide or 
Rasagiline had current attendance at a specialist clinic.  
 
 The median daily cost of antiparkinson medications was £0.74 (£0.34 to £3.82) 
for males and £0.85 (£0.34 to £3.70) for females, but this difference was not significant 
(p=0.77). The proportion of patients treated with monotherapy, Levodopa or dopamine 
agonists did not differ significantly between males and females. 
 
 Median drug cost per day varied with duration of PD diagnosis (See Figure 3.2). 
164 of 610 (26.9%) patients had been diagnosed with PD within the past 2 years. The 
median daily cost of antiparkinson medication for patients 0-2 years since diagnosis was 
£0.67 (£0.34 to £5.04). The median daily cost peaked at £1.41 (£0.37 to £3.84) for 
patients 4 - 6 years since diagnosis and expenditure decreased thereafter. This change in 
costs over time was not significant (p= 0.46). 
 
The proportion of patients prescribed either Levodopa or a dopamine agonist is 
shown against disease duration in Figure 3.3. Since dopamine agonists are significantly 
more expensive than Levodopa, and the proportion of patients prescribed Levodopa 
gradually increases with disease duration, while the proportion of patients prescribed 
dopamine agonists is highest in earlier disease, the total daily cost of antiparkinson 
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medication did not increase with disease duration. 82 of 88 (93.2%) patients more than 10 
years since diagnosis were prescribed Levodopa, while the prescription of dopamine 
agonists peaked at 38% in patients 2-4 years since diagnosis and declined to 22% in 
patients with PD for more than 10 years.   
 
 The median daily cost of antiparkinson drugs was greater for patients aged under 
70 years compared with those aged 70 years and over, but this difference was not 
statistically different (£1.36 (£0.35 to £5.18) versus £0.67 (£0.34 to £3.49), p=0.07). 
However, there were significantly more patients under 70 years prescribed dopamine 
agonists (54 of 157, 34.4%) when compared with patients 70 years or over (122 of 453, 
26.9%) (p<0.05).  
 
Discussion 
The greatest factor affecting antiparkinson drug prescription was whether patients 
were managed in hospital out-patient clinics or primary care. The daily cost of 
antiparkinson medication was significantly higher for patients who attended any clinic 
(either currently or previously) compared with patients who had never attended a clinic. 
The highest proportion of patients prescribed Levodopa monotherapy was in those who 
had never attended a specialist clinic. This is important as current best clinical practice is 
to limit doses of Levodopa in order to delay motor complications (eg. dyskinesia) and 
instead to support Levodopa with adjunct drugs. 27% of patients who had never been 
assessed in a hospital clinic for PD were treated with more than one antiparkinson 
medication compared with 41% of patients with current attendance at a specialist clinic. 
Although patients attending specialist clinics were prescribed significantly higher overall 
daily doses of dopaminergic medications (by 150mg Levodopa equivalents) this was 
largely through Levodopa sparing strategies. Whether patients not seen in clinics are 
treated optimally cannot be concluded from the current study, since the clinical status of 
the patient influences the referral decision, ie. patients were not randomised to clinic 
attendance, and baseline clinical factors are not balanced between clinical attenders and 
non-attenders. An additional potential confounding factor is a higher misdiagnosis rate 
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within primary care (see Chapter 4), which will be a further influence on choice of 
treatment and dose escalation rates.  
 
 The highest daily cost of antiparkinson medication and the greatest proportion of 
patients prescribed more than one dopaminergic drug was found in patients who had 
previously attended a clinic but were currently managed in primary care. Disease 
duration was also longest for this group. It seems most likely that this subset of patients is 
discharged back to their GP in an advanced state after therapy has been maximised, and it 
is considered that additional drug treatments will not provide added benefit.   
 
 Some factors that influenced whether patients were managed in a hospital clinic 
or in primary care were identified. Significantly more male patients had current hospital 
clinic attendance than female patients although this overall gender difference was not 
apparent when considering specialist clinic attendance. This observation was not 
explained by a greater proportion of male patients with other concurrent diagnoses. 
Patients never seen in a clinic were significantly older (by around 6 years) than patients 
who had been seen in a clinic (either currently or previously). In addition, almost 20% 
more patients under 70 years had current clinic attendance compared with those 70 years 
and older.  
 
Increased overall costs with more advanced disease  (eg. measured with the 
Hoehn and Yahr scale) are well documented (Rubenstein et al. 1997;Dodel et al. 
1997;LePen et al. 1999). We found an increased daily antiparkinson drug cost in the first 
6 years following diagnosis, but that costs were thereafter lower. The only other study to 
observe lower costs in more advanced disease was also UK-based (Findley et al. 2003). 
In the current study we found that fewer patients with longer disease duration were 
prescribed dopamine agonists and this was the major reason for the lower cost. This study 
did not examine the reasons for this difference in prescription, but this may result from 
dopamine agonists being withdrawn in some cases because of poor tolerance of higher 
doses, co-morbid disease or the simplification of drug regimens with increased cognitive 
 46 
impairment. Alternatively, drug choices may be changing over time such that more 
recently diagnosed patients are more likely to receive dopamine agonist therapy. 
 
None of the patients studied were prescribed Tolcapone, an inhibitor of catechol 
O-methyltransferase (COMT). COMT inhibitors increase „on‟ time and reduce „off‟ time 
in patients with motor complications (Lees 2008). Tolcapone was approved for treatment 
of PD in 1997, but was later withdrawn following 3 cases of fatal hepatotoxicity and 1 
case of reversible severe liver injury that were attributed to the drug (Olanow & Watkins 
2007). After the safety data were reviewed the drug was re-introduced with regular 
monitoring of liver function tests: every 2 weeks for the first year, every 4 weeks for the 
next 6 months and every 8 weeks thereafter. It is possible that these regular blood tests 
were felt to be an inconvenience for the patient and their doctor, especially when such 
monitoring was not necessary with Entacapone, another COMT inhibitor. However, there 
is some evidence that Tolcapone has greater efficacy than Entacapone with a meta-
analysis of 14 studies demonstrating that the mean difference in increased „on‟ time state 
for Tolcapone-treated patients was twice that in Entacapone-treated patients (Deane et al. 
2004). 
 
 There are surprisingly little UK data on medication costs in PD, but other 
European studies report varied costs. These studies all used the mean daily cost of 
antiparkinson medication per patient to summarise drug costs. In the current study, the 
antiparkinson medication costs were significantly positively skewed, resulting in wide 
interquartile ranges, and the mean drug cost was over 3 times higher (£2.73) than the 
median drug cost (£0.79). Fluctuations in currency exchange rate make cost comparisons 
difficult, but using the current rate (£1.00 = Euro 1.22, 20/06/2008) this is equivalent to a 
mean cost of Euro 3.33 per day. This approximates to the reported costs from a 
Norwegian study and is less than 2 German groups (Moller et al. 2005;Vossius et al. 
2006). In the current study 62% of patients were treated with antiparkinson monotherapy, 
which compares with 48% of patients in Norway and between 8% and 28% across the 2 
German studies. This is in keeping with known policies in some other European countries 
to combine lower doses of different antiparkinson drugs from a much earlier disease 
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stage (Vossius et al. 2006). However, there may have been some selection bias in these 
European studies with all patients in one of the German studies and the Norwegian study 
attending specialist clinics, and all the patients responding to a national PD support group 
questionnaire in the other German study, while our study is inclusive of all patients 
within participating general practices.  
 
We found that 29% of patients were prescribed dopamine agonists. These findings 
are very similar to the 30% from Norway and 31% from Sweden  (Hagell et al. 
2002;Vossius et al. 2006).  In contrast, in the two German cohorts 55 and 61% received 
dopamine agonists, of which a higher proportions were prescribed older ergot-derived 
dopamine agents such as Bromocriptine, Cabergoline, Lisuride and Pergolide (Dodel et 
al. 1998). The German costs are high despite greater use of ergot-derived agonists such as 
Bromocriptine and Pergolide, both of which are off-patent and therefore less expensive. 
Further, the additional drug safety monitoring for these agents would increase associated 
costs.  
 
Newer therapies such as subcutaneous apomorphine and intra-jejunal Levodopa 
(Duodopa) aim to provide continuous dopaminergic stimulation and are proving effective 
in managing the motor complications of advanced disease. These therapies are costly and 
likely to make managing advanced disease more expensive in the future. Duodopa has 
only recently been licensed and it was not surprising that it had not been prescribed in 
any of the patients studied. There are no studies to date reporting the proportion of 
patients for whom it may become appropriate. In our study 8 patients (1.3% of 610) were  
were prescribed subcutaneous Apomorphine, which was  significantly greater than the 14 
of 6500 (0.21%) reported in a German group (p<0.001) (Moller et al. 2005).  
 
Conclusion 
The most influential factor affecting antiparkinson medication prescription is 
whether the patients attended a hospital clinic or were managed within primary care. 
Patients attending hospital clinics were younger and a greater proportion were male, but 
were not different in other respects. This may reflect a biased delivery of, or variable 
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access to, specialist services across the areas studied and deserves to be examined further 
across a wider population with greater attention to individual reasons for medication 
prescription (initiation and discontinuation). Patients attending hospital clinics for 
Parkinson‟s disease are more likely to be prescribed more than 1 antiparkinson 
medication, at higher doses and at greater cost than patients managed in primary care.     
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Table 3.1: Cost of antiparkinson medication in 610 patients  
 
  No. of 
patients 
% of 
patients 
Median cost per patient 
per day on drug (£) 
% of total 
costs 
Levodopa-based 
All levodopa-based 
drugs 
543 89.0 0.35 32.0 
Stalevo 94 15.4 2.90 16.5 
Dopamine agonist 
Apomorphine 8 1.3 8.04 5.2 
Bromocriptine 2 0.3 1.45 0.2 
Cabergoline 12 2.0 8.30 5.9 
Ropinirole 98 16.1 5.83 34.9 
Pergolide 1 0.2 1.66 0.1 
Pramipexole 57 9.3 5.89 17.3 
All dopamine 
agonists 
176 28.9 5.83 63.4 
COMT inhibitors 
Entacapone 24 3.9 0.60 0.9 
Monoamine oxidase inhibitors 
Selegiline 45 7.4 0.12 0.9 
Rasagiline 5 0.8 2.53 0.8 
Anticholinergics 
All anticholinergics 21 3.4 0.75 1.3 
Other 
Amantadine 20 3.3 0.60 0.6 
Total 610 100 0.79 100 
 
Note – some patients were prescribed a combination of Madopar, Sinemet and Stalevo; and 2 patients were 
prescribed an oral dopamine agonist in addition to Apomorphine. 
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Table 3.2: Demographic and disease characteristics of 610 patients on antiparkinson 
therapy, according to clinic attendance. 
 
Current clinic 
attendance 
(specialist and 
non-specialist) 
Current 
specialist 
clinic 
attendance 
Current non-
specialist 
clinic 
attendance 
Previous clinic 
attendance 
Never attended 
a  clinic 
Unknown 
clinic 
attendance All patients 
Number of 
patients 
428 354 74 47 116 19 610 
Age in years 74.4  
(67.7 to 80.2) 
74.5  
(67.9 to 80.2) 
73.6  
(65.4 to 79.9) 
77.7  
(70.9 to 82.3) 
80.1  
(74.3 to 85.5) 
77.1  
(70.7 to 82.4) 
76.0  
(69.7 to 81.6) 
Male 58.7% 57.7% 63.5% 51.1% 47.8% 45.0% 55.6% 
Disease 
duration in 
years 
4.1  
(1.7 to 7.8) 
4.3  
(2.0 to 8.1) 
2.8  
(0.9 to 4.7) 
6.0  
(3.5 to 12.6) 
4.6  
(2.0 to 7.3) 
2.0  
(0.75 to 5.9) 
4.1  
(1.7 to 7.9) 
 
Anti-PD drug 
intake in 
LE/day 
400  
(300 to 658) 
450  
(300 to 697) 
328  
(285 to 520) 
400  
(280 to 420) 
300  
(150 to 400) 
320  
(200 to 505) 
400  
(260 to 568) 
Prescribed 
monotherapy 
60.6% 59.2% 67.6% 48.9% 73.0% 65.0% 62.3% 
Daily cost of 
anti-PD drugs 
(£) 
0.89  
(0.34 to 3.85) 
0.96  
(0.34 to 3.86) 
0.63  
(0.34 to 3.80) 
2.77  
(0.65 to 5.15) 
0.48  
(0.26 to 2.90) 
0.35  
(0.24 to 3.74) 
0.79  
(0.34 to 3.77) 
 
Data are expressed as median (interquartile range) or percentage 
PD = Parkinson‟s disease, LE = Levodopa equivalents 
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Figure 3.1: Proportion of patients prescribed antiparkinson monotherapy according to 
clinic attendance. A higher proportion of non-clinic attenders were prescribed 
monotherapy, compared to clinic attenders (either current or previous), for all disease 
durations except over 10 years.  
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Figure 3.2: Daily cost of antiparkinson medication according to disease duration. The 
median cost for patients 0-2 years since diagnosis was £0.67 (£0.34 to £5.04), peaked at 
£1.41 (£0.37 to £3.84) for patients 4-6 years since diagnosis, and decreased thereafter. 
Summary data are median and interquartile range. 
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PD = Parkinson‟s disease; L-dopa = Levodopa; DA = Dopamine agonist 
 
Figure 3.3: Proportion of patients prescribed Levodopa and dopamine agonists against 
disease duration. The percentage of patients prescribed Levodopa increased from 88% <2 
years since diagnosis and peaked at 95% 8-10 years following diagnosis. The percentage 
of patients prescribed dopamine agonist drugs is 30% <2 years since diagnosis, peaked at 
38% at 2-4 years and decreased to 22% at 8-10 years. 
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CHAPTER 4 
MEDICATION WITHDRAWAL IN PATIENTS WHO DO NOT BENEFIT FROM 
ANTIPARKINSON MEDICATION 
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Introduction 
 Parkinson‟s disease (PD) is the second most common neurodegenerative 
condition and is traditionally characterised by bradykinesia, resting tremor, muscular 
rigidity and postural instability. Accurate diagnosis of parkinsonian syndromes is 
fundamental for prognostic and therapeutic reasons and is also essential in 
epidemiological studies and clinical trials. In many cases the clinical diagnosis of PD is 
straightforward. However, a series of clinicopathological studies suggested that the 
positive predictive value of a clinical diagnosis of PD was 76 – 91% (Rajput, Rozdilsky, 
& Rajput 1991a;Hughes et al. 1992a;Hughes et al. 1992b;Hughes et al. 2002) and 
accuracy was greatest with diagnostic re-evaluation over time, the use of strict criteria, 
and assessment within a specialist movement disorder service. The most widely accepted 
clinical diagnostic criteria for PD are the UK Brain Bank criteria (Gibb & Lees 1989) and 
these are based on the correlation of clinical symptoms and neuropathology (Hughes, 
Daniel, & Lees 2001b) (See Appendix 4.1). There are 3 steps: (1) diagnosis of 
Parkinsonism, (2) exclusion of other parkinsonian syndromes, and (3) identification of 
supportive clinical features. 
 
 NICE guidelines for the management of PD within primary and secondary care 
recognise diagnostic difficulties, recommending that patients with suspected PD should 
be referred quickly for a specialist opinion and that the diagnosis should be reviewed at 
6-12 month intervals ( 2006). 
 
Recent advances in functional imaging have improved diagnosis of parkinsonian 
syndromes. Dopamine transporter (DAT) imaging using single photon emission 
computerised tomography (SPECT) allows an indirect measure of dopaminergic neuronal 
degeneration. DAT-SPECT demonstrates reduced striatal uptake of the radioligand (eg. 
FP-CIT, β-CIT, TRODAT) in patients with degenerative Parkinsonism, such as PD, 
progressive supranuclear palsy (PSP), multiple system atrophy (MSA) and corticobasal 
degeneration. DAT-SPECT is abnormal even in early PD and striatal uptake  correlates 
with disease duration and motor severity (Benamer et al. 2000b). DAT imaging is normal 
in patients with essential tremor (Asenbaum et al. 1998;Benamer et al. 2000a), and drug-
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induced (Booij et al. 2001) as well as psychogenic Parkinsonism (Tolosa et al. 
2003;Marshall & Grosset 2003a). 
 
 Misdiagnosis of PD is also recognised in randomised clinical trials. Between 1.4 
and 15% of patients in 3 large studies had normal DAT imaging (The Parkinson Study 
Group 2002;Whone et al. 2003;Seibyl et al. 2004;Fahn et al. 2004). There is also 
evidence of significant diagnostic re-evaluation within 2 UK-based community studies. 
Meara and colleagues identified 502 patients on antiparkinson therapy for PD within 74 
GP practices in North Wales (Meara, Bhowmick, & Hobson 1999), and clinically 
assessed 402. There was evidence of Parkinsonism in 299 patients (74%), with only 213 
(53%) fulfilling Brain Bank criteria. Revised diagnoses were essential tremor (48%), 
vascular Parkinsonism (36%) and Alzheimer‟s disease (16%). 
 
 A study of 15 GP practices within central London assessed 131 patients with a PD 
diagnosis (Schrag, Ben Shlomo, & Quinn 2002). 109 of 131 patients (83%) met Brain 
Bank criteria, 2 patients (1.5%) were diagnosed as possible PD and the diagnosis was 
rejected in 20 patients (15%). Revised diagnoses in this group comprised 4 patients with 
non-parkinsonian tremor (essential tremor or dystonic tremor), 6 patients with vascular 
Parkinsonism, 4 patients with progressive supranuclear palsy (PSP), 3 patients with 
multiple system atrophy (MSA), 1 patient with idiopathic torsion dystonia and 1 patient 
with dementia without Parkinsonism. 
 
We know that diagnostic accuracy in PD is improved when the patient is followed 
clinically over time. Excellent and prolonged clinical response to Levodopa and a history 
of disease progression over time are key features of PD (step 3 of Brain bank criteria for 
PD). With disease and symptom progression the dose of Levodopa (and other 
antiparkinson medication) is likely to increase over time. Therefore if there is either no 
recorded progression of symptoms over years within clinical records, a record of a poor 
clinical response to antiparkinson medication, poor compliance with medications (which 
may indicate a lack of clinical response), or no increase in the dose of medication over 
time, the diagnosis of PD may be incorrect. 
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 Studies that re-evaluated the clinical diagnosis of PD show that misdiagnosis is a 
significant problem across primary and secondary care. Patients with a non-parkinsonian 
diagnosis are unlikely to derive benefit from antiparkinson medications. However, few 
studies report therapy withdrawal in this patient group; in one single study of 11 selected 
patients in a specialist clinic, antiparkinson medication withdrawal was successful in 11 
patients, all of whom had normal FP-CIT SPECT imaging (Marshall et al. 2006). These 
patients had clinical features of Parkinsonism, carried a diagnosis of PD and have been 
termed “subjects with scans without evidence of dopaminergic deficit” or SWEDDs. 
Patients had a median follow-up period of 3 years and no clinical deterioration was noted 
following medication withdrawal. 
 
The present study was undertaken to examine these issues in greater detail, with 
larger patient numbers and on a community basis, in order to quantify the problem of 
diagnostic error and inappropriate antiparkinson drug treatment in clinical practice. The 
study objectives and endpoints were defined at baseline, and were as follows: 
 
Primary and secondary objectives 
Primary objective: To identify patients within the community who do not benefit from 
antiparkinson medications and to supervise and clinically monitor the withdrawal of 
therapy in this patient group. 
Secondary objective: To develop objective criteria for identification of patients taking 
antiparkinson medication in whom therapy can be withdrawn without clinical 
deterioration.  
 
Primary and secondary endpoints 
Primary endpoint:  The proportion of patients successfully withdrawn from 
antiparkinson therapy expressed as a percentage of patients taking such therapy for PD. 
Secondary endpoint: The difference in the proportion of patients in whom antiparkinson 
therapy is successfully withdrawn comparing those identified using specified criteria with 
matched controls of patients taking antiparkinson therapy who do not meet criteria. 
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Ethical considerations 
 This study was given multi-region ethical approval by the West Glasgow Ethics 
Committee in September 2006. Local ethics approval was then obtained from Primary 
Care for Greater Glasgow and Clyde and Lanarkshire.  
 
Methods 
All GP practices within the individual following Community Health Partnerships 
(CHP) were invited to participate in this study: South West Glasgow, South East 
Glasgow, South Lanarkshire, East Dunbartonshire and West Dunbartonshire.   
 
Step 1: Practice-based prescription database search and case note review 
Within participating GP practices searches of prescription databases were 
performed to identify all patients prescribed antiparkinson medications. A search for each 
drug was made using generic and trade names (See Table 2.1) at all available doses in 
both new and repeat prescriptions. Case record review was then undertaken for all 
identified patients, to find the underlying diagnosis leading to the drug prescription. 
Patients who were prescribed dopaminergic or anticholinergic medication for a non-PD 
diagnosis were excluded from further analysis (eg. dopamine agonists for pituitary 
tumours and restless legs syndrome; Levodopa for dopa-responsive dystonia; 
Amantadine for multiple sclerosis; anticholinergic medication for Huntington‟s disease 
and in patients prescribed neuroleptic medications). 
 
The following information was recorded for each patient with a PD diagnosis, based on 
the review of the case record and prescription database:  
 Relevant past medical and surgical history  
 Current antiparkinson prescription 
 Antiparkinson prescription 3 years preceding search date 
 Date of diagnosis of PD  
 Current or previous attendance at a hospital clinic for the PD diagnosis 
(and whether general or specialist movement disorder) 
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 Pharmacy refill data for antiparkinson drugs during the preceding 6 
months (observed doses divided by expected doses, expressed as a 
percentage, where 
o observed= total dose obtained by the patient, using prescriptions 
which were issued in the time period, and 
o expected= total dose according to drug charting) 
 Current and past drug history, including prescription of dopamine 
depleting drugs (eg. Metoclopramide, Prochlorperazine and neuroleptics) 
 Documented evidence of clinical disease progression within GP notes or 
out-patient clinic letters 
 
Step 2 – Selection for specialist out-patient review  
 Following case record review, patients prescribed antiparkinson medications for a 
PD diagnosis who met any of the selection criteria listed below were then invited for out-
patient assessment: 
 Treatment of PD with monotherapy for >5 years 
 Low doses of antiparkinson therapy for >3 years (defined as daily doses within 
the initial starting range as described in the British National Formulary – doses up 
to and including - Levodopa 150mg, Ropinirole 3mg, Pramipexole base 0.54mg, 
Cabergoline 1mg, Bromocriptine 1.5mg, Selegiline 10mg) 
 No increase (defined as either increase in drug dose or addition of a further agent) 
in antiparkinson therapy over 3 years preceding the search date 
 Pharmacy refill of <60% during 6 months preceding the search date 
 No clinical progression documented  
 Documented lack of clinical response to antiparkinson therapy 
 Co-prescription of dopamine receptor antagonist, suggestive of possible drug-
induced Parkinsonism 
 
The following served as exclusion criteria: 
 Significant co-morbidities (eg. metastatic carcinoma or end-stage cardiac, renal or 
liver disease) 
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 Documented cognitive impairment 
 Duration of antiparkinson therapy <1 year 
 Patient in nursing home or housebound 
 
Step 3 – Specialist out-patient review 
 At out-patient review history focussed on progression of movement disorder 
symptoms and clinical response to antiparkinson medication. „Wearing off‟ symptoms 
and response to antiparkinson medication was assessed using a 7-point motor fluctuation 
questionnaire (See Appendix 4.2). The patient was examined by 2 neurologists. The 
patients were then scored by a PD nurse specialist (blinded to the clinicians‟ clinical 
suspicion) on the Unified PD rating scale (UPDRS) parts 1 – 6 (Movement Disorder 
Society Task Force on Rating Scales for Parkinson's Disease 2003). The nurse specialist 
was certified for scoring patients using the UPDRS scale, based on a standard training 
video (Goetz & Stebbins 2004). 
 
The diagnosis was based on UK Brain Bank criteria. If both neurologists agreed 
that the clinical diagnosis was PD the patient was offered follow-up in the routine 
movement disorder clinic and had no further role within the study. If both neurologists 
agreed that the patient was unlikely to have degenerative Parkinsonism, the patient was 
consented for gradual reduction and cessation of antiparkinson medication under 
supervision: these patients formed the intention to treat (ITT) group. Diagnostic revision 
and plans for medication withdrawal were discussed with the patients with sensitivity to 
previous diagnosis and management. The patient‟s clinician was involved in the process 
and given the opportunity to exclude the patient from the study if they were aware of 
adverse clinical issues which would be affected by the patient being involved.   
  
In clinically uncertain cases FP-CIT SPECT imaging was requested to determine 
whether there was degenerative Parkinsonism and guide the decision on medication 
withdrawal. Alternative diagnoses were made according to established criteria and 
definitions: essential tremor (ET) (Bain et al. 2000); vascular Parkinsonism (VP)  
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(Zijlmans et al. 2004);   dystonic tremor (DT) (Schneider et al. 2007);  or indeterminate 
tremor (Deuschl et al. 1998). 
 
Step 4 – Therapy withdrawal and follow-up 
Patients who consented to medication withdrawal were given an individual 
protocol, which was detailed in writing to them and their GPs. Medications were reduced 
at a rate of 50mg every 2 weeks for Levodopa and 20-30% of total prescribed dose every 
2 weeks for dopamine agonists. Therapy withdrawal rates were based on previously 
reported figures (Marshall et al. 2006) and were designed to minimise the risk of 
Parkinsonism-hyperpyrexia syndrome (PHS). 
 
Consenting patients were given contact details for the research team. Patients 
were warned that there might be worsening of their movement disorder symptoms 
following medication withdrawal and were advised to contact the research team if there 
was any change in symptoms. The research team gave telephone advice and expedited 
out-patient appointments as necessary. If there was worsening of movement disorder 
symptoms following medication withdrawal, these drugs were promptly re-introduced. 
 
Patients were followed up in 2-3 subsequent clinics over 6-9 months with full 
clinical assessment by 2 neurologists and repeat scoring on the UPDRS scale by the same 
PD nurse specialist (who remains blinded to whether medication had been withdrawn). 
Patients able to successfully withdraw antiparkinson medication without clinical 
deterioration constituted the per protocol (PP) group. 
 
 Assessment of the control group 
 Control group patients were identified from step 1 and had all been prescribed 
antiparkinson medication for a PD diagnosis. Control patients did not meet either the 
selection criteria, or the exclusion criteria described in step 2. Controls were matched to 
those patients assessed in step 3 for sex, age (±5 years) and time since diagnosis of PD 
(±3 years). Control patients were then invited for out-patient clinic assessment. Control 
group patients underwent the clinical assessment described in step 3 for active patients. If 
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a control patient was diagnosed as unlikely to have degenerative Parkinsonism, therapy 
withdrawal under supervision, again following the same procedure as active patients, was 
offered.  
 
Results 
 92 of 120 (77%) GP practices contacted agreed to participate. Searches of 
prescription databases and case record review within participating practices were 
completed during December 2006 to August 2007. The total population covered by 92 
GP practices was 511,927 (49.5% male, 50.5% female).  
 
Patients with a Parkinson‟s disease diagnosis 
610 patients (55.6% male, 44.4% female) taking antiparkinson medications for a 
PD diagnosis were identified. 428 of 610 (70.2%) patients regularly attended a hospital 
out-patient clinic for their PD: 354 (58.0%) a specialist movement disorder clinic and 74 
(12.1%) a non-specialist clinic (general medical or general neurology). 47 of 610 (7.7%) 
had previously attended a specialist clinic but had no on-going clinic attendance for their 
PD. 116 of 610 (19.0%) had never attended a hospital clinic, and clinic attendance was 
unknown for 19 of 610 (3.1%). 
 
Patients identified by selection criteria 
89 of 610 (14.6%) fulfilled step 2 of the selection criteria and were invited for 
out-patient assessment. 64 of these 89 (71.9%) patients (33 male, 31 female) meeting 
selection criteria were assessed, either in an out-patient clinic or at home. The mean age 
of patients assessed was 76.3 years (SD 5.0) and mean time since PD diagnosis was 7.0 
years (SD 5.0). 16 of 64 (25%) attended a specialist movement disorder clinic and 3 of 64 
(4.7%) a non-specialist clinic. Clinical findings of patients assessed within the study 
group are detailed within Table 4.3. 
 
Following clinical assessment (Step 3) there was clinical diagnostic uncertainty in 
25 of 64 (39.1%) patients and FP-CIT SPECT imaging was performed in each of these 
cases. 10 of these 25 (40%) patients demonstrated reduced striatal uptake of FP-CIT, in 
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keeping with a diagnosis of degenerative Parkinsonism, while 14 (56%) patients had 
normal uptake, effectively excluding degenerative Parkinsonism. In the remaining one 
case, the scan was initially reported as abnormal but this was later amended to normal by 
the reporting clinician.  
 
The diagnostic breakdown for patients meeting selection criteria and control 
group patients is in Table 4.1. Following initial assessment of patients meeting selection 
criteria (including FP-CIT SPECT imaging), 25 of 64 patients (39.1%) were considered 
to have PD. These patients were all offered routine follow-up within a movement 
disorder clinic. The ITT group comprised 39 patients, or 60.9% of the 64 patients who 
attended for assessment.  
 
The revised diagnoses made in the ITT group were as follows: 15 essential 
tremor; 12 VP; 5 indeterminate tremor; 3 dystonic tremor; 3 drug-induced Parkinsonism; 
and 1 gait ignition apraxia.  
 
Antiparkinson medication withdrawal 
Antiparkinson medication withdrawal was discussed with all ITT patients. 36 of 
the 39 (92.3%) consented to therapy withdrawal under supervision. 1 patient declined 
supervised therapy withdrawal due to ill health, while 2 patients declined in case their 
movement disorder symptoms would worsen.   
 
Patients who consented to therapy withdrawal were followed up for a mean of 8.2 
months (SD 2.3 months).  1 patient initially consented to therapy withdrawal but 
withdrew consent after 3 months. 2 of 35 patients (5.7%) who reduced and stopped 
antiparkinson medication described deterioration in their movement disorder symptoms, 
and had an increase (worsening) in UPDRS part 3 of 16 and 17 points. The baseline 
diagnoses for these patients (prior to therapy withdrawal) were essential tremor and 
vascular Parkinsonism. Both patients experienced worsening of symptoms at 3 months 
following medication withdrawal. FP-CIT SPECT imaging was subsequently undertaken 
and proved abnormal in both cases. Antiparkinson medications were re-introduced in 
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both cases with resultant symptomatic improvement. The final diagnosis in both cases 
was PD.  
 
33 of 35 patients (94.3%) successfully reduced and stopped antiparkinson 
medications without significant deterioration in UPDRS part 3 scores at serial follow-up 
appointments. The mean change in UPDRS part 3 scores between initial and final 
assessment in this group was an improvement of 2.2 points (95% CI: improvement of 0.5 
to 3.8 points).  
 
Patients who completed successful antiparkinson medication withdrawal (n= 33) 
had a mean motor fluctuation questionnaire score of 0.42 out of 7 (SD 1.0) compared 
with 0.69 out of 7 (SD 1.4) for patients who were confirmed as having PD (n=25). This 
difference was not significant (p=0.38). 
 
At the time of writing therapy withdrawal has not been discussed with the patient 
whose FP-CIT SPECT scan result was changed from abnormal to normal.  
 
Control group and remaining patients 
97 patients were invited for assessment as part of the control group. 64 of 97 
(66.0%) agreed to clinical assessment. The reasons for 33 of 97 control patients not 
agreeing were: non-response to invitation (n=20), too unwell (n=8) and unwilling (n=5). 
61 of 64 (95.3%) of the control group patients assessed were considered to have PD 
following assessment. FP-CIT SPECT scanning was performed in 4 of 64 (6.3%) patients 
in whom there was clinical uncertainty. 3 of 4 scans (75%) demonstrated normal striatal 
uptake of the radioligand. 2 of 3 (66.7%) of these patients were diagnosed as ET and 1 of 
3 (33.3%) was diagnosed as VP. All 3 patients consented to gradual therapy withdrawal 
under supervision and completed this without significant deterioration in movement 
disorder symptoms or change in UPDRS part 3 score, with a mean deterioration of 0.7 
points (95% CI: deterioration of 4.5 to improvement of 3.1 points). 1 of 4 (25%) patients 
had abnormal DAT SPECT imaging and this patient was considered to have PD.  
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The criteria described in step 2 of the methods identified a significantly higher 
proportion of patients with a non-PD diagnosis, compared with the control group (odds 
ratio 16.0 (95% confidence interval 5.2 – 49.2), p<0.0001). 
 
In addition to the cases identified through the above processes (ITT and control 
patients), further patients were re-diagnosed as not having PD, during the period in which 
the study was performed. Within the 610 patients identified by searches of prescription 
databases with GP practices, 3 patients were identified by the investigators in routine out-
patient clinics as demonstrating clinical features which were not in keeping with a PD 
diagnosis. All three patients were attending a specialist movement disorder clinic and 
described a poor clinical response to antiparkinson medication and little progression of 
symptoms over time. However, none of these patients had fulfilled criteria for step 2 of 
the selection criteria. Clinical findings for these 3 patients are detailed in Appendix 4.4. 
FP-CIT SPECT scanning was normal in all 3 cases. 2 patients were diagnosed as 
essential tremor and 1 as VP. Antiparkinson medication was successfully withdrawn in 
all 3 patients without significant change in UPDRS part 3 score, with mean improvement 
of 2.3 points (95% CI: deterioration of 7.7 to improvement of 12.4 points). 
 
Overall therapy withdrawal rates 
The total number of patients in whom antiparkinson medication was successfully 
withdrawn (including patients meeting selection criteria, control group patients, and 
routine care patients) was 39 of 610 patients (6.4%). 17 of 39 (43.6%) were male and the 
mean age was 75.0 years (SD 8.9) (See Table 4.2). 25 of 39 (64.1%) had no current 
attendance at a specialist clinic and the mean time since diagnosis of PD was 6.8 years 
(SD 5.6). The mean time since PD diagnosis was longer for patient with no specialist 
clinic attendance (8.6 compared with 3.5 years, p<0.005), but there was no significant 
difference in age between the two groups (P=0.71). The total annual cost of antiparkinson 
medication for these 39 patients was £41,800. 
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Prevalence of inaccurate Parkinson‟s disease diagnosis 
The total number of patients within the 610 with a non-PD diagnosis can be 
estimated from:  
(a) 33 of 64 respondents (52%) in the active group who successfully stopped 
antiparkinson therapy. In the remaining 25 cases meeting selection criteria (but not 
responding to the invitation to study participation), assuming the same diagnostic 52% 
error rate, an additional 13 cases would exist. However, if the proportion of non-
respondent patients who did not have PD was only 26% (ie. half that of the respondents) 
the additional case numbers who did not have PD would be reduced to six.    
(b) The proportion of patients successfully stopping antiparkinson therapy within 
the control group (3/64, 4.7%) scaled up to the remaining 457 patients not meeting 
selection criteria, giving an additional 21 patients. 
 
The range for the total number of cases who did not have PD amongst the 610 
study population is therefore as follows: 
(i) lower estimate: 63 (or 10.3%) (derived from 33+6=39 from (a) above, plus 21 
from (b) above)  
(ii) upper estimate: 70 (or 11.5%) (adding 7 cases from (i) above).  
 
See Table 4.5 for tests of the selection criteria using these upper and lower 
estimates. 
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Discussion 
 
 In keeping with previous UK studies, this report indicates significant 
misdiagnosis of PD within the community. Diagnosis of PD can be difficult, but some 
cases of PD misdiagnosis are avoidable and diagnosis should be re-evaluated over time, 
preferably within a specialist clinic.  
 
Reduction and cessation of antiparkinson medications is not without risk: 
movement disorder symptoms may worsen and in rare cases the patient may develop 
PHS, characterised by Parkinsonism, hyperpyrexia and autonomic changes. There is also 
a theoretical risk of PHS in patients who do not have degenerative Parkinsonism, 
although there are no cases in the literature describing this. Our findings suggest that 
supervised medication withdrawal is safe in patients thought to have an alternative 
diagnosis (further details are in chapter 6).  
 
The most common alternative diagnoses found in this series were ET and VP, in 
keeping with previous community studies (Meara, Bhowmick, & Hobson 1999;Schrag, 
Ben Shlomo, & Quinn 2002). It may be difficult to clinically differentiate between 
benign tremor disorders and early PD, and FP-CIT SPECT may be useful in such cases 
(Benamer et al. 2000a). There was no clinical deterioration following medication 
withdrawal in any of the 21 patients with normal FP-CIT SPECT scans. The role of FP-
CIT SPECT in facilitating the diagnosis of PD has been previously established (Scherfler 
et al. 2007). Dopamine transporter (DAT) imaging is abnormal in early degenerative 
Parkinsonism and its main role is in early differentiation between with isolated tremor 
symptoms not fulfilling PD or essential tremor criteria, drug-induced, psychogenic and 
vascular Parkinsonism as well as dementia with Lewy bodies. However, the mean time 
since initial PD diagnosis in the 32 patients who underwent FP-CIT SPECT in this series 
was 6.2 years (SD 4.7) suggesting that SPECT scanning also has a later diagnostic role in 
patients whose clinical features of PD are not clinically progressing over time as expected 
(See Chapter 5). This application of the test would likely decline over time as prevalent 
cases are tested, although there remains significant potential for this application as the 
rate of such scanning in new patients is low in many centres. 
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It has been suggested that there is a role for dopaminergic therapy in VP with 
doses of up to 1000mg/day Levodopa recommended. There is little evidence to support 
such high doses and in practice it may be difficult as patients experience dopaminergic 
side-effects such as nausea, confusion and postural hypotension. In one retrospective 
series of patients with pathologically confirmed VP, 12 of 17 reported an excellent 
clinical response to Levodopa (mean dose: 450mg/day; range: 100 – 1000mg/day) 
(Zijlmans et al. 2004). 3 of 17 patients in this series showed no response to Levodopa 
(300 - 400mg/day) and presumably were not able to escalate this dose further. All of the 
patients in the current study considered to have VP indicated little or no clinical response 
to Levodopa when assessed on the motor fluctuation scale. These patients were 
prescribed a mean of 275 Levodopa equivalents per day (SD 145) and there was no 
clinical deterioration following therapy withdrawal. It is possible that patients may have 
experienced symptomatic improvement at higher Levodopa doses, but this had not been 
undertaken clinically and was not attempted in this study.  
 
The selection criteria described were effective at identifying misdiagnosed 
patients, with 16 times the likelihood of stopping antiparkinson therapy after fulfilling 
selection criteria compared to randomly selected patients. In practical terms, the current 
study required clinical assessment of 64 cases identified by selection criteria, while 576 
cases selected at random would need to be assessed to achieve the same number of cases 
successfully stopping antiparkinson therapy. However, identification of further 
misdiagnosed cases (among those not fulfilling selection criteria) from the remainder of 
546 patients within the control group and from the out-patient clinic (identified outwith 
study procedures) suggests that the criteria were unable to identify all misdiagnosed 
cases. These observations are reflected in the criteria having an estimated specificity 
exceeding 90% while sensitivity was only 62 to 66%. The main culprit amongst the 
exclusion criteria of step 2, for patients identified as not having PD, was an increased 
antiparkinson dose over time exceeding that specified. A greater number of misdiagnosed 
cases would be identified by assessing all 610 patients, but this would be far more labour 
intensive. We consider the selection criteria as defined to be the most appropriate starting 
point for testing in further populations; specific attention to the rate of dose escalation of 
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antiparkinson drugs would be appropriate, to determine whether a different threshold 
value improved case ascertainment. 
 
Screening for misdiagnosis in PD and the supervised withdrawal of antiparkinson 
medication meets many of World Health Organisation (WHO) principles for a screening 
programme (Wilson & Jungner 1968). Usually sensitivity, specificity, predictive values 
and likelihood ratios are measures of the effectiveness of a diagnostic test in identifying a 
disease and are commonly applied to screening programmes. In this instance we used 
these measures to assess the value of the selection criteria in identifying misdiagnosis (or 
lack) of PD. These estimates made certain assumptions, namely that there would be 
further misdiagnosed cases within the patients meeting criteria who did not agree to 
clinical assessment, and that the 64 control group patients assessed were representative of 
the remaining cases. Whether these assumptions are accurate requires testing in a further 
population; in particular there may be variation in the rate of therapy withdrawal in 
control subjects, as the confidence interval is wide for only 3 patients within the 64 
control subjects.  
 
 2 of 36 patients within the ITT group deteriorated clinically following medication 
withdrawal. Both cases subsequently had abnormal FP-CIT SPECT scanning and were 
re-diagnosed as PD. At initial assessment neither patient fulfilled Brain Bank criteria. 
This reinforces the evidence that the clinical diagnosis of PD can be problematic, even 
with the rigorous specialist assessment of a strict research protocol. However, the clinical 
deterioration was recognised early in both patients and was reversed without long-term 
sequelae. 
 
The present study suggests that step 3 of Brain Bank criteria is not applied 
rigorously in routine clinical practice. The presence of one or more of the key factors had 
not alerted the treating clinician to diagnostic reconsideration. We deliberately omitted 
patients taking antiparkinson therapy for less than one year, since we considered the 
approach of a trial of antiparkinson therapy (as a diagnostic adjunct) much less likely 
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after this time. Moreover, we did not identify a single case of intercurrent therapy 
withdrawal occurring because of diagnostic reconsideration, outwith the processes of the 
study and its investigators. These observations collectively suggest that „routine‟ 
diagnostic revision and treatment cessation is a rare event in clinical practice, for patients 
diagnosed as PD and established on antiparkinson treatment for more than a year. 
 
The estimated total number of misdiagnosed cases within the study population 
was between 63 and 70 of 610 (10.3 to 11.5%). This compares with rates between 15 and 
26% in previous UK-based community studies (Meara, Bhowmick, & Hobson 
1999;Schrag, Ben Shlomo, & Quinn 2002) and 1.4 – 15% within the randomised 
controlled trials (Fahn 1999;Parkinson Study Group 2000;Whone et al. 2003;Seibyl et al. 
2004). In the 39 patients successfully withdrawn from antiparkinson medications in the 
current study the mean time since PD diagnosis was 6.8 years. In the 2 previous UK-
based community studies, the time since PD diagnosis was not declared. However, given 
that these studies were also cross-sectional, the average disease duration would also be 
expected to be at least 5 years. The much higher diagnostic error rate in the community 
studies, including the current study, compared to clinical trials, at a much later average 
duration since diagnosis, suggests that the patient population and diagnostic process 
differ, eg. selection criteria, frequency of review and proportion of specialist 
involvement. 
 
It is for these reasons that the National Institute for Clinical Excellence 
emphasises that the diagnosis of PD may be difficult and recommends that all patients 
with a suspected  diagnosis of PD attend a specialist clinic and that individual diagnoses 
are reviewed every 6 months ( 2006). Whilst we found a significant proportion of patients 
on therapy for PD not attending a specialist clinic, misdiagnosis amongst patients 
attending a clinic was significant, being 41% of the 39 patients in whom antiparkinson 
medications were successfully withdrawn. This demonstrates that it remains important 
for the PD diagnosis to be questioned over time in patients attending clinics. In those 
patients in whom antiparkinson drugs were successfully withdrawn who were attending 
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clinics, we did not specifically examine case records for evidence that the diagnosis was 
reconsidered at review assessments. However, by implication the absence of a record of 
disease progression, good therapy response, and increase in antiparkinson medication 
over time suggested that the process of diagnostic reassessment was not evident. A higher 
proportion of patients in the control group were attending a hospital clinic compared with 
the study group. This difference resulted from fulfilment of the selection criteria by the 
active patient group, since such patients were more likely to be non-clinic attenders. 
Whether the diagnostic error rate, and ability to stop antiparkinson therapy, would be 
greater in controls matched for clinic attendance, is not known, but again would be worth 
testing in further research.  
 
Antiparkinson medications, especially dopamine agonists, are expensive. The 
annual cost of antiparkinson medications in patients who underwent successful therapy 
withdrawal in this series was £48,200 per year. The cumulative drug costs are much 
higher given the long duration of diagnosis and treatment. This cost must be offset 
against the study costs including medical, nursing and clerical personnel and the cost of 
FP-CIT SPECT scanning. The total cost of carrying out this study was £53,000 (FP-CIT 
SPECT: £19,200; new and return out-patient assessment: £28,200; clerical assistance: 
£5,000). There are also additional costs (return clinic appointments and increasing 
antiparkinson medications) for assessing patients previously managed by their GP. The 
cost of antiparkinson medication in patients misdiagnosed as PD (who do not gain 
benefit) represents a significant governance issue. Without this study, many patients in 
whom antiparkinson medications were successfully withdrawn may have stayed on these 
drugs for years, with the associated costs and potential of side-effects and drug 
interactions. A full cost-benefit analysis of this process was beyond the scope of the 
current work, but the outline data suggest that cost-savings would at least partially offset 
process costs (many of which are non-recurrent), particularly if similar results could be 
achieved outwith a full research protocol. 
 
It is interesting to note that no patients identified in the study were rediagnosed as 
a Parkinson plus syndrome (eg. PSP and MSA).  Brain bank studies have suggested that 
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this is the most common cause of misdiagnosis within the specialist clinic (Hughes et al. 
1992b;Hughes et al. 2002). However, there is selection bias in patients coming to post-
mortem examination and the criteria used here would not readily identify such patients 
because they have more rapid disease progression, and would likely have antiparkinson 
dose escalation. Further, control numbers were small to identify these rarer diagnoses. 
 
Conclusion 
 This community study demonstrates that patients are often labelled as Parkinson‟s 
disease when the underlying diagnosis is essential tremor or vascular Parkinsonism. 
These patients can be identified from searches of prescription databases and GP case 
records, and can undergo supervised withdrawal of antiparkinson medications safely. 
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Table 4.1: Final diagnosis of patients in study and control groups 
 
 STUDY (N=64) CONTROL (N=64) 
Degenerative Parkinsonism 
Parkinson‟s disease 26 (40.6%) 61 (95.3%) 
Non- Parkinson’s disease diagnosis 
Essential tremor 15 (23.4 %) 2 (3.1%) 
Vascular Parkinsonism 11 (17.2%) 1 (1.6%) 
Drug-induced Parkinsonism 3 (4.7%) 0 
Dystonic tremor 3 (4.7%) 0 
Indeterminate tremor 5 (7.8%) 0 
Gait ignition apraxia 1 (1.6%) 0 
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Table 4.2: Clinical features in 39 patients successfully withdrawn from antiparkinson 
medication, according to clinic attendance 
 
Type of clinic 
attendance 
Number 
of cases 
(%) 
Percentage 
male 
Age  in 
years 
Years 
since PD 
diagnosis 
Antiparkinson 
medication dose 
in Levodopa 
equivalents/day 
Specialist 
clinic 
14 
(35.9%) 
21.4% 76.3 
(6.6) 
3.5     
(1.9) 
200                
(171) 
Non-specialist 
clinic 
1  
(2.6%) 
0% 
 
86.9 5.0 400 
No clinic 
attendance 
24 
(61.5%) 
58% 73.8 
(9.8) 
8.8     
(6.3) 
302               
(253) 
All patients 39 43.6% 75.0 
(8.9) 
6.8     
(5.6) 
268               
(227) 
Data are mean (standard deviation) unless otherwise specified 
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Table 4.3: Clinical features of 64 patients meeting selection criteria for the study and 
undergoing clinical assessment 
 
Patient 
number /  
age (yrs) / 
sex 
Time since 
PD 
diagnosis 
(yrs) Clinical features 
Antiparkinson 
medication 
(doses per day) 
FP-CIT 
SPECT 
Preliminary 
diagnosis 
Final 
diagnosis 
1/63/F 12.0 Mild hypophonia and hypomimia; jaw tremor; 
moderate right hand and leg rest tremor; 
rigidity at neck and in upper limbs; mild 
bilateral bradykinesia; mild stoop; short 
steppage gait 
Pramipexole 
2.8mg 
Abnormal PD  
2/84/F 6.1 Mild resting, postural and kinetic tremor both 
hands; no rigidity or bradykinesia; mild stoop; 
preserved arm swing 
Levodopa 
400mg 
Not done ET  
3/84/M 2.9 No tremor, rigidity or bradykinesia; stooped, 
mild postural instability, hesitant gait 
Levodopa 
200mg 
Not done Gait apraxia  
4/86/F 5.0 Rest, postural and kinetic tremor of hands, no 
bradykinesia or rigidity, stooped, shuffling 
gait, postural instability 
Levodopa 
400mg 
Not done ET  
5/80/M 5.8 Mild hypomimia; mild right-sided rest and 
postural tremor; no rigidity or bradykinesia; 
stooped; gait slow with loss of arm swing 
Pramipexole 
0.804mg; 
Procyclidine 
15mg 
Abnormal VP PD 
6/72/F 1.5 Resting and postural tremor of hands; no 
rigidity or bradykinesia; mild stoop; slowed 
gait 
Levodopa 
70mg 
Abnormal ET PD 
7/64/M 1.6 Rest, postural and kinetic tremor of hands, no 
rigidity or bradykinesia; slowed gait 
Pramipexole 
0.264mg 
Abnormal PD  
8/75/M 4.0 Hypomimia and hypophonia; chin tremor; rest 
tremor of hands; moderate limb rigidity; 
marked bilateral bradykinesia; stooped; short 
steppage gait with loss of arm swing 
Levodopa 
500mg 
Not done PD  
9/77/F 9.3 Hypophonia and hypomimia; jaw tremor; 
moderate rest tremor right hand and leg; 
increased tone in limbs; moderate 
asymmetrical bradykinesia; stooped; short 
steppage gait with loss of arm swing 
Orphenadrine 
100mg 
Not done PD  
10/74/M 5.7 Hypomimia and hypophonia; mild rest tremor 
of right hand; bilateral postural tremor of 
arms; no rigidity; moderate bilateral 
bradykinesia; stooped; short steppage gait with 
loss of arm swing 
Levodopa 
600mg 
Abnormal PD  
11/83/F 3.6 Rest and postural tremor of hands; mild left 
leg rigidity; no bradykinesia 
Levodopa 
280mg 
Not done ET  
12/69/M 10.1 Postural and kinetic tremor of arms; no 
rigidity or bradykinesia; mild postural 
instability 
Levodopa 
150mg 
Not done ET  
13/83/F 2.1 Hypomimia and hypophonia; resting, postural 
and kinetic tremor; mild rigidity right arm; 
mild asymmetrical bradykinesia; stooped; 
short steppage gait with loss of arm swing 
 
Procyclidine 
15mg 
Not done PD  
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14/77/F 3.5 Hypomimia and hypophonia; rest tremor both 
hands and right leg; postural tremor right arm;  
Levodopa 
200mg 
Not done PD  
15/84/F 8.0 Cognitive impairment; jaw tremor; bilateral 
rest, postural and kinetic tremor of arms; no 
rigidity or bradykinesia 
Levodopa 
280mg 
Not done ET  
16/56/M 12.4 Postural and kinetic tremor of arms; increased 
tone at neck and in right arm no bradykinesia; 
mild stoop 
Levodopa 
150mg 
Normal DT  
17/86/M 5.2 Hypomimia and hypophonia; rest tremor right 
hand, right leg and left leg; postural tremor 
right arm; symmetrical moderate bradykinesia; 
stooped; shuffling gait with freezing and loss 
of arm 
Levodopa 
200mg 
Not done PD  
18/86/M 4.4 Hypomimia and hypophonia; chin tremor; 
increased tone right arm, right leg and left leg; 
moderate asymmetrical bradykinesia; stooped; 
short steppage gait with reduced arm swing 
Levodopa 
520mg 
Not done PD  
19/90/F 8.6 Mild hypomimia; rest tremor right leg; 
increased tone limbs; mild bilateral 
bradykinesia; short steppage gait with 
preserved arm swing 
Levodopa 
300mg 
Abnormal PD  
20/69/F 10.2 Hypomimia and hypophonia; postural tremor 
of arms; increased tone all limbs; moderate 
bilateral bradykinesia; stooped 
Levodopa 
520mg 
Not done PD  
21/70/M 7.2 Bilateral kinetic tremor arms; no rigidity or 
bradykinesia; mild stoop; gait slowed 
Levodopa 
100mg 
Not done Indeterminate 
tremor 
 
22/71/F 3.9 Jaw tremor; rest, postural and kinetic tremor of 
arms; no bradykinesia or rigidity; mild stoop 
Levodopa 
100mg 
Not done ET  
23/78/M 15.2 „No-no‟ head tremor; jaw tremor; bilateral rest 
tremor of hands; marked bilateral postural and 
kinetic tremor of arms; increased tone at neck; 
no bradykinesia; mild stoop; mild postural 
instability 
Levodopa 
300mg; 
Selegiline 
10mg 
Normal ET  
24/80/M 9.6 Hypomimia and hypophonia; dyskinetic 
movements of limbs; bilateral postural tremor 
of arms; mild rigidity; moderate asymmetrical 
bradykinesia; stooped; shuffling gait with 
reduced arm swing 
Levodopa 
700mg 
Not done PD  
25/84/M 7.8 Postural and kinetic tremor both arms; 
pyramidal weakness right arm and leg; 
stooped; gait slowed; mild postural instability, 
Levodopa 
400mg 
Not done ET  
26/45/M 1.4 Rest, postural and kinetic tremor of arms; no 
rigidity or bradykinesia 
Levodopa 
70mg 
Not done ET  
27/65/F 2.1 Postural and kinetic tremor arms; increased 
tone lower limbs; no bradykinesia; stooped; 
reduced arm swing 
Pramipexole 
0.54mg 
Normal VP  
28/75/F 3.9 Jaw tremor; mild rest and postural tremor of 
arms; no bradykinesia; tone increased at neck; 
posture stooped; gait slowed with reduced 
bilateral arm swing 
Pramipexole 
2.1mg 
Normal VP  
29/80/F 2.1 Rest, postural and kinetic tremor of arms; mild 
rigidity in upper limbs; no bradykinesia; short 
steppage gait with reduced arm swing; 
moderate postural instability 
Levodopa 
300mg 
Abnormal PD  
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30/86/F 6.4 Vocal and chin tremor; mild bilateral rest and 
postural tremor of arms; no rigidity or 
bradykinesia; stooped; gait slowed with 
reduced arm swing 
Levodopa 
150mg 
Not done VP  
31/84/M 9.5 Hypophonia; chin tremor; rest and postural 
tremor of arms; increased tone at neck and in 
limbs; moderate asymmetrical bradykinesia; 
stooped 
Levodopa 
420mg 
Not done PD  
32/72/M 4.0 Moderate hypophonia and hypomimia; jaw 
tremor; bilateral resting tremor of hands; 
bilateral postural tremor of arms; mild 
symmetrical bradykinesia; stooped; shuffling 
gait with bilateral loss of arm swing 
Levodopa 
600mg; 
Selegiline 
10mg 
Normal Drug-induced 
Parkinsonism 
 
33/75/M 7.1 Hypomimia; postural and kinetic tremor of 
arms; rigidity at neck; no bradykinesia; 
stooped; slow gait with reduced arm swing 
Levodopa 
100mg; 
Pramipexole 
2.1mg 
Abnormal PD  
34/64/M 4.5 „Yes-yes‟ head tremor; postural and kinetic 
tremor of arms; rigidity in lower limbs; no 
bradykinesia; stooped; short steppage gait with 
reduced arm swing 
Levodopa 
300mg 
Not done VP  
35/76/M 4.3 Hypophonia and hypomimia; chin tremor; 
mild neck and left arm rigidity; moderate 
asymmetrical bradykinesia; stooped; short 
steppage gait with reduced arm swing 
Levodopa 
300mg 
Abnormal PD  
36/77/M 6.5 Hypophonia; dyskinetic movements of neck 
and limbs; moderate limb rigidity; moderate 
asymmetrical bradykinesia; stooped; short 
steppage gait with loss of arm swing 
Levodopa 
750mg; 
Entacapone 
600mg 
Not done PD  
37/62/M 8.9 Hypophonia and hypomimia; rest tremor left 
hand; postural tremor of arms; neck and limb 
rigidity; marked asymmetrical bradykinesia; 
stooped; short steppage gait with loss of arm 
swing 
Levodopa 
540mg 
Not done PD  
38/71/M 10.7 Mild hypophonia and hypomania; chin tremor; 
moderate rest tremor both hands; increased 
tone at neck and in limbs; moderate 
symmetrical bradykinesia; stooped 
Levodopa 
1260mg 
Normal Drug-induced 
Parkinsonism 
 
39/79/M 7.7 Rest tremor both hands and left leg; postural 
and kinetic tremor of arms; increased tone in 
limbs; moderate asymmetrical bradykinesia; 
stooped; short steppage gait with frequent 
freezing and loss of arm swing 
Levodopa 
420mg 
Not done PD  
40/82/F 4.8 Cognitive impairment; rest tremor right hand; 
bilateral postural and kinetic tremor of arms; 
no bradykinesia; difficulty standing; stooped; 
mild postural instability 
Levodopa 
400mg 
Normal VP  
41/79/F 5.7 Chin tremor; rest and postural tremor of left 
arm; no bradykinesia; stooped; Gait slowed 
with reduced arm swing 
Pramipexole 
1.08mg 
Not done Indeterminate 
tremor 
 
42/79/M 2.7 Hypomimia and hypophonia; jaw tremor; rest 
tremor left hand; rigidity at neck and in limbs; 
marked bilateral bradykinesia; stooped; short 
steppage gait with reduced arm swing 
 
 
Levodopa 
300mg; 
Entacapone 
600mg 
Not done PD  
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43/71/F 2.0 Mild hypomimia and hypophonia; jaw tremor; 
moderate rest tremor all 4 limbs; moderate 
bilateral bradykinesia; mild stoop; slow gait 
with reduced arm swing 
Pramipexole 
0.264mg 
Normal Drug-induced 
Parkinsonism 
 
44/74/F 3.9 Mild rest tremor right hand; bilateral postural 
and kinetic tremor arms; no rigidity or 
bradykinesia 
Levodopa 
400mg 
Not done ET  
45/75/M 5.4 Mild hypomimia; dyskinetic movements of 
limbs; jaw tremor; intermittent rest tremor 
right hand; moderate postural tremor of arms; 
increased tone at neck; no bradykinesia; mild 
stoop; reduced right-sided arm swing 
Levodopa 
300mg; 
Ropinirole 
15mg 
Abnormal PD  
46/87/F 6.0 Jaw tremor; rest tremor left hand and both 
legs; mild postural tremor of arms; mild 
asymmetrical bradykinesia; stooped; short 
steppage gait with absent arm swing 
Levodopa 
150mg 
Not done PD  
47/87/F 4.2 „No-no‟ head tremor; bilateral postural and 
kinetic tremor of arms; no rigidity or 
bradykinesia 
Levodopa 
100mg 
Not done ET  
48/73/M 6.1 Mild rest tremor left hand; bilateral postural 
and kinetic tremor of arms; no rigidity or 
bradykinesia 
Levodopa 
100mg 
Not done ET  
49/79/F 24.7 Intermittent „no-no‟ head tremor; mild 
bilateral postural and kinetic tremor of arms; 
no rigidity or bradykinesia; slowed gait with 
preserved arm swing 
Levodopa 
300mg 
Not done ET  
50/72/M 2.0 Dysarthria and expressive dysphasia; right-
sided pyramidal weakness of arm and leg; 
increased tone at neck and in right arm and 
leg; no bradykinesia; stooped  
Levodopa 
150mg 
Not done Indeterminate 
tremor 
 
51/56/M 11.8 Dysarthria; bilateral postural tremor of arms; 
no rigidity or bradykinesia; mild stoop 
Levodopa 
200mg 
Not done Indeterminate 
tremor 
 
52/81/M 4.5 Mild bilateral rest tremor of hands; bilateral 
postural and kinetic tremor of arms; increased 
tone at neck; no bradykinesia; stooped; slowed 
gait with preserved arm swing 
Levodopa 
300mg 
Not done DT  
53/81/M 6.9 Bilateral postural and kinetic tremor; tone 
increased at the neck; no bradykinesia; mild 
stoop 
Levodopa 
400mg 
Not done DT  
54/76/M 5.7 Mild dysarthria; hypomimia; no tremor; 
rigidity in all limbs; symmetrical bradykinesia; 
stooped; unsteady gait 
Levodopa 
400mg 
Normal VP  
55/80/M 18.7 Jaw tremor; rest tremor right hand; bilateral 
postural and kinetic tremor of arms; no rigidity 
or bradykinesia; mild stoop 
Levodopa 
300mg 
Not done Indeterminate 
tremor 
 
56/72/F 8.7 „No-no‟ head tremor; bilateral rest tremor of 
hands; moderate bilateral postural tremor of 
arms; mild bilateral bradykinesia; stooped; 
gait slow with reduced arm swing 
Levodopa 
50mg 
Normal VP  
57/74/F 5.2 „No-no‟ head tremor; intermittent rest tremor 
both hands; bilateral postural and kinetic 
tremor; bilateral bradykinesia; markedly 
stooped; gait slow with loss of arm swing 
 
Levodopa 
200mg 
Normal VP  
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58/77/F 23.3 Rest, postural and kinetic tremor of arms; 
increased tone at neck and in limbs; mild 
symmetrical bradykinesia; stooped; slowed 
gait with reduced arm swing 
Levodopa 
200mg; 
Bromocriptine 
30mg 
Abnormal PD  
59/82/F 6.4 Mild hypomimia; jaw tremor; rest, postural 
and kinetic tremor of arms; increased tone at 
neck; mild symmetrical bradykinesia; stooped; 
slowed gait with reduced arm swing 
Levodopa 
300mg 
Abnormal PD  
60/76/M 5.4 Mild hypomimia and hypophonia; rest tremor 
both hands; increased tone at neck and in right 
arm; moderate symmetrical bradykinesia; 
stooped; short steppage gait with reduced arm 
swing 
Levodopa 
400mg 
Not done PD  
61/77/F 8.1 „No-no‟ head tremor; jaw tremor; rest tremor 
both hands; bilateral postural and kinetic 
tremor; mild left-sided bradykinesia; moderate 
stoop; preserved arm swing 
Levodopa 
300mg 
Normal VP  
62/72/F 8.4 Rest tremor left hand; bilateral postural tremor 
of arms; increased tone at the neck; mild 
bilateral bradykinesia; stooped; slow, unsteady 
gait 
Levodopa 
300g/day 
Normal VP  
63/84/F 23.2 „No-no‟ head tremor; rest tremor right arm and 
leg; postural and kinetic tremor of arms; 
increased tone at neck; no bradykinesia; 
stooped; slow and unsteady gait; marked 
postural instability 
Levodopa 
400mg 
Not done VP  
64/84/F 4.9 Dyskinetic movements of neck and limbs; 
postural and kinetic tremor of arms; increased 
tone at neck; moderate symmetrical 
bradykinesia; mild stoop; slowed gait with 
reduced arm swing 
Levodopa 
560mg 
Not done PD  
PD= Parkinson‟s disease; DT= dystonic tremor; ET= essential tremor; VP= vascular Parkinsonism 
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Table 4.4: Clinical features of 3 patients identified in routine out-patient clinics who 
successfully underwent supervised antiparkinson medication withdrawal 
 
Patient 
number / 
age (yrs)/ 
sex 
Time 
since PD 
diagnosis 
(yrs) Clinical features 
Antiparkinson 
medications 
(doses per day) 
FP-CIT 
SPECT Diagnosis 
1/75/F 1.9 Jaw and „no-no‟ head tremor; bilateral rest 
tremor  of hands; postural and kinetic 
tremor of outstretched arms; rigidity at 
neck; moderate symmetrical bradykinesia; 
stooped; unsteady gait with loss of arm 
swing 
Levodopa 
400mg; 
Entacapone 
800mg 
Normal VP 
2/74/M 6.7 No rest tremor; bilateral postural and 
kinetic tremor of outstretched arms; no 
rigidity or bradykinesia; gait normal with 
preserved arm swing 
Pramipexole 
1.08mg 
Normal ET 
3/70/F 1.8 No rest tremor; mild bilateral postural and 
kinetic tremor of outstretched arms; no 
rigidity or bradykinesia; mild stoop 
Pramipexole 
2.8mg 
Normal ET 
ET= essential tremor; VP= vascular Parkinsonism 
 
 
 
Table 4.5: Comparison of estimates for prevalence of misdiagnosed cases among 610 
Parkinson‟s disease patients 
 
 Lower estimate  
(63 of 610 cases misdiagnosed) 
Upper estimate 
(70 of 610 cases misdiagnosed) 
Sensitivity 0.62 (0.49 – 0.74) 0.66 (0.53 – 0.76) 
Specificity 0.91 (0.88 – 0.93) 0.92 (0.89 – 0.94) 
PPV 0.44 (0.33 – 0.55) 0.52 (0.41 – 0.62) 
NPV 0.95 (0.93 – 0.97) 0.95 (0.93 – 0.97) 
Likelihood ratio 6.9 (4.9 – 9.4) 8.3 (5.9 – 11.5) 
PPV= positive predictive value; NPV = negative predictive value 
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Figure 4.1: Consort diagram for medication withdrawal in patients who do not benefit from 
antiparkinson medication 
Dopa 
responsive 
dystonia, n= 16 
Not 
selected 
as 
controls 
n=415 
NO n=33 
No response n=20 
Unwilling n=5 
Unwell n=8 
 
 
 
Selected as controls n=97 
NO n=25 
No response n=10 
Unwilling n=4 
Unwell n=11 
 
 
 
NO n=28 
 Probable PD n=25 
No consent n= 2 
Unwell n= 1 
NO n=61 
Probable PD n=61 
(95.3% of 64) 
 
 
NO n=3 
PD worse n=2 
Consent withdrawn n=1 
YES n=33 
(91.7% of 36, 
5.2% of 610) 
YES n=3 
(75% of 4, 
0.5% of 610) 
Fulfilled screening criteria 
n=89 (14.8% of 610) 
 
 
Agreed to assessment 
YES n=64  
(10.6% of 610,  
71.9% of 89) 
 
 
YES n=64  
(10.6% of 610, 
66.0% of 97) 
 
Appropriate for therapy withdrawal 
YES n=36 
(56.2% of 64) 
YES n=3 
(4.7% of 64) 
Completed therapy withdrawal 
Did not fulfil screening criteria 
n=512 (85.2% of 610) 
PD patients on antiparkinson medication, n=610 
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CHAPTER 5 
FP-CIT SPECT IN PATIENTS WITH AN UNCERTAIN DIAGNOSIS OF PARKINSON‟S 
DISEASE 
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Introduction 
The advent of in vivo imaging of the presynaptic dopaminergic system, disrupted 
in degenerative Parkinsonism, has given a new mechanism to test the accuracy of clinical 
diagnosis of Parkinson‟s disease (PD). Thus the earlier clinicopathological studies which 
reported significant misdiagnosis of PD in up to 25% of patients  (Rajput et al. 
1991b;Hughes et al. 1992a) can now be pre-dated in the living patient with a diagnostic 
test. It should be noted, however, that a proportion of the misdiagnosis of PD is for other 
degenerative parkinsonian conditions (eg. multiple system atrophy (MSA), progressive 
supranuclear palsy (PSP) and corticobasal degeneration (CBD)) in which presynaptic 
dopamine imaging is also abnormal (Scherfler et al. 2007). While postsynaptic dopamine 
receptor imaging might theoretically assist in differentiating among these conditions, in 
clinical practice the sensitivity and specificity of such testing has not been sufficiently 
high. In the present study, the main interest was in differentiating degenerative PD from 
non-degenerative conditions which are much commoner; hence these concerns were not 
of major significance. Some additional considerations regarding diagnostic accuracy are 
relevant to the material reported in the present chapter. Firstly, clinical diagnostic 
accuracy is greatest when Brain Bank criteria are strictly employed and when patients are 
assessed within a specialist movement disorder service (Hughes et al. 2002). Secondly, 
diagnostic accuracy improves when the patient is followed over time. Accordingly, the 
difficulties of differentiating PD from essential tremor (ET), especially with asymmetry 
of clinical features and rest tremor which are both recognised in ET (Louis et al. 
1998;Cohen et al. 2003), should be reduced if patients have a long-standing diagnosis; 
and this differentiation should be enhanced in uncertain cases by applying presynaptic 
dopamine receptor imaging. Similar arguments apply to other non-degenerative 
movement disorders which may be difficult to differentiate from PD (eg. vascular 
Parkinsonism and dystonic tremor).  
 
Measuring DAT using SPECT 
The main dopaminergic neurones are found within the substantia nigra pars 
compacta and the ventral tegmental area. The dopamine transporter (DAT) is a sodium 
chloride-dependent protein located on the presynaptic dopaminergic neurone. It controls 
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dopamine levels by active reuptake of dopamine after it interacts at the postsynaptic 
receptor (Jaber et al. 1997). Appropriate ligands, such as β-CIT: [123I] 2-carboxymethoxy-
3-(4-iodophenyl) tropane and [
123
I]FP-CIT: [
123
I]N-w-fluoropropyl-2-carbomethoxy-3-(4-
iodophenyl)nortropane, bind to presynaptic DAT and therefore  provide an indirect 
measure of dopaminergic neuronal degeneration when imaged using SPECT.  
 
The time of optimal scan acquisition is 3-6 hours after injection with FP-CIT. 
Image analysis either uses quantitative region of interest (ROI) ratios and/or qualitative 
visual assessment. Striatal uptake of the radioligand is calculated in relation to a reference 
site with negligible DAT activity (commonly the occipital or cerebellar cortex).  DAT 
imaging is considered safe and radiation doses acceptable being equivalents for an FP-
CIT SPECT and a CT brain scan; and is also more widely available than positron 
emission tomography (PET) scanning. 
 
Imaging using
 18
F-dopa PET 
Like SPECT, positron emission tomography (PET) imaging allows the in vivo 
assessment of the nigrostriatal system. The presynaptic radiotracer 18-fluorodopa (
18
F-
dopa) was first used in PD in 1983. Following intravenous administration 
18
F-dopa is 
decarboxylated to fluorodopamine within dopaminergic nerve terminals. Region-of-
interest (ROI) activity reflects the number of functional dopaminergic neurons, 
incorporating presynaptic dopa uptake, decarboxylation to dopamine and storage. The 
major reduction in striatal 
18
F-dopa  in PD is in keeping with post-mortem studies and 
correlates with bradykinesia and rigidity (Snow et al. 1993). 
  
PET imaging can detect pre-clinical disease, such as in clinically unaffected co-
twins of a patient with Parkinson‟s disease and asymptomatic subjects with a strong 
family history (Piccini et al. 1997;Laihinen et al. 2000). PET scanning has also been 
applied to neuroprotective studies, e.g. the REAL-PET study in which186 newly 
diagnosed patients were randomized to ropinirole or levodopa (Whone et al. 2003). After 
2 years, putamen uptake declined by 13% for ropinirole cases compared to 20% for 
levodopa cases.  
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Within Europe FP-CIT is licensed as a radiotracer for diagnosis of PD. FP-CIT 
SPECT is increasing available for clinical use across the UK, whilst the more expensive 
PET scanning remains a research tool. 
 
Clinical application of DAT imaging 
DAT SPECT demonstrates significantly reduced asymmetrical striatal uptake in 
PD (Booij et al. 1997). Striatal uptake correlates with disease duration and motor severity 
(Benamer et al. 2000b). Abnormal radiotracer uptake progresses from putamen to caudate 
and matches contralaterally the more clinically affected side. The main clinical 
application of DAT imaging is in assessing patients in whom there is diagnostic doubt 
between degenerative Parkinsonism and other non-degenerative tremor disorders.  
 
The conditions most commonly misdiagnosed as PD within the community are 
ET and vascular Parkinsonism (VP) (Meara, Bhowmick, & Hobson 1999). DAT imaging 
is normal in ET (Asenbaum et al. 1998;Benamer et al. 2000a). DAT imaging can assist 
the identification of VP in the presence of focal deficit which matches basal ganglia 
infarction often seen on CT brain imaging, distinct from the pattern seen in PD (Tzen et 
al. 2001). DAT SPECT is normal in drug-induced Parkinsonism (Lavalaye et al. 2001) 
and psychogenic tremor (Booij et al. 2001).  
 
DAT SPECT in misdiagnosis of Parkinson‟s disease 
DAT imaging is normal in a subset of patients clinically labelled as having PD 
(Benamer et al. 2003;Marshall & Grosset 2003a;Marshall & Grosset 2003b). 
Misdiagnosis of PD is recognised in randomised clinical trials with between 1.4 and 15% 
of patients in 3 large clinical studies having normal presynaptic dopaminergic imaging 
(The Parkinson Study Group 2002;Whone et al. 2003;Seibyl et al. 2004;Fahn et al. 2004).  
 
Central to this thesis was a study in which patients, misdiagnosed as PD, were 
identified from searches of GP practice prescription databases and had antiparkinson 
medications gradually withdrawn under supervision (See Chapter 4). In the current 
chapter the results from FP-CIT SPECT scans performed as part of this larger study are 
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reported. The aim of the current study was to examine further the use of FP-CIT SPECT 
in the assessment of patients on antiparkinson therapy for a PD diagnosis in whom there 
is diagnostic doubt. 
 
Methods 
The patient identification process is described in detail in Chapter 4. In brief 
summary, searches of prescription databases and GP case records for patients prescribed 
antiparkinson medication for a PD diagnosis were completed in 92 West Scotland GP 
practices. Patients with features which raised the possibility that they did not have PD 
were invited for out-patient assessment, which amounted to 64 patients meeting selection 
criteria. In addition, 64 matching control patients were seen. Clinical assessment was 
undertaken in all cases by 2 movement disorder specialists. Patients considered to have 
PD were discharged from further follow-up and patients considered to have an alternate 
diagnosis were offered supervised antiparkinson medication withdrawal. Brain Bank 
criteria were used in assessment of the diagnosis of PD. Alternative diagnoses were made 
according to established criteria and definitions: ET (Bain et al. 2000); VP  (Zijlmans et 
al. 2004);   dystonic tremor (DT) (Schneider et al. 2007);  or indeterminate tremor 
(Deuschl, Bain, & Brin 1998). FP-CIT SPECT scanning was performed in clinically 
uncertain cases, primarily in patients with overlapping features between different criteria 
(eg. patients with a prolonged history suggesting ET, but with emerging features raising 
the possibility of PD). 
 
FP-CIT SPECT scanning was also performed in further patients labelled as PD, 
identified during the same time period as the above study, but within routine movement 
disorder clinics (by study investigators) as having clinical features inconsistent with 
degenerative Parkinsonism. 
 
Data from the community study was compared with a subset (from the same 
centre as the present study) of patients who had serial FP-CIT SPECT scans part of a 
prospective 3-year multicentre European prospective FP-CIT study (Marshall et al. 
2008). In that study, patients were recruited on the basis of clinical diagnostic uncertainty 
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between degenerative Parkinsonism and non-degenerative tremor disorders; patients were 
scanned at baseline and had repeat scans at 18 and 36 months. Data from patient scans at 
36 months following initial scan were used as the comparator group to the patients in this 
study, since the patients in the present study had long duration diagnosis which was 
closest to the 3 year scan time-point in the prior work.  
 
Age, sex and time from initial PD diagnosis to the date of the scan were recorded 
for all patients. All FP-CIT SPECT scans were performed using the same scanner 
(Institute of Neurological Sciences, Glasgow) and were interpreted by the same 
radiologist using standardised methodology, with measurement of the ratio of striatal 
radioligand uptake (divided into its anterior area representing the caudate, and its 
posterior area representing the putamen) to the uptake within the occipital cortex. The 
primary area of interest was defined as the lower of right or left sided uptake ratios for 
putamen, since this is the area which degenerates first in PD. 
 
Statistical analysis 
Mean putamen uptake between scans from the community and European 
prospective FP-CIT studies were compared using unpaired t-tests. Change in mean 
putamen uptake over serial scans for patients within the European prospective FP-CIT 
study was compared using one-way ANOVA. 
 
Results 
Community study 
FP-CIT SPECT scans were performed in 37 patients (22 female, 15 male): 
 24 of 64 (37.5%) of the active group;  
 4 of 64 (6.3%) of the control group; and 
 9 patients identified within out-patient clinics, as follows: 
 
Patients identified within out-patient clinics (n = 9) had features inconsistent with 
degenerative Parkinsonism: 
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 3 of 9 patients (33%) were also among those identified from GP practice database 
searches, but neither fulfilled selection criteria nor were selected as controls. 
 6 of 9 patients (67%) originated from outwith the catchment area of the GP 
practice searches. 
 
Mean age at time of FP-CIT SPECT scanning was 74.0 years (SD 7.3 years). 
Time since initial PD diagnosis was positively skewed; median time was 4.4 years 
(interquartile range: 1.9 to 7.5 years). Clinical features, scan results and final diagnosis 
are detailed in Table 5.1. 
 
 25 of 37 (67.6%) scans were reported as normal and 12 of 37 (32.4%) were 
reported as abnormal. All patients with abnormal FP-CIT scans were diagnosed as PD 
(diagnosis was based on clinical plus imaging features of PD). 13 of 25 patients (52%) 
with normal scans had a clinical plus imaging diagnosis of VP; 6 of 25 (24%) were 
diagnosed as ET; 3 of 25 (12%) were diagnosed as drug-induced Parkinsonism; 2 of 25 
(8%) were diagnosed as dystonic tremor and 1 of 25 (4%) was diagnosed as 
indeterminate tremor. 
 
All patients with normal scans were offered supervised antiparkinson medication 
withdrawal. 24 of 25 patients (96%) consented to therapy withdrawal.  23 of 24 patients 
(95.8%) completed therapy withdrawal and 1 patient (4.2%) withdrew consent.  Patients 
were followed up for a mean period of 7.2 months (SD 3.1 months). The mean change in 
UPDRS motor score after therapy cessation was an improvement of 1.3 points (95% 
confidence interval: deterioration of 0.3 to improvement of 3.0 points).  (Note for 
clarification: These UPDRS scores represent all patients who had normal FP-CIT SPECT 
and stopped antiparkinson therapy successfully during the current work. This includes 23 
patients, 19 of whom are already included in Chapter 4, and in addition a further 4 
patients identified in out-patient clinics. The present figures differ slightly from those in 
Chapter 4 because those results did not include the additional 4 out-patient cases). 
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Data from the European prospective FP-CIT study 
This work was not performed as part of the present thesis but is summarised 
briefly as a framework for understanding and comparison with the present study. 32 
patients (20 male, 12 female) with a clinically uncertain Parkinsonism / tremor disorder 
(which could be either degenerative or non-degenerative) underwent 3 FP-CIT SPECT 
scans (at baseline, 18 and 36 months). 14 of 32 scans (43.8%) were reported as normal. 
Mean minimal putamen uptake was 3.17 (SD 0.38) for scans reported as normal and 1.35 
(SD 0.43) for scans reported as abnormal. 
 
Figure 5.1 demonstrates the change in minimal putamen uptake over the 3 scans. 
The scan result did not change from normal to abnormal (or vice versa) in any case. 
There was no significant change in mean uptake over 3 scans for patients with normal 
scans (p=0.48) and although the mean uptake show a trend to decreasing over 3 scans in 
abnormal scans, this change was not significant (p=0.63).  
 
Figure 5.2 compares minimal putamen uptake for scans from the community and 
European prospective FP-CIT studies.  Mean minimal putamen uptake ratios for normal 
scans was 2.94 (SD 0.58) in the community study patients and 3.17 (SD 0.43) in the 
European prospective FP-CIT study (36 month scans).  Mean minimal putamen uptake 
ratio for abnormal scans was significantly less for patients within community study than 
patients from European prospective FP-CIT study (scanned at 36 months following 
baseline) (0.75 (SD 0.29) versus 1.03 (0.38), p<0.05). 
 
Examples of FP-CIT SPECT images from the current study are in Figures 5.3-5.5. 
 
Discussion 
 This community study further confirms the tendency for overdiagnosis of PD, 
observed in previous community and clinicopathological studies (Hughes et al. 
1992b;Meara, Bhowmick, & Hobson 1999;Schrag, Ben Shlomo, & Quinn 2002). Normal 
DAT imaging has also been reported in a subset of patients (labelled as PD) entering 
clinical trials of antiparkinson therapies (Fahn 1999;The Parkinson Study Group 
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2000;Whone et al. 2003;Seibyl et al. 2004). These patients have previously been referred 
to as SWEDDs (subjects with scans without evidence of dopamine deficiency) and there 
is debate as to the underlying pathology. Either these patients: 
a) Do not have PD; or 
b) Do have PD without presynaptic neuronal degeneration; or  
c) Have nigrostriatal degeneration that is not detectable on SPECT or positron 
emission tomography (PET) scanning. 
 
In clinical trials a higher proportion of SWEDDs is found in early disease. In 
ELLDOPA 14% of cases were SWEDDs (mean disease duration, 6.5 months), versus 
11% SWEDDs (16-month duration) in REAL-PET, 4% SWEDDs (18-month duration) in 
CALM-PD, and 1.4% (23-month duration) in NIL-A-CIT. If misdiagnosis is more 
common in earlier disease this argues against a non- nigrostriatal form of PD in which the 
proportion would remain constant over time. There are no clinicopathological correlates 
for SWEDDs in the literature. 
 
Given that abnormal DAT imaging has been reported in patients with olfactory 
disturbance who go on to develop clinical Parkinsonism (ie. patients in the pre-motor 
phase of PD) (Stiasny-Kolster et al. 2005) and that more than 50% of dopaminergic 
neurones are lost at the time of presentation of motor symptoms of PD it is unlikely that a 
normal scan could represent early PD. Gradual reduction in putamen DAT uptake has 
been described in PD patients, with 6 to 13% annual reduction compared to 0 to 2% in 
healthy controls (Scherfler et al. 2007). Therefore, a normal scan in a patient with a long-
established PD diagnosis (a median of 4.4 years in the present study and an upper range 
of 23.3 years ago) is even less likely to represent PD.  
 
The present study gives the highest proportion of SWEDDs (25 of 37 scans, 
67.6%) ever reported. It should be realised that this was in a highly selected population, 
specifically identified through clinical criteria which were designed to identify patients 
unlikely to have PD despite being on established therapy for this diagnosis. However, 
even considering that only 19 patients out of 610 (the population of patients on 
 91 
antiparkinson therapy for a diagnosis of PD identified from GP practice searches) had 
normal scans, this still amounts to 3.1% of SWEDDs in a community series. The real 
proportion of SWEDDs is clearly much higher; we did not submit patients for FP-CIT 
unless there was either baseline uncertainty or an unexpected deterioration following 
antiparkinson therapy withdrawal. Accordingly, it is perhaps appropriate to define a new 
entity, combining the clinically rediagnosed case (who does not undergo FP-CIT or 
similar scanning) with the SWEDD patients, for which we have invented the acronym 
SEDAPs (subjects erroneously diagnosed as PD). The proportion of community patients 
in this capacity has already been described and discussed in Chapter 4. 
 
In keeping with previous community studies the most common alternative 
diagnosis in patients with normal scans in the community series were ET and VP (Meara, 
Bhowmick, & Hobson 1999). The lack of deterioration in movement disorder symptoms 
following antiparkinson therapy withdrawal in these cases further supports the 
assumption of a non-PD diagnosis. DAT-imaging is abnormal in degenerative 
Parkinsonism and does not differentiate between different types (eg. PD, PSP, MSA, 
CBD). All patients with abnormal FP-CIT SPECT imaging in this study were considered 
clinically to have PD.  
 
The lack of reduction in minimal putamen uptake ratio in the normal scans on 
serial imaging (over 3 years) in the European prospective FP-CIT study is in keeping 
with previously reported sequential scanning of SWEDDs (Whone et al. 2003;Fahn et al. 
2004). Although we did not see a decline in uptake ratios over time in patients with 
abnormal scans at baseline, each patient showed persistence of an abnormal scan at repeat 
after 18 and 36 months. Collectively these observation reinforce the conclusions of the 
present study, specifically that patients with a normal FP-CIT SPECT are „true negative‟ 
regarding the diagnosis of PD, and that patients in the current study with abnormal FP-
CIT SPECT in the present study are „true positive‟ regarding the diagnosis of PD. On this 
basis, we would argue that, in this patient population, a properly conducted FP-CIT 
SPECT scan can be used to „over-rule‟ a contradictory clinical diagnosis. 
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Conclusion 
A subset of patients labelled as having Parkinson‟s disease and prescribed 
antiparkinson therapy have been misdiagnosed. FP-CIT SPECT is an extremely useful 
tool, if used appropriately, in the identification of such misdiagnosed cases, being able to 
differentiate degenerative Parkinsonism from non-degenerative disorders, in particular 
when the patient has carried the PD diagnosis for a prolonged time.  
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Table 5.1: Clinical features and FP-CIT SPECT result for 37 patients undergoing FP-CIT SPECT 
 
Patient 
number /  age 
(yrs) / sex 
Time since 
PD 
diagnosis 
(yrs) Clinical features 
Minimal 
putamen 
uptake ratio Report Diagnosis 
1/80/F 2.1 Rest, postural and kinetic tremor of arms; mild rigidity in 
upper limbs; no bradykinesia; short steppage gait with 
reduced arm swing; moderate postural instability 
1.05 Abnormal PD 
2/63/F 12.0 Mild hypophonia and hypomimia; jaw tremor; moderate 
right hand and leg rest tremor; rigidity at neck and in 
upper limbs; mild bilateral bradykinesia; mild stoop; short 
steppage gait 
0.71 Abnormal PD 
3/64/M 1.6 Rest, postural and kinetic tremor of hands, no rigidity or 
bradykinesia; slowed gait 
2.17 Normal ET 
4/74/M 5.7 Hypomimia and hypophonia; mild rest tremor of right 
hand; bilateral postural tremor of arms; no rigidity; 
moderate bilateral bradykinesia; stooped; short steppage 
gait with loss of arm swing 
0.49 Abnormal PD 
5/80/M 5.8 Mild hypomimia; mild right-sided rest and postural 
tremor; no rigidity or bradykinesia; stooped; gait slow 
with loss of arm swing 
0.48 Abnormal PD 
6/75/F 3.9 Jaw tremor; mild rest and postural tremor of arms; no 
bradykinesia; tone increased at neck; posture stooped; gait 
slowed with reduced bilateral arm swing 
2.68 Normal VP 
7/90/F 8.6 Mild hypomimia; rest tremor right leg; increased tone 
limbs; mild bilateral bradykinesia; short steppage gait 
with preserved arm swing 
1.42 Abnormal PD 
8/56/M 12.4 Postural and kinetic tremor of arms; increased tone at 
neck and in right arm no bradykinesia; mild stoop 
2.51 Normal DT 
9/78/M 15.2 „No-no‟ head tremor; jaw tremor; bilateral rest tremor of 
hands; marked bilateral postural and kinetic tremor of 
arms; increased tone at neck; no bradykinesia; mild stoop; 
mild postural instability 
2.93 Normal ET 
10/65/F 2.1 Postural and kinetic tremor arms; increased tone lower 
limbs; no bradykinesia; stooped; reduced arm swing 
2.76 Normal VP 
11/72/M 4.0 Moderate hypophonia and hypomimia; jaw tremor; 
bilateral resting tremor of hands; bilateral postural tremor 
of arms; mild symmetrical bradykinesia; stooped; 
shuffling gait with bilateral loss of arm swing 
2.07 Normal DIP 
12/75/M 7.1 Hypomimia; postural and kinetic tremor of arms; rigidity 
at neck; no bradykinesia; stooped; slow gait with reduced 
arm swing 
0.63 Abnormal PD 
13/76/M 4.3 Hypophonia and hypomimia; chin tremor; mild neck and 
left arm rigidity; moderate asymmetrical bradykinesia; 
stooped; short steppage gait with reduced arm swing 
 
0.53 Abnormal PD 
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14/71/M 10.7 Mild hypophonia and hypomania; chin tremor; moderate 
rest tremor both hands; increased tone at neck and in 
limbs; moderate symmetrical bradykinesia; stooped 
 
3.43 Normal DIP 
15/82/F 4.8 Cognitive impairment; rest tremor right hand; bilateral 
postural and kinetic tremor of arms; no bradykinesia; 
difficulty standing; stooped; mild postural instability 
2.57 Normal VP 
16/71/F 2.0 Mild hypomimia and hypophonia; jaw tremor; moderate 
rest tremor all 4 limbs; moderate bilateral bradykinesia; 
mild stoop; slow gait with reduced arm 0.53swing 
3.36 Normal DIP 
17/75/M 5.4 Mild hypomimia; dyskinetic movements of limbs; jaw 
tremor; intermittent rest tremor right hand; moderate 
postural tremor of arms; increased tone at neck; no 
bradykinesia; mild stoop; reduced right-sided arm swing 
0.53 Abnormal PD 
18/72/F 8.7 „No-no‟ head tremor; bilateral rest tremor of hands; 
moderate bilateral postural tremor of arms; mild bilateral 
bradykinesia; stooped; gait slow with reduced arm swing 
2.96 Normal VP 
19/72/F 8.7 „No-no‟ head tremor; bilateral rest tremor of hands; 
moderate bilateral postural tremor of arms; mild bilateral 
bradykinesia; stooped; gait slow with reduced arm swing 
3.54 Normal VP 
20/77/F 23.3 Rest, postural and kinetic tremor of arms; increased tone 
at neck and in limbs; mild symmetrical bradykinesia; 
stooped; slowed gait with reduced arm swing 
0.65 Abnormal PD 
21/82/F 6.4 Mild hypomimia; jaw tremor; rest, postural and kinetic 
tremor of arms; increased tone at neck; mild symmetrical 
bradykinesia; stooped; slowed gait with reduced arm 
swing 
0.96 Abnormal PD 
22/72/F 1.5 Resting and postural tremor of hands; no rigidity or 
bradykinesia; mild stoop; slowed gait 
0.96 Abnormal PD 
23/77/F 8.1 „No-no‟ head tremor; jaw tremor; rest tremor both hands; 
bilateral postural and kinetic tremor; mild left-sided 
bradykinesia; moderate stoop; preserved arm swing 
2.79 Normal VP 
24/72/F 8.4 Rest tremor left hand; bilateral postural tremor of arms; 
increased tone at the neck; mild bilateral bradykinesia; 
stooped; slow, unsteady gait 
2.99 Normal VP 
25/80/F 2.0 Jaw tremor; rest, postural and kinetic tremor of arms; no 
rigidity or bradykinesia; stooped; slowed gait with 
reduced arm swing; mild postural instability 
2.79 Normal ET 
26/77/F 1.6 Chin tremor; increased tone at neck and in all limbs; 
moderate symmetrical bradykinesia; mild stoop; slowed 
gait with reduced arm swing 
3.64 Normal VP 
27/81/F 5.1 Rest tremor right hand; postural and kinetic tremor both 
arms; increased tone at neck; no bradykinesia; mild stoop; 
unsteady gait with mild postural instability 
3.60 Normal ET 
28/88/F 7.8 Postural and kinetic tremor of arms; increased tone at 
neck; mild left-sided bradykinesia; mild stoop; slowed 
gait with preserved arm swing 
0.61 Abnormal PD 
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29/71/F 1.5 Jaw tremor; rest, postural and kinetic tremor both hands; 
increased tone at neck and in right arm and leg; moderate 
symmetrical bradykinesia; mild stoop; slowed gait with 
reduced arm swing 
3.83 Normal VP 
30/67/M 0.1 „No-no‟ head tremor; rest, postural and kinetic tremor of 
arms (worse on left side); increased tone at neck and in 
lower limbs; no bradykinesia; mild stoop; slowed gait 
with reduced left arm swing; moderate postural instability 
 
4.24 Normal IT 
31/59/M 1.1 „Yes-yes‟ head tremor; high frequency rest tremor; 
postural and kinetic tremor of outstretched arms; no 
bradykinesia; stooped; slowed and unsteady gait; mild 
retropulsion 
3.04 Normal DT 
32/72/M 1.7 Dysarthric speech; postural and kinetic tremor of arms; 
increased tone at neck; no bradykinesia; mild stoop; 
reduced arm swing 
2.41 Normal VP 
33/74/F 2.9 Chin tremor; postural and kinetic tremor of arms (worse 
on right); increased tone at neck and in both arms; no 
bradykinesia; mild stoop; slowed and unsteady gait with 
reduced arm swing; moderate postural instability 
2.38 Normal VP 
34/70/M 1.2 „No-no‟ head tremor; rest and postural tremor right hand; 
no rigidity; mild right sided bradykinesia; mild stoop; 
slowed gait with reduced right arm swing; moderate 
postural instability 
3.60 Normal VP 
35/74/M 6.6 Mild postural and kinetic tremor of arms; no rigidity or 
bradykinesia; preserved arm swing; no postural instability 
2.42 Normal ET 
36/65/F 2.0 „No-no‟ head tremor; jaw tremor; rest and postural tremor 
of arms; increased tone at neck; no bradykinesia; mild 
stoop; short steppage gait with reduced arm swing; 
marked postural instability 
2.61 Normal VP 
37/70/F 1.7 „No-no‟ head tremor; rest and postural tremor of arms; no 
rigidity or bradykinesia; mild stoop; normal gait with 
preserved arm swing; no postural instability 
2.17 Normal ET 
PD = Parkinson‟s disease; ET = essential tremor; VP = vascular Parkinsonism; DIP = drug-induced 
Parkinsonism; DT = dystonic tremor; IT = indeterminate tremor 
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Figure 5.1: Minimal putamen uptake for patients undergoing repeat scans (at baseline, 18 
and 36 months) according to scan report (normal or abnormal, graded blind to clinical 
presentation) as part of European prospective FP-CIT study.  
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Figure 5.2: Scatter plots comparing minimal putamen uptake in patients who underwent 
FP-CIT SPECT scans. (Upper) Results for patient scanned as part of the community 
study and (lower) results for 36 month scan for patients scanned as part of a European 
prospective FP-CIT study are shown in Figure 5.2. There was a striking similarity 
between the 2 series, and clear-cut differentiation of abnormal from normal in both 
datasets. 
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Figure 5.3: Image from normal FP-CIT SPECT scan demonstrating normal striatal uptake 
of the radioligand, in both putamen (green arrow) and caudate (yellow arrow). 
Right 
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Figure 5.4: Image from abnormal FP-CIT SPECT scan demonstrating reduced, 
asymmetrical radiotracer uptake within the putamen, most evident on the patient‟s left 
side (green arrow), but also showing early reduction on the patient‟s right side (yellow 
arrow). 
Right 
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Figure 5.5: Image from abnormal FP-CIT SPECT scan demonstrating gross presynaptic 
dopaminergic deficit with radiotracer uptake limited to the caudate bilaterally (absent 
putamen uptake highlighted by green arrows). 
Right 
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CHAPTER 6 
RISKS OF WITHDRAWAL OF ANTIPARKINSON MEDICATION 
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Misdiagnosis of Parkinson‟s disease (PD) is recognised within cross sectional 
community studies and clinical trials (Meara, Bhowmick, & Hobson 1999;Fahn 
1999;Schrag, Ben Shlomo, & Quinn 2002;Whone et al. 2003;Seibyl et al. 2004). None of 
these studies reported withdrawal of antiparkinson medication in these misdiagnosed 
cases. Successful medication withdrawal in patients with clinical signs of Parkinsonism 
and normal presynaptic dopamine transporter imaging has been reported (Marshall et al. 
2006). It is appropriate, considering that antiparkinson medication withdrawal was a 
central component of the research in this thesis, to consider the potential risks of such a 
procedure. Two illustrative clinical vignettes highlight potential difficulties in this field. 
These are then used to discuss the issues in a wider context. 
 
Clinical vignette 1: a patient with Parkinsonism in whom medication stoppage 
contributed to an adverse outcome 
A 53-year old man without significant past medical history presented with a 12 
month history of worsening tremor of the right hand and scuffing of his right foot when 
walking. Clinical examination demonstrated a mild rest and postural tremor of the right 
arm, increased tone in the neck and right arm and leg, and generalised bradykinesia. FP-
CIT SPECT brain scanning demonstrated reduced striatal uptake of the radioligand, 
supporting the clinical diagnosis of degenerative parkinsonism. There was little clinical 
improvement with Madopar (increased to 125mg four times daily). Subsequent 
development of impaired speech and vertical eye movements raised the likelihood of 
progressive supranuclear palsy (PSP). He was admitted to the medical unit with acute 
confusion, visual hallucinations and agitation. Dehydration and chest infection were 
treated intravenously with fluids and Amoxicillin 1g three times daily and Clarithromycin 
500mg twice daily. On admission, antiparkinson medication was stopped in view of his 
cognitive state; after 3 days the conscious level dropped, speech became 
incomprehensible, and he was unable to follow commands. There was a leucocytosis and 
a chest X-Ray showed lobar pneumonia. Despite high-flow oxygen and an adjusted 
antibiotic regimen  (Ceftriaxone 2g once daily and Metronidazole 500mg three times 
daily), his conscious level dropped further over 48 hours, he became pyrexial (41˚C) and 
tone was increased axially and in all 4 limbs. Creatine kinase (CK) was markedly 
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elevated (>14,000) and Parkinsonism-hyperpyrexia syndrome (PHS) was diagnosed. 
Despite 400mg/day Madopar (via nasogastric tube) and intravenous fluids, he died 48 
hours later with respiratory and renal failure. 
 
Clinical vignette 2: Parkinsonism-hyperpyrexia syndrome in a PD patient treated with a 
dopamine antagonist 
 An 80-year old man presented with a 5-year history of rest tremor affecting his 
right hand and slowing of gait. He described difficulty getting washed and dressed and 
hypersalivation. Past medical history included hypertension, hypercholesterolaemia and 
several transient ischaemic attacks. His family had noticed recent memory disturbance, 
but the patient denied any visual hallucinations. Daily drug therapy comprised 
Clopidogrel 75mgs, Atorvastatin 40mgs and Perindopril 2mgs. He was the main carer for 
his wife who had advanced dementia. On examination speech was quiet and dysarthric, 
and facial expression slightly reduced. There was a mild and postural tremor of the right 
arm. Tone was increased at the axially and in both lower limbs. There was mild right-
sided bradykinesia on finger taps and rapid alternating movements. Posture was good but 
gait was slowed with reduced arm swing. CT-brain scanning demonstrated previous 
lacunar infarcts and widespread small vessel disease. An FP-CIT SPECT scan 
demonstrated reduced striatal uptake of the radioligand and the diagnosis was therefore a 
combination of PD and cerebrovascular disease. He was commenced on Levodopa 
200mgs/day resulting in moderate improvement. Over the next 12 months there was 
significant deterioration in his cognitive state and both he and his wife were moved into a 
nursing home. He became increasingly agitated and disorientated (especially at night), for 
which haloperidol 1mg/day was introduced, but without much improvement in his mental 
state. This dose was increased over a 4-week period to 5mgs/day. Over several days 
nursing staff found the patient to be increasingly confused. When his conscious level 
deteriorated further he was admitted to an acute medical ward. On examination eyes 
opened to pain, speech was incomprehensible and he could localise to pain. Tone was 
increased axially and in all 4 limbs. Temperature was 40.5˚C, CK was elevated (>8,000) 
and PHS was diagnosed. The patient was treated with intravenous fluids and 200mg/day 
Madopar (via nasogastric tube) and haloperidol was discontinued. His conscious level 
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improved within 48 hours. He was transferred to a rehabilitation unit where he received 
physiotherapy. He was subsequently transferred back to the nursing home after 3 weeks. 
As an in-patient his mobility improved but did not return to his pre-morbid state. He was 
commenced on Quetiapine 50mgs/day for agitation. 
   
These 2 vignettes illustrate the risk of PHS in the PD patient. In the first case this 
resulted from abrupt withdrawal of antiparkinson medication and in the second case PHS 
was precipitated by prescription of a traditional dopamine depleting neuroleptic given at 
an escalating dose. The first case was observed during routine clinical practice by the 
movement disorder team, but was not part of the patient study groups reported in this 
thesis. The second case had been assessed as part of the medication withdrawal study 
described in Chapter 4, but his antiparkinson medication was maintained and the PHS 
complication occurred after study follow-up was completed. 
 
The time profile of the therapeutic response is therefore now discussed, with 
particular reference to its evolution if antiparkinson therapy is discontinued. 
 
Short and long-duration response to Levodopa 
Withdrawal of antiparkinson medication in PD patients may result in the return of 
the „off‟ symptoms of PD. Tremor, rigidity, gait, posture may all worsen and patients 
may develop dystonia. Patients may experience the return of non-motor symptoms such 
as depression, apathy, fatigue anxiety and pain (Schrag & Quinn 2000;Schrag 2006). 
Simple and choice reaction times are also slower for patients once Levodopa is 
withdrawn (Jahanshahi et al. 1992;Harrison et al. 1995). 
 
In PD patients a single dose of Levodopa produces an immediate clinical 
improvement in symptoms known as the short-duration response (SDR). Chronic 
treatment with Levodopa induces a gradual improvement in motor symptoms that may 
take days to fully develop and lasts many days after discontinuation of treatment and is 
known as the long-duration response (LDR) (Stocchi et al. 2003a;Stocchi et al. 2003b). 
The LDR is not present in early PD and has been implicated in the development of motor 
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fluctuations (Nutt et al. 1997;Zappia et al. 1999). The LDR appears to be unrelated to 
Levodopa pharmacokinetics and has also been reported in patients treated with dopamine 
agonists (Stocchi et al. 2001). The underlying mechanism responsible for the LDR 
remains unknown, although it is thought to originate from pre-synaptic or post-synaptic 
mechanisms. 
 
In one series Levodopa was deliberately withheld for a mean duration of 44 hours 
in 9 PD patients with „on/off‟ fluctuations (Turjanski et al. 1993). All patients 
experienced a marked worsening of motor symptoms within 12 hours and a further mild 
delayed deterioration over days was also seen. One patient withdrew from the study 
following sudden onset of confusion and visual hallucinations after 23 hours. The 
minimum therapeutic dose of subcutaneous Apomorphine needed to produce 
improvement in motor symptoms was unchanged before and after medication 
withdrawal, providing no clinical evidence for alteration in dopamine receptor sensitivity 
following Levodopa withdrawal. 
 
A report of 16 patients undergoing 3-5 days of Levodopa withdrawal also 
described a delayed response (Nutt et al. 1995) with gradual emergence of motor 
disability, as measured by change in tapping rate, occurring days after drug withdrawal. 
This LDR was not improved following intravenous Levodopa at the end of the therapy 
withdrawal period. 
 
Drug holidays in PD 
In the 1970‟s and 1980‟s the practice of „drug holidays‟ in PD patients was 
commonplace. This involved acute  and complete withdrawal of Levodopa for 4-10 days 
and was claimed to temporarily improve motor complications following re-introduction 
of Levodopa (Sweet et al. 1972;Friedman 1985). It had been thought that the down-
regulation of striatal dopamine receptor sensitivity as a result of chronic dopaminergic 
drug therapy was temporarily reversed following Levodopa withdrawal (Weiner et al. 
1980). Due to recognised complications of acute drug withdrawal and no clear 
demonstration of benefit, this practice is no longer recommended (Mayeux et al. 1985). 
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However, in a recent study of 12 patients with motor complications, Levodopa was 
withdrawn for 3 days and intravenous Amantadine was administered (Koziorowski & 
Friedman 2007). Follow-up demonstrated improved UPDRS parts 3 and 4 up to 4 months 
following the drug holiday. 
 
Recognising Parkinsonism-hyperpyrexia syndrome 
Neuroleptic malignant syndrome (NMS) was first described in early trials of 
haloperidol (Delay et al. 1960). It is a rare but potentially fatal side effect of drugs that 
block D2 dopamine receptors. Clinically it presents with fever, autonomic instability, 
muscular rigidity, reduced conscious level, diaphoresis and raised serum CK. It is 
commoner in young and middle-aged male patients and symptoms typically develop 
within the first week after introducing a neuroleptic agent. The incidence of NMS is less 
with atypical antipsychotics, but NMS affects 0.2% of patients started on all 
antipsychotic medications (Kipps et al. 2005). NMS is more likely when antipsychotic 
doses are relatively high, or titrated rapidly, or given parenterally (Keck, Jr. et al. 
1989;Berardi et al. 1998) and results from an acute reduction in central dopamine 
transmission (Caroff et al. 2005). 
 
A very similar syndrome, first described in 1981 in a PD patient who had not been 
exposed to neuroleptics, occurred after large doses of antiparkinson drugs were 
discontinued (Toru et al. 1981). Many further reports have followed, giving a variety of 
names including NMS, neuroleptic malignant-like syndrome, Levodopa-withdrawal 
hyperthermia, Parkinsonism-hyperpyrexia syndrome (PHS), dopaminergic malignant 
syndrome and acute dopamine depletion syndrome. The term PHS is preferred for the 
syndrome in the PD patient (by this author), since neither neuroleptic drugs nor Levodopa 
withdrawal are essential for its development. PHS also occurs in other forms of 
degenerative Parkinsonism (eg. progressive supranuclear palsy and  multiple system 
atrophy) (Konagaya et al. 1997;Takubo et al. 2003). 
 
The most common trigger for PHS is withdrawal of antiparkinson medication, 
especially Levodopa. „Drug holidays‟ are no longer recommended, largely for fear of 
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inducing PHS  (Mayeux et al. 1985). However, there remain circumstances in which 
dopaminergic medications are discontinued. The patient or carer may stop one or more 
drugs due to side-effects, or may omit one or more of their antiparkinson drugs through 
self-experimentation (Grosset D et al. 2008). Antiparkinson medication may be changed 
or stopped on hospital admission, often in the context of an alternative acute illness 
(which may be medical or surgical). 
 
Other triggers to PHS are described in the PD patient, of which co-prescription of 
neuroleptic medication (exemplified in case vignette 2) is the most obvious.  The 
importance of infection, dehydration, intestinal absorption changes, and pre-menstrual 
state (Mizuta et al. 1993;Gordon & Frucht 2001;Shimada et al. 2006;Douglas & Morris 
2006) is less certain; changes in antiparkinson medication accompanying such events 
may be more relevant. PHS is also reported following bilateral subthalamic nucleus deep 
brain stimulation; again there was a rapid reduction of antiparkinson medications (Factor 
2007).  
 
Parkinsonism-hyperpyrexia syndrome (PHS): the clinical profile 
Typically symptoms develop between 18 hours and 7 days following the trigger. 
The patient becomes rigid, sometimes with tremor, and over hours progresses to an 
immobile state (Ueda et al. 1999) (See Table 6.1). The clinical picture is one of severe 
acute Parkinsonism. Within 72-96 hours most patients develop pyrexia and a reduced 
conscious level, ranging from confusion to coma. Autonomic dysfunction with 
tachycardia, labile blood pressure and diaphoresis follow. Laboratory tests may reveal a 
leucocytosis, elevated CK and sometimes deranged liver function tests (elevated CK is 
not a pre-requisite for the diagnosis). Complications of PHS include aspiration 
pneumonia, deep venous thrombosis and pulmonary embolism, disseminated 
intravascular coagulation (DIC), rhabdomyolysis, acute renal failure and seizures. Poor 
prognostic indicators in PHS include older age and higher pre-morbid Parkinson severity 
(Sato et al. 2003). 
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In the largest reported series of PHS, 99 episodes occurred in 93 patients (72 
patients with PD, 8 with PSP, 6 with MSA, 4 with vascular Parkinsonism, 2 with 
dementia with Lewy bodies and 1 with Parkinsonism secondary to vasculitis) in 5 
Japanese centres (Takubo et al. 2003). The usual trigger (55% of cases) was cessation or 
withdrawal (by patient or carer) of dopaminergic drugs, most commonly because of 
confusion or hallucinations. Other triggers included infection, poor oral intake, 
dehydration and intestinal ileus; 69% of episodes resulted in recovery to the pre-morbid 
state and 4% of patients died. This compares with reported mortality from NMS of 11.6% 
(Shalev et al. 1989). In both PHS and NMS development of DIC and renal failure was 
associated with a poorer outcome.  
 
A further series of 11 PD patients developed PHS following withdrawal of 
Levodopa and other antiparkinson medications (Serrano-Duenas 2003). Patients had 
mean disease duration of 9 years and developed symptoms of PHS on average 93 hours 
following medication withdrawal. All of the cases had increased rigidity as the presenting 
sign. No patients died in this series. These 11 cases occurred over 9 years and accounted 
for 3.6% of the total PD patient population regularly treated by the authors. 
 
Hashimoto et al. described 16 episodes of PHS occurring in 14 PD patients 
between 1992 and 1999 (Hashimoto et al. 2003). Most cases resulted from 
discontinuation or withdrawal of dopaminergic drugs, but pre-morbid deterioration of 
parkinsonian symptoms, dehydration and infection were all considered to be risk factors. 
 
 As in NMS the underlying pathological mechanism for PHS is sudden 
suppression of central dopaminergic activity. A reduced CSF concentration of the 
dopamine metabolite homovanillic acid (HVA), which was attributed to abrupt 
medication withdrawal, has been found in PHS (Ueda et al. 1999;Ueda et al. 2001), but 
this is an expected biochemical change and does not imply a  causative association.  
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Treating Parkinsonism-hyperpyrexia syndrome 
The main key to treating PHS is early diagnosis, with the underlying cause being 
identified and corrected. Antiparkinson medications which have been discontinued 
should be promptly re-started. They can be given orally or via a nasogastric tube (See 
Table 6.2). If nasogastric feeding is contraindicated (e.g. because of ileus) Levodopa-
based treatment can be administered intravenously (50-100mg of L-dopa infused over 3 
hours), and this can be repeated four times daily until the patient can take medications 
orally. Patients should be given the same dose of Levodopa as taken prior to onset of 
PHS. If there has been no alteration in dopaminergic medication other causes should be 
sought (e.g. prescription of neuroleptic, infection, dehydration). 
 
Patients often require high dependency or intensive care, with respiratory support  
and central venous pressure monitoring if necessary (Ikebe et al. 2003;Factor SA & 
Santiago A 2005). Supportive measures such as intravenous fluid replacement, anti-
pyretics and cooling blankets are recommended.  Patients are at high risk of aspiration 
pneumonia and antibiotics should be commenced early if infection is suspected. Renal 
function, coagulation factors and CK should be closely monitored. If CK is elevated 
urinary myoglobins should be tested for rhabdomyolysis.   
  
Dantrolene is a skeletal muscle relaxant, inhibiting intracellular release of calcium 
from the sarcoplasmic reticulum and has been shown to be efficacious in cases of 
malignant hyperthermia (Rosenberg et al. 2007). Both Bromocriptine (5-10mg three 
times per day) and Dantrolene Sodium (10mg/kg per day in 3-4 divided doses) are 
traditionally recommended in treatment of PHS, although there are no studies 
demonstrating efficacy (Mueller et al. 1983;Ikebe et al. 2003). Other dopamine agonists 
(oral ropinirole or pramipexole, transdermal rotigotine, or subcutaneous apomorphine) 
have been used more recently. 
 
Complications of PHS should also be managed. DIC may require intravenous 
heparin and platelet transfusion and acute renal failure may necessitate haemodialysis. In 
a randomised placebo-controlled trial, 3 days of 1g intravenous Methylprednisolone in 40 
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cases of PHS shortened the illness duration, but there was significant overlap between the 
active and placebo groups (Sato et al. 2003). All patients in this study also received 
Levodopa, Bromocriptine and Dantrolene Sodium. 
 
Preventing Parkinsonism-hyperpyrexia syndrome 
 The most common trigger for the parkinsonian patient to develop PHS is 
reduction or cessation of antiparkinson medications (Takubo et al. 2003).  The most 
common drug implicated is Levodopa, but PHS can be caused by acute reduction in any 
dopaminergic drug. Drug holidays are no longer practised, but patients and their carers 
often reduce dopaminergic drugs due to side effects (especially confusion and 
hallucinations). Patients should be advised not to suddenly stop antiparkinson medication. 
While dopaminergic drug dose reduction should generally be gradual, the circumstance 
of acute psychosis in PD patients with an intercurrent illness (typically infective) may 
necessitate stopping adjunctive dopaminergic therapy (eg. dopamine agonists, MAO-B 
inhibitors). Maintaining some antiparkinson medication (such as Levodopa-based 
treatment) will help prevent PHS. No specific guidelines inform the correct approach, and 
clinical judgement should assess the severity of the mental state, pre-existing cognitive 
problems, and the dose of different drug classes. However, the message should be clear: 
complete and abrupt cessation of established antiparkinson medication in a PD patient 
should almost always be avoided. The potential risks of neuroleptic drugs mean that they 
should be used sparingly in PD patients, but they are quite often beneficial in the more 
advanced PD patient with cognitive problems, hallucinations, and/or agitation.   
 
The risk of PHS on admission to hospital is also pertinent. Retrospective audit of 
all acute hospital admission for PD patients in a District General Hospital in North Kent 
illustrated poor prescription and knowledge of antiparkinson medications (Magdalinou et 
al. 2007).  While  26/35 (74%) of admitted PD patients had antiparkinson medications 
stopped, omitted or prescribed inappropriately, further details of this and the „significant 
sequelae‟ in 16/26 (62%) were not reported, although 1 of their cases did require 
intensive care support. No case was specifically diagnosed with PHS.  
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Conclusions 
The risks of stopping antiparkinson therapy are one of the key considerations in 
managing a patient who may have an incorrect diagnosis of PD. The most serious 
consequence of acute medication withdrawal in PD patients is the Parkinsonism-
hyperpyrexia syndrome (PHS). To minimise the risk of this potentially fatal syndrome, 
we tapered antiparkinson drugs slowly, and made arrangements for easy and early contact 
in the event of any uncertainty amongst patients and their carers about the effects of 
stopping treatment. This is essential as the early recognition of symptoms, replacement of 
dopaminergic medications, and introduction of supportive therapies and treatment of 
complications can improve patient outcome in the event of PHS. 2 of 41 (4.9%) patients 
undergoing therapy withdrawal clinically deteriorated and went back on therapy and an 
additional 1 case developed PHS remote from the study processes (See clinical vignette 
2). While we cannot define exactly the risks of PHS due to the small numbers in our 
study coming off treatment, it is reassuring that no case of PHS attributable to study 
processes occurred. 
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Table 6.1: Clinical features of Parkinsonism-hyperpyrexia syndrome  
 
Signs and Symptoms 
 Muscle rigidity (with or without tremor) 
 Pyrexia (>38˚C) 
 Reduced conscious level (confusion to coma) 
 Autonomic instability (labile blood pressure, tachycardia, diaphoresis, urinary 
incontinence) 
 Dysarthria, dysphagia 
Laboratory findings 
 Raised creatine kinase  
 Leucocytosis 
 Deranged liver function tests 
 Metabolic acidosis 
 
Complications 
 Acute renal failure 
 Rhabdomyolysis 
 Aspiration pneumonia 
 Deep venous thrombosis / pulmonary thromboembolism 
 Disseminated intravascular coagulation 
 Respiratory failure 
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Table 6.2: Recommended treatment for Parkinsonism-hyperpyrexia syndrome 
 
Replace antiparkinson medications 
Levodopa (pre-morbid dose) orally, via nasogastric tube or via intravenous infusion (50-
100mg infused over 3 hours) 
Dopamine agonist therapy, oral or nasogastric: traditionally Bromocriptine 7.5 - 15.0mg 
three times daily (Ropinirole 1 – 2mg three times daily, or Pramipexole 0.18 – 0.36mg 
(base) three times daily may be preferred); transdermally: Rotigotine 2 – 4mg/24 hours; 
subcutaneously: Apomorphine 1.0 – 2.0 mg/hour (Grosset et al. 2004) 
Supportive measures 
Manage patient in high dependency or intensive care setting 
Intravenous fluid replacement 
Anti-pyretics and cooling  measures 
Dantrolene (10mg/kg per day in 3-4 divided doses) (if rigidity is severe and not 
responding to other measures) 
Management of complications 
Antibiotics for infection 
Mechanical ventilation if respiratory failure 
Haemodialysis for acute renal failure 
Intravenous Heparin (5-15 units/kg per hour) and platelet transfusion if evidence of 
disseminated intravascular coagulation 
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CHAPTER 7 
DISCUSSION AND INTERPRETATION 
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This work was undertaken against a background of recently emerging data about 
diagnostic accuracy in PD and movement disorders. The most important aspects of the 
findings in the current work are reviewed in this Chapter, and followed by discussions 
about next steps in such research programmes. 
The main aims of this thesis were to: 
1. Identify cases misdiagnosed as PD from searches of prescription databases 
and case records within primary care.  
2. Undertake supervised antiparkinson medication withdrawal in this group, 
assessing for worsening of movement disorder symptoms during the 
follow up period. 
The methodology employed in this study also allowed for an analysis of the 
prevalence of parkinsonian disorders and prescription of antiparkinson medications. 
 
A number of features make this work unique: 
 Searches of prescription databases and case records within 92 West Scotland GP 
practices allowed assessment of a population in excess of half a million, making 
this the largest UK-based PD prevalence study.  
 Employing the same searching strategies across all practices allowed differences 
between primary care regions (community health partnerships) to be examined 
closely. 
 Case record review, in addition to searches of prescription databases, ensured that 
the indication for antiparkinson medication was established in all cases. Previous 
PD prevalence studies using drug tracer methodologies have only estimated the 
proportion of patients prescribed antiparkinson drugs for non-PD diagnoses (eg. 
pituitary adenoma, restless legs syndrome, dopa-responsive dystonia).  
 Antiparkinson drug costs and patterns of prescription within a large cohort of UK-
based PD patients according to age, disease duration and clinic attendance were 
examined.  
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 A set of criteria were developed that successfully allows patients misdiagnosed as 
PD to be identified. 
 A large number of patients, previously misdiagnosed as PD, underwent successful 
antiparkinson therapy withdrawal. There are no equivalent therapy withdrawal 
series in the literature. 
 The use of FP-CIT SPECT imaging in patients, previously labelled as PD, in 
whom there is diagnostic doubt is examined. 
 
The prevalence of Parkinson‟s disease in West Scotland 
The prevalence of PD in the current study is in keeping with previous UK reports.  
We found crude prevalence to be 119.2 per 100,000 while the range in other UK studies 
was from 108 to 164 per 100,000 (Brewis et al. 1966;Mutch et al. 1986;Sutcliffe & 
Meara 1995;Porter et al. 2006). The prevalence age-adjusted to the population of 
Scotland was 129.5 per 100,000, indicating that the population studied was younger than 
the average for Scotland.  
 
The use of prescription databases within prevalence studies of PD has been 
established (Menniti-Ippolito et al. 1995;van de Vijver et al. 2001;Lai et al. 2003;Brandt-
Christensen et al. 2006). A major advantage of drug tracer methodologies is that a large 
population can be studied with relative ease. However, this type of study omits patients 
who have not yet come to medical attention and those who have been diagnosed as 
having PD (by GP or hospital specialist) but have not yet been commenced on 
antiparkinson therapy.  In addition, many previous prevalence studies of this type have 
not included case record review. Case record review allows the clinical indication for 
prescription of antiparkinson drug to be established. PD prevalence would be 
significantly over-estimated if the real indication for drug prescription was unknown as 
we found that nearly 60% of patients prescribed antiparkinson drugs had non-PD 
diagnoses (the majority of whom were co-prescribed anticholinergics with antipsychotic 
medication). If patients prescribed anticholinergic monotherapy were omitted from 
database searches the proportion of patients prescribed antiparkinson medications for a 
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non-PD diagnosis was 25%. In future studies of large prescription databases, the PD 
prevalence could be estimated (without performing case record review) by omitting 
anticholinergic monotherapy from database searches and calculating 75% of the total 
number of patients prescribed antiparkinson medication, but this would not take account 
of differences in prescribing patterns in other regions in the prescription of antiparkinson 
drugs for alternative diagnoses (eg. greater use of such drugs for restless legs syndrome). 
 
We described how 39 patients, previously misdiagnosed as PD, were identified 
and underwent successful antiparkinson medication withdrawal. Consequently, crude 
prevalence fell in our series from 119.2 to 111.5 per 100,000. The total number of 
misdiagnosed cases (among the 610 PD patients identified) was estimated at 63 to 70 
patients. This would further decrease the prevalence to 105.5 - 106.9 per 100,000. Higher 
prevalence rates in previous studies may also result from overdiagnosis of PD. This has 
not previously been used to adjust rates in any of the reported prevalence studies but 
merits further investigation. 
 
Perhaps the most surprising finding was the difference in PD prevalence between 
areas studied. This difference was most pronounced when considering the age-adjusted 
PD prevalence for males in South Lanarkshire was more than double that for South 
Glasgow (202.7 per 100,000 versus 98.3 per 100,000).  Methodological differences (eg. 
case finding, diagnostic error) are largely considered to be the explanation for differences 
between populations in previous prevalence studies. However, in this present study the 
methodology was the same in all regions studied. The age structure of the population may 
differ between areas, and prevalence of PD is known to increase exponentially with 
increasing age. When age-correction was applied in this study, the differences between 
regions became even more pronounced. Although other factors previously known to 
influence PD prevalence were considered (eg. cigarette smoking, education, access to 
services and rural living) these were felt unlikely to account for a difference of such 
magnitude.  
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One potential reason for the higher reported prevalence within South Lanarkshire 
is that misdiagnosis rates were higher in this region. Of the 39 misdiagnosed patients who 
underwent successful antiparkinson medication withdrawal, 27 (69%) were from South 
Lanarkshire compared with 10 (26%) from South Glasgow. Improved diagnostic 
accuracy has been reported within specialist movement disorder services (Hughes et al. 
2002). A significantly higher proportion of patients in South Glasgow had on-going 
attendance at a hospital clinic for PD compared with those in South Lanarkshire (134 of 
164 (81.7%) versus 197 of 323 (61.0%), p<0.0001) and there are likely to be more 
misdiagnosed cases among patients managed exclusively in primary care. 
 
The correlation of poor access to specialist PD services with high misdiagnosis 
rates is of great importance, may partially explain the variation in prevalence reported in 
previous studies; and merits further investigation. In a period of greater de-centralisation 
of services within the NHS, patients with suspected PD must be able to access specialist 
out-patient clinics as recommended by NICE ( 2006).  If an area with an unexpectedly 
high PD prevalence were identified (in a separate study) access to services for this region 
should be examined with a view to targeting future resources.  
 
Prescription of antiparkinson medication 
Analysis of prescription of antiparkinson medication suggested that, despite 
availability of a wide range of drugs, Levodopa remains the mainstay of drug therapy in 
PD. Within Scotland the Scottish Medicines Consortium (SMC) provide advice to NHS 
Boards and their Area Drug and Therapeutics Committees (ADTCs) about all newly 
licensed medicines (NHS Scotland 2008). Both Rasagiline (a monoamine oxidase B 
inhibitor) and Duodopa (intestinal gel preparation of Levodopa) are not approved by 
the SMC as antiparkinson drug treatments. Although, individual cases can be made 
for each drug, the SMC ruling undoubtedly influences actual drug prescription with 
only 5 of 610 PD patients (0.8%) prescribed Rasagiline and no patients prescribed 
Duodopa in this study. 
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The greatest factor influencing choice of antiparkinson drug was whether the 
patient‟s PD was managed within primary care or a hospital clinic, with patients 
attending specialist clinics more likely to be prescribed: 
 higher doses of antiparkinson drugs; 
 more than one antiparkinson drug; and 
 more expensive antiparkinson drugs 
 
However, there were some differences between the groups of patients attending 
specialist clinics and those managed within primary care. These are addressed in the next 
section. 
 
Previous European studies examining drug costs in PD have reported mean daily 
cost (LePen et al. 1999;Findley et al. 2003;Moller et al. 2005;Vossius et al. 2006). 
However, we found that drug costs were positively skewed and therefore we summarised 
these using medians and interquartile ranges. Previous studies have also reported costs 
for those patients attending  a hospital clinic for the management of their PD and have 
largely excluded patients managed within primary care. In the present study we report 
costs for both categories and therefore have comparative data showing these differences. 
Whilst it is difficult to compare drug costs with other European countries (variable 
exchange rate and difference in costs of individual drugs between countries) we found 
there was significantly less expenditure on antiparkinson drugs than reported in previous 
German studies, probably largely relating to the co-prescription of dopamine agonists 
with Levodopa drugs from the earliest stages of the disease, while it is routine practice in 
the UK to maximise the dose (to either the manufacturer‟s maximum or to the maximally 
tolerated level) of one antiparkinson drug before the addition of another. 
 
Newer dopamine agonists (eg. Apomorphine, Ropinirole and Pramipexole) were 
amongst the most expensive antiparkinson drugs available and significantly influenced 
overall drug costs. We found the cost of antiparkinson drugs changed with disease 
duration. Drug costs were highest for those patients 4-6 years following diagnosis and 
 120 
then decreased thereafter, reflecting simplification of drug regimens and reduced 
prescription of dopamine agonists in advancing disease.  These costs considered 
dopaminergic medications and ignored medications that may be co-prescribed in the 
patient with advanced PD (eg. Donepezil (an acetylcholinetserase inhibitor) for cognitive 
impairment, or Quetiapine (an atypical antipsychotic) for psychosis). However, by far the 
largest financial cost in a patient with advanced PD is the cost of social care required 
(Findley et al. 2003). Consideration of these costs was beyond the scope of this study. 
 
Clinic attendance for management of Parkinson‟s disease 
Only 70.3% of 610 patients studied had current attendance at a hospital clinic for 
management of PD; and 58.0% of 610 currently attended a specialist PD clinic. This falls 
short of national guidelines within England and Wales that have recommended that all 
patients with suspected PD are assessed within a specialist clinic and that the diagnosis is 
under regular review ( 2006).  
 
Recently the Parkinson‟s disease Society (PDS) published results from a patient 
survey of over 13,000 members across the UK (Parkinson's Disease Society 2008). One 
of the key findings was that 15% of responders had never been seen by a movement 
disorder specialist, compared with 19% in our own study. Despite the obvious selection 
bias of a patient support group survey, this clearly suggests that problems with access to 
PD specialist services, and therefore misdiagnosis of PD, in West Scotland are replicated 
across the UK. 
 
Several factors were found to influence specialist clinic attendance. There was a 
significant difference in specialist clinic attendance between regions studied, with the 
highest attendance rates within East Dunbartonshire (84.6%) and lowest within South 
Lanarkshire (41.8%). Therefore a higher proportion of patients is managed within 
primary care and non-specialist clinics within South Lanarkshire, reflecting poorer access 
to services in this area. We also found that age and sex influenced clinic attendance, with 
a greater proportion of younger and male patients being managed within a hospital clinic. 
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The reasons for this apparent selection bias are not clear from this study, but are 
deserving of further study. 
 
Identifying misdiagnosis in Parkinson‟s disease 
Misdiagnosis in PD is important. If the same rates of misdiagnosis were applied in 
cancer or heart disease, there would surely be a public outcry. Patients are often given 
incorrect prognostic information and are prescribed medications which may give rise to 
side-effects.  The cost of these medications is also significant. We calculated the annual 
cost of antiparkinson drugs in the patients who underwent successful therapy withdrawal 
was £48,200. The cumulative drug costs for this group are much higher as misdiagnosed 
patients can remain on antiparkinson drugs for many years. The mean time since PD 
diagnosis in the group of patients in whom antiparkinson medication was successfully 
withdrawn was 6.8 years (SD 5.6). However, 1 patient had been taking Levodopa for 
24.7 years, meaning a huge cumulative cost. We feel this represents a significant clinical 
governance issue. 
 
The diagnosis of PD can be difficult at initial presentation. Patients with early 
disease may not yet fulfil diagnostic criteria (eg. they may have tremor and or rigidity 
without bradykinesia) and DAT imaging has been established as a valuable tool in the 
assessment of such patients. However, access to DAT imaging is variable. In West 
Scotland FP-CIT SPECT has been available since 2000 in South Glasgow, 2003 in North 
Glasgow and 2007 in South Lanarkshire. Many UK centres have availability of SPECT 
scans „capped‟ on cost grounds. There is one-off cost for FP-CIT SPECT scanning of 
approximately £560 per patient which must be balanced against the annual and 
cumulative antiparkinson drug costs for patients misdiagnosed as PD.  
 
PD is a progressive neurodegenerative disorder and if symptoms do not progress 
over years and there is little clinical response to Levodopa the diagnosis of PD should be 
questioned. All patients identified by searches of the GP prescription databases in this 
study were prescribed antiparkinson medication for a presumed PD diagnosis. We 
described criteria (devised by the authors) to help identify misdiagnosed cases from 
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searches within primary care. The criteria selected patients whose antiparkinson 
medication had not increased over time, in whom there was no recorded progression of 
disease or who were co-prescribed dopamine depleting drugs (relatively contraindicated 
in PD).We estimated that 63 to 70 of 610 (10.3 to 11.5%) PD patients identified were 
misdiagnosed. If these results were replicated elsewhere in the UK this would mean 630 
to 700 misdiagnosed cases within Scotland and 7,700 to 8,500 misdiagnosed cases in the 
UK; with annual antiparkinson drug costs of £780,000 to £865,000 across Scotland and 
£9.5 to £10.5 million across the UK. Although this study clearly merits assessment in a 
separate population, all the evidence suggests that misdiagnosis is not a local issue. Not 
only in the local or UK setting is there a potential issue of failure to identify the non-
progressing „apparently benign‟ PD case – across Europe the process of referral of 
„difficult to manage‟ cases would tend to miss the apparently benign patients who are 
misinterpreted as doing well and having a good response to medication. It appears most 
likely from the present work that this exact subset of patients is the major source of 
patients with a misdiagnosis of PD.  
 
Unfortunately the selection criteria proposed were not able to identify all 
misdiagnosed cases. Some misdiagnosed cases were recognised within the control group 
(not meeting selection criteria) and a further 3 misdiagnosed cases were identified during 
routine out-patient clinic assessment (neither meeting selection criteria nor selected as 
controls). However 33 of 64 patients (51.6%) meeting selection criteria were considered 
to have an alternate diagnosis and underwent successful withdrawal of antiparkinson 
medication. The likelihood of undergoing successful antiparkinson medication 
withdrawal was 16 times higher in patients meeting selection criteria compared with 
randomly selected controls. These criteria are clearly valuable in screening for 
misdiagnosis, but require to be tested in a separate population. 
 
Patients from nursing homes and long-term care institutions were excluded from 
the therapy withdrawal study. It may be difficult to judge therapy response, examine for 
bradykinesia or gain informed consent for such as study if patients are cognitively 
impaired.  PD prevalence rates of 12,500 per 100,000 have been reported (ie. Almost 100 
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times the „background‟ rate of 129.5 per 100,000 found in our study)  in institutionalised 
patients in Germany (von Campenhausen et al. 2005). The diagnostic error rate in such 
patients has never been analysed.  It is likely to be at least similar to the rates in the 
current study, but could be considerably greater. Confounding clinical features include 
the usually mild extrapyramidal features in Alzheimer‟s disease and the coexistence of 
tremor and/or Parkinsonism in vascular dementia. This certainly merits further 
examination. 
 
Withdrawal of antiparkinson medication in patients considered to have a non-Parkinson‟s 
disease diagnosis 
 Clinical trials of antiparkinson drugs in which patients have had normal 
presynaptic dopaminergic imaging have not reported therapy withdrawal despite 
suggesting that these patients have an alternative underlying diagnosis such as ET 
(Whone et al. 2003;Fahn et al. 2004). It may be difficult for this to be achieved or 
collated in a multi-centre trial, perhaps requiring significant amendment to the study 
protocol. In addition, drug withdrawal is not the primary aim of the sponsors of such 
trials. There may also be concerns about the adverse effects of withdrawing treatment, 
such as the worsening of movement disorder symptoms or development of Parkinsonism-
hyperpyrexia syndrome (PHS). Successful antiparkinson medication withdrawal has been 
reported in 11 patients with normal FP-CIT imaging (Marshall et al. 2006). We reported 
successful antiparkinson therapy withdrawal in 39 patients misdiagnosed as PD in a 
larger community study and a further 4 patients, identified within out-patient clinics 
outwith the main study. While apparently modest, this is the largest reported series.   
 
We described 2 patients, both of whom were initially considered to have a non-
PD diagnosis. Both patients consented to antiparkinson medication withdrawal. 
Following therapy withdrawal, both reported worsening of movement disorder symptoms 
and had increased UPDRS part 3 scores. Both subsequently had abnormal FP-CIT 
SPECT imaging and improved clinically following prompt re-introduction of 
antiparkinson drugs. These two cases illustrate that even movement disorder specialists 
can get the clinical diagnosis of PD wrong in the early stages. In both cases this would 
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have been avoided if FP-CIT SPECT imaging were carried out prior to medication 
withdrawal. No cases of PHS occurred within the medication withdrawal study. Given 
PHS is a potentially fatal complication; its occurrence in even a single patient would 
counterbalance any benefits for the remaining cases. More liberal use of FP-CIT SPECT 
is recommended for any future study as a safeguard to prevent PHS following therapy 
withdrawal. In the current study medication was initially withdrawn in 22 patients 
without FP-CIT SPECT scanning being performed. In the 2 of 22 patients (9.1%) who 
clinically deteriorated following medication withdrawal FP-CIT SPECT scanning was 
abnormal in both cases. If all 22 of these patients had undergone FP-CIT SPECT this 
one-off total cost would approximately be £12,320, which should be considered against 
the total annual antiparkinson drug cost of £4,930 in these 22 cases, and a much greater 
cumulative cost (to date) of £31,600 for the 22 cases. 
  
The most common alternate diagnoses for patients who underwent successful 
medication withdrawal were ET and VP. The role of dopaminergic therapy in VP is 
unclear with reports of some patients deriving an excellent clinical response to Levodopa 
(Zijlmans et al. 2004). However, the ability of patients to tolerate higher doses of 
Levodopa treatment in this situation is poor. Although Zijlmans et al. suggested a trial of 
up to 1000mg/day Levodopa, most patients in their report were unable to tolerate a dose 
above 600mg/day. In the current study we found that patients diagnosed as VP did not 
clinically deteriorate when antiparkinson therapy was withdrawn. These patients may 
have derived symptomatic benefit from escalation of Levodopa dose, but this was not 
attempted in this study.   
 
In dopa-responsive dystonia (DRD) there may be mild bradykinesia which 
improves with low-dose Levodopa. Patients usually present less than 12 years of age with 
foot dystonia or gait disorder. It is possible that a DRD patient could be misdiagnosed as 
juvenile PD, but no such cases were found in this series. FP-CIT SPECT is normal in 
DRD.   
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Blueprint for further work 
1. This study should be repeated in a separate population 
The protocol could be modified as follows: 
 Patients in nursing home and long-term care institution should be a 
component of further work in this area. As commented above, they 
may have at least as high a diagnosis error rate and a careful study 
involving the patient, their families and carers is appropriate to 
assess this cohort. 
 FP-CIT SPECT could be applied more readily if there was concern 
about the risk of PHS following antiparkinson medication 
withdrawal. However, the cost of a greater number of FP-CIT 
SPECT scans has to be considered. 
2. Encourage referral of patients from primary care to specialist centres 
 GPs should be made aware of the problem of misdiagnosis of PD in the 
community and the value of specialist input in PD patients. 
 GPs should be advised to refer all patients with suspected PD or new onset 
of tremor for specialist assessment. 
These recommendations are already embodied within the NICE guidelines and are 
expected to feature prominently in the Scottish Intercollegiate Guidelines Network 
(SIGN) which are under current development. 
 
The publication plan for the present thesis is for this study to appear in the wider 
general medical literature, rather than exclusively within the specialist PD and neurology 
journals, in order to publicise the results of the study and encourage GPs to understand 
the rationale for specialist involvement at an early stage in the diagnostic process, and the 
potential issues around maintaining ineffective antiparkinson therapy in erroneously 
diagnosed cases. 
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Appendix 1: UK Parkinson‟s Disease Society Brain Bank clinical diagnostic criteria for 
Parkinson‟s disease 
 
Step 1: Diagnosis of a parkinsonian syndrome 
 Bradykinesia (slowness of initiation of voluntary movement with progressive reduction in 
speed and amplitude of repetitive actions) 
 And at least one of the following: 
o Muscular rigidity 
o 4-6 Hz rest tremor 
o Postural instability not caused by primary visual, vestibular, cerebellar, or 
proprioceptive dysfunction 
 
Step 2: Exclusion criteria for Parkinson’s disease 
 History of repeated strokes with stepwise progression of parkinsonian features 
 History of repeated head injury 
 History of definite encephalitis 
 Oculogyric crisis 
 Neuroleptic treatment at onset of symptoms 
 More than one affected relative 
 Sustained remission 
 Strictly unilateral features after three years 
 Supranuclear gaze palsy 
 Cerebellar signs 
 Early severe autonomic involvement 
 Early severe dementia with disturbances of memory, language and praxis 
 Babinski‟s sign 
 Presence of a cerebral tumour or communicating hydrocephalus on CT scan 
 Negative response to large doses of Levodopa 
 
Step 3: Supportive criteria for Parkinson’s disease 
(Three or more required for diagnosis of definite Parkinson’s disease) 
 Unilateral onset 
 Rest tremor present 
 Progressive disorder 
 Persistent asymmetry affecting side of onset most 
 Excellent response (70-100%) to Levodopa 
 Severe Levodopa induced chorea 
 Levodopa for five years or more 
 Clinical course of 10 years or more 
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Appendix 2: The Motor Fluctuation Questionnaire (Brooks et al. 2005)  
Do you often experience the return of any of the following symptoms of Parkinson’s 
Disease before you take your next dose of medication? 
An increase in tremor (shaking) of the hand   Y⁮  N⁮ 
Slowing of hand movements (e.g. buttons, tools, cutting food) Y⁮  N⁮ 
Smaller or further slowing of handwriting     Y⁮  N⁮ 
Slower or increased effort at arising from sitting    Y⁮  N⁮ 
Smaller step, increased slowness at walking, or more shuffling  Y⁮  N⁮ 
Decreased volume or clarity of the voice    Y⁮  N⁮ 
Increased generalised stiffness of the muscles   Y⁮  N⁮ 
 
 
 
 
 
 
 
